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Study objectives 
Chlamydia suis is widespread in farmed pigs and causes important economic losses (Schautteet et 
al., 2013). C. suis can cause conjunctivitis, rhinitis, pneumonia and enteritis as demonstrated by 
experimental infection of pigs (Rogers et al., 1996; Rogers and Andersen, 1996, 1999, 2000; 
Sachse et al., 2004; Reinhold et al., 2008; Guscetti et al., 2009). C. suis infections are also 
associated with numerous reproductive disorders, such as abortion, mummification, perinatal and 
neonatal mortality, repeat breeding, vaginal discharge and endometritis in addition to orchitis, 
epididymitis and urethritis in boars (Sarma et al., 1983; Woollen et al., 1990; Schiller et al., 
1997b; Eggemann et al., 2000; Kauffold et al., 2006a; Schautteet et al., 2013). Moreover, C. suis 
has been detected in the semen of boars, suggesting the possibility of venereal transmission 
during mating or artificial insemination (Kauffold et al., 2006b; Teankum et al., 2006; Schautteet 
et al., 2013). However, the role of C. suis in reproductive problems is still controversial because 
studies involving experimental genital tract infection of pigs with C. suis are lacking. 
Nevertheless, considering the possibility of venereal transmission, genital C. suis infections and 
re-infections are probably common in breeder sows, since they are mated or inseminated a 
minimum of twice a year and generally two to three inseminations per oestrus are carried out. 
Therefore, the first aim of this thesis was to reveal the characteristic features of genital C. suis 
infection and re-infection in female pigs. To this end, conventionally raised Chlamydia-negative 
pigs were intravaginally infected and re-infected with C. suis strain S45, whereafter the immune 
response, pathological changes, replication of chlamydiae in the urogenital tract and vaginal 
excretion of viable bacteria were investigated. 
 
The human pathogen Chlamydia trachomatis is worldwide the most common cause of bacterial 
sexually transmitted disease, with over 100 million new infections each year (WHO, 2012). 
Urogenital infection with noninvasive C. trachomatis strains can result in cervicitis, urethritis and 
post-infection complications such as pelvic inflammatory disease, ectopic pregnancy, infertility, 
chronic pelvic pain, epididymitis and infant pneumonia. The LGV strains cause a more invasive 
disease called lymphogranuloma venereum (LGV). LGV usually manifests as acute inguinal 
lymphadenitis with abscess formation following urogenital inoculation, whereas anorectal 
entrance of the bacteria can lead to acute hemorrhagic proctitis (Perine and Stamm, 1998; Mabey 
and Peeling, 2002). Without treatment, persistent infections with chronic inflammation arise, 
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resulting in strictures and fistulas of the involved region, which can eventually result in serious 
complications such as genital elephantiasis, esthiomene and the frozen pelvis syndrome with 
infertility (Aggarwal et al., 2002; Gupta et al., 2006). LGV infections have been less intensively 
studied than infections with noninvasive urogenital serovars, because LGV is considered a rare 
tropical disease. However, since 2003, an ongoing LGV outbreak has been observed among men 
who have sex with men in developed countries (Götz and Nieuwenhuis, 2004; Plettenberg et al., 
2004; von Holstein et al., 2004; Nieuwenhuis et al., 2004; Vall Mayans et al., 2005; Berglund et 
al., 2005; Kropp and Wong, 2005; Liassine et al., 2005; Ahdoot et al., 2006; Morton et al., 
2006). In these countries, LGV is rarely found in women, but this may change in the near future 
by dissemination of the disease to bisexual men and subsequently to women (Verweij et al., 
2012). Women are more prone to develop serious complications, since LGV infections remain 
more often asymptomatic, and thus untreated, in women (Stary and Stary, 2008). Therefore, the 
second objective of this thesis was to obtain more knowledge about female genital tract infection 
with LGV serovars. To this end, we infected and re-infected conventionally raised pigs 
intravaginally with the most recently discovered LGV strain, called L2c, since pigs were shown 
to be a suitable animal model for studying female genital tract infection with C. trachomatis 
(Vanrompay et al., 2005). 
 
Uncomplicated C. trachomatis infections can be treated effectively with antibiotics, but once 
infection and pathology are established, treatment may not prevent complications. Moreover, due 
to the asymptomatic nature of C. trachomatis genital tract infection, the spread of infection 
cannot be successfully controlled by treating only the individuals with clinical symptoms. 
Therefore, vaccination is considered as the most effective approach to control genital 
C. trachomatis infection (Stagg, 1998). However, despite the many efforts that have been made 
in this field, there is currently no vaccine against C. trachomatis infection. During previous 
vaccination studies in pigs, intravaginal and combined intravaginal and intranasal immunization 
with an unformulated DNA vaccine induced significant protection against genital C. trachomatis 
challenge (Schautteet et al., 2011a, 2012). However, complete protection was never observed. 
The potency of the previously used DNA vaccine can probably be improved by increasing its 
transfection efficiency, as the spontaneous uptake of naked nucleic acids by host cells is very 
inefficient. Therefore, nucleic acids can be complexed with carriers that facilitate their 
Study objectives  3 
intracellular delivery. The third aim of this thesis was to identify non-viral gene delivery carriers 
that can efficiently transfect porcine tracheal cells and are not negatively affected by 
aerosolization, as this is the preferred method for intranasal vaccine administration. Furthermore, 
we wanted to investigate whether aerosolization is also suitable to deliver complexes to the 
vaginal tract of pigs and, simultaneously, evaluate the in vivo transfection efficiency of some 
selected complexes. 
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Part of this chapter has been published as:  
De Clercq, E., Kalmar, I. & Vanrompay, D. (2013). Animal models for studying Chlamydia 
trachomatis female genital tract infection. Infection and Immunity, 81(9), 3060–7.  
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1. Introduction 
Chlamydiaceae are obligate intracellular Gram-negative bacteria that cause a variety of diseases 
in humans, other mammals and birds. They have a serious impact on both human and animal 
health and are therefore of major economic importance worldwide. Chlamydial infection in 
animals can result in abortion, infertility, respiratory disease, enteritis, conjunctivitis, 
encephalomyelitis or arthritis (Longbottom and Coulter, 2003). In humans, Chlamydia (C.) 
trachomatis and C. pneumoniae are the most common chlamydial pathogens, but several other 
chlamydial species can cause zoonotic disease. C. trachomatis is the leading cause of infectious 
blindness (trachoma) and sexually transmitted disease, whereas C. pneumoniae is associated with 
respiratory infections and atherosclerosis. Chlamydiaceae are disseminated by aerosols or by 
direct contact and require no alternate vector for transmission (Everett, 2000). These bacteria 
show a unique biphasic replicative cycle characterized by two distinct morphological forms, the 
elementary bodies (EB) and the reticulate bodies (RB) (Moulder, 1991). The primary sites of 
replication are mucosal epithelial cells of the respiratory, gastrointestinal and urogenital tract, the 
conjunctival epithelium, as well as monocytes and macrophages (Pospischil et al., 2010). 
 
2. Taxonomy 
The family Chlamydiaceae belongs to the bacterial order Chlamydiales, which consists of at least 
eight families (Horn, 2008).  The order Chlamydiales has been reclassified several times over the 
last decades. In 1999, Everett et al. (1999) proposed to divide the single genus Chlamydia into 
two genera, Chlamydia and Chlamydophila, based on phylogenetic analysis of 16S and 23S 
rRNA genes and phenotypic, morphologic and genetic information. The genus Chlamydia 
comprised the species C. trachomatis, C. muridarum and C. suis. The genus Chlamydophila (Cp.) 
contained six species, namely Cp. pneumoniae, Cp. psittaci, Cp. abortus, Cp. pecorum, Cp. felis 
and Cp. caviae. However, comparative genome analysis of the different Chlamydiaceae species 
revealed that host-divergent chlamydial species are biologically and ecologically closely related 
and that the taxonomic separation of the family into two genera is not consistent with their 
natural evolutionary history. Consequently, all nine Chlamydiaceae species (Table I-1) are 
currently reunited into a single genus, Chlamydia (Stephens et al., 2009).  
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Table I-1: The family Chlamydiaceae (adapted from Kerr et al. (2005)) 
Species Host Disease/symptoms 
Chlamydia trachomatis Humans Chronic conjunctivitis and blindness (trachoma) 
Sexually transmitted disease, pelvic inflammatory 
disease, infertility 
Lymphogranuloma venereum 
   
Chlamydia muridarum
  Mice, hamsters 
 
Respiratory and genital tract infection 
 
Chlamydia suis
 b Pigs Conjunctivitis, rhinitis, pneumonia, enteritis, 
reproductive disorders 
   
Chlamydia pneumoniae Humans, koalas Respiratory tract infection; associated with 
atherosclerosis, reactive arthritis and asthma 
   
Chlamydia psittaci
 a Birds Respiratory tract infection 
 
Chlamydia abortus
 a Ruminants, pigs Abortion  
   
Chlamydia pecorum  Ruminants, pigs, 
koalas 
Conjunctivitis, pneumonia, enteritis, reproductive 
disorders, polyarthritis, encephalomyelitis 
   
Chlamydia felis
 b Cats Conjunctivitis, respiratory tract infection 
   
Chlamydia caviae
 b Guinea pigs Ocular and genital tract infection 
a zoonotic pathogen  
b 
probable zoonotic pathogen  
 
3. Developmental cycle 
Chlamydiaceae have a unique intracellular biphasic developmental cycle in which they alternate 
between two different developmental forms: the extracellular, infectious EBs and the 
intracellular, metabolically active RBs. In addition, intermediate bodies (IBs) can be formed 
during the maturation from RBs to EBs (Vanrompay et al., 1996).  
Elementary bodies are spherical, electron-dense, metabolically inert structures with a diameter of 
0.2-0.3 μm. They have a rigid cell envelope with extensive disulfide bridging between cysteine 
and methionine residues of outer membrane proteins (Newhall and Jones, 1983). Consequently, 
EBs are osmotically stable and poorly permeable, which makes them resistant to physical and 
chemical factors in the extracellular environment. Therefore, EBs are able to survive up to 
several months outside the host cell (Longbottom and Coulter, 2003). 
Reticulate bodies are also spherical, but have a larger diameter (0.5-1.6 μm) and a low electron 
density. Their cell envelope is less rigid and more permeable because the disulfide bonds between 
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the outer membrane proteins are reduced (Newhall and Jones, 1983). RBs are metabolically 
active, so their cytoplasm contains more RNA and ribosomes, which are necessary for protein 
synthesis (Ward, 1988). The non-infectious RBs can replicate intracellularly by binary fission. 
IBs are sometimes observed in the host cells and are 0.3 to 1.0 μm in diameter. IBs appear to be 
infectious, since they are able to infect host cells in vitro (Vanrompay et al., 1996). 
 
 
 
 
Figure I-1: Schematic representation of the developmental cycle of Chlamydiaceae. Numbers refer to 
hours post infection, but the timing of the different stages in the life cycle can vary depending on the 
chlamydial species and the host cell (Geens, 2005). 
 
The chlamydial developmental cycle is schematically represented in Figure I-1. Infection is 
initiated when the EBs attach to eukaryotic host cells and induce their internalization into host-
derived, membrane-bound endosomes, termed chlamydial inclusions. The exact nature of 
attachment and entry remains elusive, since different mechanisms such as receptor-mediated 
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endocytosis into clathrin-coated pits (Hodinka et al., 1988; Vanrompay et al., 1996) and 
microfilament dependent phagocytosis (Byrne and Moulder, 1978), have been identified. The 
chlamydial inclusions are able to evade fusion with host lysosomes and different C. trachomatis 
inclusions can fuse into a larger inclusion (Ridderhof and Barnes, 1989). Within 8-12 hours after 
infection, the EBs differentiate into RBs. Subsequently, the RBs migrate towards the periphery of 
the inclusion, where they replicate by binary fission in close contact with the inclusion 
membrane. Following several rounds of replication, RBs get detached from the inclusion 
membrane and transform back into EBs. At 48-72 hours post infection, depending on the 
chlamydial species, EBs and some non-differentiated RBs are released from the host cell, which 
allows further propagation of the infection in neighboring cells. Release of the EBs occurs by 
cytolysis or by extrusion of the whole inclusion, which leaves the host cell intact. 
Chlamydiaceae can interrupt their normal replication cycle and enter a persistent state under 
stressful conditions such as antibiotic exposure, nutrient deficiency, heat shock and exposure to 
interferon (IFN)-γ (Mpiga and Ravaoarinoro, 2006). Persistence allows the bacteria to remain 
dormant in the host cell and resist host defense mechanisms and antibiotic treatment. After 
removal of the stress-inducing factor, persistent bodies revert to RBs and the normal 
developmental cycle is resumed. 
 
4. Chlamydia suis 
4.1. Epidemiology 
Chlamydia suis seems to be common and widespread in pigs, which are the only known natural 
hosts for this chlamydial species (Schautteet and Vanrompay, 2011). However, the epidemiology 
of C. suis is still largely unknown and there is a large variation in reported prevalences between 
various detection methods (Hoelzle et al., 2000; Sachse et al., 2003; Englund et al., 2012). 
Serological studies in European countries revealed a relatively high prevalence of chlamydial 
infections in the commercial pig population. Chlamydial infections appeared to be endemic in the 
Belgian pig herds, since 96.5% of the examined farms were seropositive for Chlamydiaceae 
(Vanrompay et al., 2004). In Germany, 33 to 72% of the sows and 10 to 47% of the boars were 
positive for Chlamydiaceae-specific antibodies in ELISA (Eggemann et al., 2000). In 
Switzerland, seroprevalence rates of Chlamydiaceae infections were 62% in sows, 6.9% in 
piglets younger than 4 weeks and 48.1% in piglets older than 4 weeks (Camenisch et al., 2004). 
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Di Francesco et al. (2006) could detect Chlamydiaceae-specific antibodies in 63.5 to 80.3% of 
the Italian finishing pigs. In Lithuanian pigs, a Chlamydiaceae seroprevalence rate of 7.7% was 
found (Bagdonas et al., 2005). However, the currently available serological tests can only detect 
Chlamydiaceae-specific antibodies and fail to identify the distinct chlamydial species occurring 
in pigs, namely C. abortus, C. pecorum, C. psittaci and C. suis (Schautteet and Vanrompay, 
2011).  
Recently, chlamydial species-specific nucleic acid amplification tests such as real-time PCR and 
microarray have been developed, which allow to examine the prevalence of C. suis in pigs 
(Sachse et al., 2005; Pantchev et al., 2010; De Puysseleyr et al., 2014b; Lis et al., 2014). C. suis 
appears to be the major agent causing chlamydioses in swine. In Belgium, Germany and 
Switzerland, C. suis was detected in the vast majority of pigs suffering from chlamydial intestinal 
infections (Zahn et al., 1995; Szeredi et al., 1996; Schiller et al., 1997b). Becker et al. (2007) 
found a high prevalence of C. suis in eye samples of Swiss and German pigs with conjunctivitis 
(79-90%) or without clinical symptoms (23-88%). In Sweden, C. suis was detected in high 
prevalences in growing pigs with or without diarrhea, and in finisher pigs with or without 
conjunctivitis (Englund et al., 2012). In a German study, C. suis often occurred in mixed 
infections with C. abortus in the lungs and intestines of pigs (Hoelzle et al., 2000). 
C. suis is phylogenetically highly related to the human pathogen C. trachomatis (Everett et al., 
1999) and hence might be a potential zoonotic pathogen (Schautteet and Vanrompay, 2011). 
Recently, C. suis was found in conjunctival samples from a few trachoma patients in Nepal (Dean 
et al., 2013). Furthermore, De Puysseleyr et al. (2014a, 2014b) could detect C. suis in the eyes of 
two Belgian slaughterhouse employees without disease symptoms. These recent studies 
demonstrate the zoonotic potential of C. suis. 
 
4.2. Pathogenesis 
C. suis has frequently been detected in clinically healthy pigs (Hoelzle et al., 2000; Camenisch et 
al., 2004; Englund et al., 2012), but has also been associated with a wide variety of diseases. 
C. suis was capable of inducing conjunctivitis, rhinitis, pneumonia and enteritis in experimentally 
infected gnotobiotic pigs (Rogers et al., 1996; Rogers and Andersen, 1996, 1999; Guscetti et al., 
2009). The pathogenic potential of C. suis for the porcine respiratory system has been confirmed 
by experimental aerosol challenge of conventionally raised pigs (Sachse et al., 2004; Reinhold et 
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al., 2008). All infected animals showed clinical signs of an acute infection, since they suffered 
from fever, dry cough, serous nasal discharge and severe dyspnoea. However, the majority of the 
natural intestinal C. suis infections seems to be subclinical (Zahn et al., 1995; Szeredi et al., 
1996; Englund et al., 2012) and the bacterium was found to cause only an asymptomatic 
intestinal infection without diarrhea in young weanling pigs (Rogers and Andersen, 2000). 
Interestingly, Becker et al. (2007) found that C. suis was significantly related to conjunctivitis in 
extensive pig production systems, whereas no correlation to conjunctivitis was observed in 
intensive farming systems. Englund et al. (2012) also noted no differences in the prevalence of 
C. suis between pigs with conjunctivitis and clinically asymptomatic pigs.  
Furthermore, C. suis has been associated with arthritis, pericarditis and polyserositis in piglets 
(Willigan and Beamer, 1955), periparturient dysgalactiae syndrome (PDS) in sows (Eggemann et 
al., 2000) and numerous reproductive disorders. In sows, C. suis was implicated as a cause of 
vaginal discharge, endometritis and poor reproductive performance, such as return to oestrus, 
abortion, mummification, delivery of weak piglets and increased perinatal and neonatal mortality 
(Woollen et al., 1990; Schiller et al., 1997b; Eggemann et al., 2000; Kauffold et al., 2006a; 
Schautteet et al., 2013). C. suis infections in boars have been correlated with orchitis, 
epididymitis, urethritis and inferior semen quality (Sarma et al., 1983; Schautteet and 
Vanrompay, 2011). For most of the reproductive disorders, the exact role of C. suis still has to be 
defined, since studies concerning experimental genital tract infection of pigs with C. suis are 
lacking. However, we recently demonstrated the pathogenic potential of C. suis for the female 
porcine urogenital tract (chapter II). 
 
4.3. Prevention and treatment 
C. suis infections are generally treated with tetracycline or its derivatives, since they are most 
effective and rather cheap (Chopra and Roberts, 2001). However, tetracycline resistant (Tc
r
) 
C. suis strains are currently emerging in the U.S. and European pig industry (Andersen and 
Rogers, 1998; Di Francesco et al., 2008; Borel et al., 2012; Schautteet et al., 2013; De Puysseleyr 
et al., 2014b). The C. suis Tc
r
 phenotype is manifested through the tetracycline resistance gene 
tet(C), which is integrated into the chlamydial chromosome (Dugan et al., 2004). The occurrence 
of stable Tc
r
 in C. suis may be a function of the feeding of large amounts of tetracycline and other 
antibiotics as growth promoters to swine, cattle and poultry in the past (Roberts, 1996; Chopra 
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and Roberts, 2001). It is likely that this practice established an environment where the tet(C) gene 
could be acquired and maintained by C. suis (Dugan et al., 2004). Quinolones, such as 
enrofloxacin, or macrolides, such as erythromycin, can be used to treat infections with Tc
r
 C. suis 
strains (Schautteet and Vanrompay, 2011).  
Vaccination would be the best approach to protect pigs against C. suis infections, but at present 
no vaccines are available. Obviously, a better insight into this disease and the associated 
protective immune responses is required, before a potential vaccine candidate can be developed 
(Schautteet and Vanrompay, 2011). 
 
5. Chlamydia trachomatis 
5.1. Biovars and serovars 
Chlamydia trachomatis comprises two biovars: the trachoma biovar which includes ocular and 
urogenital strains and the lymphogranuloma venereum (LGV) biovar (Moulder, 1984; Batteiger, 
1996). The two biovars are subdivided into 22 serologically distinguishable variants termed 
serovars, which arise from variation in the major outer membrane protein (MOMP) (Everett et 
al., 1999). MOMP is the predominant outer membrane protein covering the surface of chlamydial 
EBs and RBs. This protein has four surface-exposed variable regions and five conserved regions 
(Stephens et al., 1987). MOMP is highly immunogenic and contains genus-, species- and serovar-
specific epitopes (Caldwell et al., 1981).  
The ocular serovars A, B, Ba and C infect the conjunctival epithelium and can give rise to 
trachoma, the leading cause of preventable blindness in developing countries (WHO, 2008). The 
urogenital serovars D to K, including Da, Ga, Ia and Ja, usually cause sexually transmitted genital 
infections. The LGV biovar comprises the serovars L1, L2, L3, L2a, L2b and L2c, which cause 
an invasive sexually transmitted disease called lymphogranuloma venereum. These serovars 
transiently infect mucosal epithelial cells and then penetrate into the submucosal tissues to infect 
macrophages and monocytes, which facilitates the dissemination of the infection to regional 
draining lymph nodes (Schachter, 1999). This section will mainly focus on infections with 
urogenital C. trachomatis serovars. Additionally, some aspects of LGV infections will be 
discussed. 
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5.2. Epidemiology 
5.2.1. Urogenital infection (non-LGV) 
C. trachomatis infection is the most common bacterial sexually transmitted disease in the world, 
and in Europe. World Health Organization (WHO) estimated that 105.7 million new cases of 
genital C. trachomatis infection occurred worldwide in 2008 (WHO, 2012). In 2012, 385 307 
cases of genital chlamydial infection were reported in 26 European countries, with an overall rate 
of 184 per 100 000 population. Chlamydial infections were reported more often in women than in 
men, with an overall rate of 211 per 100 000 in women and 153 per 100 000 in men. The true 
incidence of C. trachomatis infections is likely to be considerably higher than these reported 
rates, as differences in testing methods, coverage and surveillance systems across Europe mean 
that many infections are either not diagnosed or not reported. Two thirds (68%) of all Chlamydia 
cases occurred in young people between 15 and 24 years of age, with the highest rates reported 
among women aged 20 to 24 years (1 684 cases per 100 000) (ECDC, 2014). However, lack of 
consistency in Chlamydia surveillance and variations in testing policies and practices make it 
difficult to estimate the incidence and prevalence of genital C. trachomatis infections in Europe 
or to make cross-country comparisons. Nevertheless, general trends in a number of European 
countries with consistent reporting show an increase in the rate of genital chlamydial infections. 
In Sweden and Finland, where testing has been widespread for many years, the incidence of 
Chlamydia decreased in the early 1990s but has been increasing since 1995 (ECDC, 2009). The 
decrease in the first half of the 1990s mirrors that of other sexually transmitted infections which 
declined in many European countries, probably as a result of safe sex campaigns and the fear of 
AIDS (Nicoll et al., 2001; Low, 2007; ECDC, 2009). The overall rate for countries which have 
reported consistently between 2003 and 2012 (Denmark, Estonia, Finland, Iceland, Ireland, 
Latvia, Lithuania, Sweden, and the United Kingdom) has increased by 90 % from 182 to 345 per 
100 000 (Figure I-2) (ECDC, 2014). Prevalence surveys in several European countries estimated 
a population prevalence of 1.4 to 3.0% in age groups 18 to 44 years (ECDC, 2009). In England, 
the national Chlamydia screening program reported a rate of 10.1% in sexually active people 
aged under 25 years in 2005-2006 (Health Protection Agency, 2006). 
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Figure I-2: Reported cases of genital C. trachomatis infection per 100 000 population in nine 
European countries with consistent reporting (Denmark, Estonia, Finland, Iceland, Ireland, Latvia, 
Lithuania, Sweden, and the United Kingdom) between 2003 and 2012, by gender (ECDC, 2014).  
 
The greatest risk factors for contracting genital C. trachomatis infection are age, with those aged 
15-24 most affected, and gender, with women at more risk than men. Other factors associated 
with genital chlamydial infection include unmarried status, nulliparity, black race and poor socio-
economic condition. A large number of sexual partners, a new sexual partner, lack of use of 
barrier contraceptive devices and concurrent gonococcal infection are also known to be 
associated with C. trachomatis infection (Novak and Novak, 2013; Malhotra et al., 2013). 
 
5.2.2. LGV infection 
Lymphogranuloma venereum is endemic in parts of Africa, South-East Asia, South America and 
the Caribbean, while it is considered a rare disease in the Western world (Viravan et al., 1996; 
Behets et al., 1999; Mabey and Peeling, 2002). However, since 2003 LGV outbreaks among men 
who have sex with men (MSM) have been reported in Australia (Morton et al., 2006), North 
America (Kropp and Wong, 2005; Ahdoot et al., 2006) and Europe (Götz and Nieuwenhuis, 
2004; Plettenberg et al., 2004; von Holstein et al., 2004; Nieuwenhuis et al., 2004; Vall Mayans 
et al., 2005; Berglund et al., 2005; Liassine et al., 2005). The incidence of LGV is rapidly 
increasing in Europe. In 2012, 830 LGV cases were reported in eight European countries. 
Compared with 2011, the number of cases reported in 2012 has increased by 17%, mainly related 
to increased reports from the Netherlands (ECDC, 2014). However, it must be noted that the 
actual incidence of LGV is probably much higher, as the disease is frequently not identified 
16 Chapter I 
because of low clinical awareness and because LGV is still not a reportable disease in many 
European countries (Kapoor, 2008). Of the reported cases, all but one occurred among MSM and 
71% of the LGV patients were HIV positive (ECDC, 2014). Remarkably, the vast majority of 
infections was caused by serovar L2b (Spaargaren et al., 2005).  
The main risk factors for LGV are HIV seropositivity and concurrent sexual transmitted 
infections. Furthermore, like other sexually transmitted infections, LGV is more common among 
individuals that have had multiple sexual partners, involve in unprotected sex and/or belong to 
low socio-economic groups (Richardson and Goldmeier, 2007).  
 
5.3. Pathogenesis 
5.3.1. Urogenital serovars  
The urogenital C. trachomatis serovars can infect the mucosal epithelium of the genital tract, the 
urethra, the rectum and rarely also the throat and the conjunctiva (Manavi, 2006). Rectal infection 
with these serovars can result in mild proctitis, but is typically asymptomatic and has no long-
term sequelae, which is in contrast to the severe symptomatic proctitis caused by the LGV 
serovars (White, 2009). Pharyngeal C. trachomatis infection is uncommon and mostly mild or 
asymptomatic and transient (McMillan et al., 1981). Conjunctival infection with urogenital 
C. trachomatis serovars usually occurs through direct inoculation with infected genital secretions. 
The sexually acquired inclusion conjunctivitis is characterized by mucopurulent discharge and 
can lead to corneal scarring in chronic infections (Manavi, 2006).  
In the urogenital tract, the primary site for C. trachomatis infection is the columnar epithelium in 
the endocervix of women and the urethra of men. Infection can result in intense inflammation 
characterized by redness, edema and mucosal discharge, leading to mucopurulent cervicitis in 
women and non-gonococcal urethritis in men. Despite initiating local inflammation, 
C. trachomatis infections remain largely subclinical in approximately 70% of women and 50% of 
men and consequently are often not detected (Peipert, 2003; Brunham and Rey-Ladino, 2005). In 
symptomatic patients, the incubation period generally ranges from one to three weeks following 
infection (Manavi, 2006). 
Women with symptomatic chlamydial cervicitis may complain of abnormal vaginal discharge, 
intermenstrual bleeding, postcoital bleeding and lower abdominal pain (Peipert, 2003). 
Regardless the presence of symptoms, at least one third of infected women shows local signs of 
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infection on vaginal examination. The most commonly reported signs are mucopurulent 
endocervical discharge, hypertrophic cervical ectopy and easily induced bleeding of the cervical 
epithelium (Brunham et al., 1984). Chlamydial cervicitis can also be associated with infection of 
the urethra. Clinical symptoms of chlamydial urethritis in women include abnormal frequency of 
urinating, painful urination (dysuria) and a high concentration of white blood cells in the urine 
(pyuria) (Bebear and de Barbeyrac, 2009). In 20-40% of the untreated women, the initial 
C. trachomatis infection ascends from the cervix to the endometrium and the fallopian tubes to 
cause endometritis and salpingitis, which leads to the development of pelvic inflammatory 
disease (PID) (Manavi, 2006; Price et al., 2013). The most common clinical symptoms of PID are 
lower abdominal pain, painful intercourse and abnormal vaginal discharge or bleeding. However, 
a significant proportion of women have subclinical PID (Manavi, 2006). If left untreated, PID 
will eventually lead to severe reproductive complications, including tubal factor infertility, 
ectopic pregnancy and chronic pelvic pain (Westrom et al., 1992; Haggerty et al., 2010). The 
chlamydial disease complications are the result of fibrosis and scarring in the reproductive organs 
caused by chronic inflammation. Repeat or multiple infections with C. trachomatis increase the 
likelihood to develop adverse sequelae (Hillis et al., 1997). 
Genital C. trachomatis infection during pregnancy is associated with postpartum PID and a 
number of adverse outcomes of pregnancy such as preterm labor, premature rupture of 
membranes, low birth weight and neonatal death (Andrews et al., 2000; Mårdh, 2002). Moreover, 
pregnant women with genital chlamydial infection may transmit the infection to the infant during 
delivery. The risk of transmission to the newborn through infected genital secretions is high (50-
70%). Approximately 30-50% of infants infected with C. trachomatis develop 5 to 10 days after 
delivery neonatal conjunctivis. At least 50% of newborns with conjunctivitis will also have 
nasopharyngeal infection. In 30% of these infants, chlamydial pneumonia develops after an 
incubation period of 2-3 weeks (Darville, 2005). 
In men, the most common clinical manifestation of urogenital C. trachomatis infection is non-
gonococcal urethritis. In fact, C. trachomatis causes approximately 35-50% of non-gonococcal 
urethritis cases in heterosexual men. Clinical symptoms of chlamydial urethritis may develop 
after 7-21 days of incubation and include dysuria and mild-to-moderate clear or whitish urethral 
discharge (Peipert, 2003). Urethral C. trachomatis infection can ascend from the lower genital 
tract and cause epididymitis, epididymo-orchitis and prostatitis. Epididymitis is an inflammation 
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of the epididymis, a structure on the back of the testicle where sperm is stored. Epididymitis is 
characterized by pain and swelling and palpation may reveal a tender induration of the 
epididymis (Berger et al., 1978; Trojian et al., 2009). Epididymo-orchitis occurs when the 
inflammation spreads from the epididymis to the adjacent testicle and presents as testicular pain 
and swelling (Ness et al., 1997; Trojian et al., 2009). The role of C. trachomatis in prostatitis is 
controversial, but the organism has been detected in up to 35-50% of patients with prostatitis. 
Symptoms in these men included dysuria, painful ejaculation and pelvic pain (Cunningham and 
Beagley, 2008). Inflammation of the testes and the prostate as a consequence of C. trachomatis 
infection may impair the normal functionality of these glands and therefore can have an impact 
on male fertility. However, this issue is still under debate, with some reports arguing no effect on 
male fertility and others reporting altered semen quality. Some studies demonstrated that 
urogenital C. trachomatis infection is associated with a decrease in sperm concentration and 
motility, a higher proportion of sperm abnormalities, altered semen pH and a reduced ejaculate 
volume (Mackern-Oberti et al., 2013). Moreover, C. trachomatis infection may also affect the 
male fertility by directly damaging the sperm (Hosseinzadeh et al., 2001). 
Urogenital C. trachomatis infections have also been associated with reactive arthritis and Reiter‘s 
syndrome, which is a triad of aseptic arthritis, urethritis and conjunctivitis. These conditions 
occur nine times more often in men than in women (Carter and Hudson, 2009). Furthermore, 
chlamydial infection of the genital tract can increase susceptibility to HIV (Plummer et al., 1991; 
Laga et al., 1993). For HIV-infected persons, a concurrent genital C. trachomatis infection may 
increase shedding of the virus and thus facilitate its transmission (Shahmanesh et al., 2009). 
Some studies also observed a positive association between genital tract infection with 
C. trachomatis and cervical cancer (Koskela et al., 2000; Samoff et al., 2005). 
 
5.3.2. LGV serovars 
LGV is an invasive disease with tropism for the lymphatic system (Schachter and Osoba, 1983). 
LGV can be transmitted through vaginal, anal or oral sexual contact. Access to lymphatic vessels 
is gained through microtrauma in the skin or mucous membranes. The clinical manifestations of 
the disease depend on the gender of the patient and the site of inoculation and are traditionally 
divided into three stages (Stary and Stary, 2008).  
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The primary stage involves the site of inoculation, usually the prepuce or glans in men and the 
vulva or vaginal wall in women, where a small, painless papule, which may ulcerate, appears 
after an incubation period of 3-30 days. This lesion heals spontaneously without scarring. It may 
not always occur and frequently passes unnoticed by the patient (Mabey and Peeling, 2002). The 
initial infection can also occur in the urethra, cervix or rectum, producing asymptomatic 
urethritis, cervicitis or proctitis, respectively (Martin-Iguacel et al., 2010). 
The secondary stage emerges some weeks after the onset of the primary symptoms. It involves 
the local lymph nodes draining the site of primary infection or the anus and rectum. The classic 
manifestation of secondary-stage LGV following urogenital exposure is the inguinal syndrome, 
resulting from the spread of inflammation to the inguinal lymph nodes. The inguinal syndrome is 
more common in men, since the lymphatic drainage of the vagina and cervix is to the 
retroperitoneal rather than the inguinal lymph nodes. When the primary infection occurs in the 
rectum, the deep iliac lymph nodes are affected. Therefore, diagnosis of LGV is more difficult in 
women and MSM, since they often have no inguinal symptoms. The inguinal syndrome is 
characterized by the presence of painful inguinal and/or femoral lymphadenopathy, which is 
unilateral in the majority of patients (D‘Aunoy and von Haam, 1939). The presence of inflamed 
and enlarged lymph nodes above and below the inguinal ligament results in the characteristic 
‗groove sign‘ in 10-20% of the patients (Schachter and Osoba, 1983). Small areas of necrosis 
develop in the inflamed lymph nodes, which may enlarge to form stellate abscesses. In one-third 
of the patients, abscesses coalesce and rupture spontaneously, which is accompanied by drainage 
of pus and scarring. If the bacterium entered anorectally or spread via lymphatic vessels from the 
cervix or urethra, the secondary stage manifests as the anorectal syndrome. This is characterized 
by ulcerative proctitis with perirectal lymphadenopathy and rectal discharge, pain and bleeding. 
The secondary stage also often involves systemic symptoms such as fever, malaise and lethargy 
(Mabey and Peeling, 2002; Stary and Stary, 2008).  
Without adequate treatment, a proportion of LGV patients will progress to a tertiary stage with 
chronic inflammation. In this stage, the inflammatory process leads to fibrosis, which can destroy 
the normal structure of the lymph nodes and can obstruct the lymphatic vessels. This can cause 
disfiguring conditions such as genital elephantiasis and esthiomene, which refers to hypertrophic 
enlargement and ulceration of the external genitalia. Rectal involvement can lead to the formation 
of fistulas and strictures (Mabey and Peeling, 2002; Stary and Stary, 2008).  
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5.4. Prevention and treatment 
Uncomplicated chlamydial infections can be treated effectively with antibiotics. In general, 
C. trachomatis infections are resolved by treatment with antibiotics that are able to cross the 
plasma membranes to reach the chlamydial RBs, which are metabolically active and thus most 
susceptible to treatment. Several drugs are effective against C. trachomatis, including the 
tetracyclines (doxycycline and tetracycline), macrolides (erythromycin and azithromycin), 
quinolones (ofloxacin and levofloxacin) and penicillins (amoxicillin) (Guaschino and Ricci, 
2002; Mpiga and Ravaoarinoro, 2006). The current recommended treatment for urogenital 
C. trachomatis infection is azithromycin (1 g, single dose) or doxycycline (100 mg, twice daily 
for 7 days) (WHO, 2003). Both treatments have a similar microbiological cure rate of 97-98% 
(Lau and Qureshi, 2002). There is currently no solid evidence of any in vivo antibiotic resistance 
for urogenital C. trachomatis infection (Schachter and Stephens, 2008; Stamm, 2008; Rekart and 
Brunham, 2008). Although recurrent infections are common, it is unclear if they are due to 
treatment failures (Taylor and Haggerty, 2011). 
Since genital tract infections with C. trachomatis often remain subclinical, the spread of infection 
cannot be successfully controlled by treating only the individuals with clinical symptoms. 
Asymptomatic individuals can be identified through screening programs, but, although this 
approach may be feasible for developed countries, it is likely to be too costly for developing 
countries (Stagg, 1998). Screening at risk populations enables early antibiotic treatment, which 
shortens the duration of infection and reduces infection-associated reproductive sequelae. 
However, despite the realization of Chlamydia screening programs, the number of case rates 
continues to increase. Brunham et al. (2005) reported that following the implementation of a 
Chlamydia control program, the incidence of infection initially decreased, but afterwards returned 
to, and even increased above prescreening levels. It has been suggested that early antibiotic 
treatment interferes with the development of protective immune responses, thereby increasing the 
risk of re-infection. This has been termed the arrested immunity hypothesis (Brunham et al., 
2005; Brunham and Rekart, 2008). Evidence for blunting of protective immunity by early 
antibiotic treatment can also be found in animal models of genital C. muridarum infection (Su et 
al., 1999). 
Vaccination is considered as the most effective approach to control genital C. trachomatis 
infections. A vaccination program would be much cheaper and have a greater impact on 
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controlling C. trachomatis infections worldwide than a screening program or treating infections 
with antibiotics (Stagg, 1998). An ideal vaccine should generate long-lasting and sterilizing 
immunity while avoiding immunopathology and should be effective against the many serovars of 
C. trachomatis. A more feasible goal of a chlamydial vaccine would be to protect individuals, 
especially women, from disease rather than infection. A vaccine that prevents ascending infection 
and reduces shedding would already have a major economic benefit (Hafner et al., 2008). Indeed, 
computer modeling suggests that even a partially efficacious chlamydial vaccination program 
would rapidly reduce the prevalence of genital infection (de la Maza and de la Maza, 1995). 
However, despite the many efforts that have been made in this field, there is currently no vaccine 
against C. trachomatis genital tract infection. 
 
6. Immune response to genital Chlamydia trachomatis infection 
In order to develop an effective vaccine for controlling and preventing C. trachomatis infections, 
it is important to understand the complex immunological mechanisms underlying the protective 
and pathological responses to chlamydial infection (Longbottom, 2003). Protection of the host 
against potential pathogens is provided by a variety of measures that can be grouped into two 
broad categories: innate and adaptive immunity (Figure I-3) (Wira et al., 2005).  
 
6.1. Innate immunity 
The innate immune system consists of antigen-nonspecific defenses that are constitutively present 
and can be rapidly mobilized upon infection. Since the adaptive immune system at mucosal 
surfaces may take days to be activated and effective against pathogens, the innate immune 
responses are essential to prevent and control the invasion of pathogens (Wira et al., 2005). 
The first line of defense against a genital C. trachomatis infection is the mucosal barrier of the 
reproductive tract. The lower female genital tract (vagina and ectocervix) is lined with stratified 
squamous epithelium, while the upper genital tract (endocervix, uterus and fallopian tubes) is 
lined with a single layer of columnar epithelium. Tight junctions between the epithelial cells of 
the upper genital tract maintain the integrity of the mucosal monolayer and restrict transepithelial 
movement of molecules (Quayle, 2002; Wira et al., 2005). The epithelial cells of the female 
reproductive tract also secrete mucus, which provides a protective covering in the cervix and 
vagina, and a barrier to pathogen entrance into the uterus (Quayle, 2002). Moreover, the mucus 
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contains bactericidal and bacteriostatic molecules, such as secretory leukocyte protease inhibitor, 
lysozyme, lactoferrin, zinc and defensins, including human defensin-5 (HD-5) and human β-
defensins 1 to 4 (HBD-1 to HBD-4) (Quayle, 2002; Fahey and Wira, 2002; Ganz, 2003). The 
secretion of defensins may be constitutive or rapidly induced by infection and generally, they 
disturb the microbial membranes by creating pores or affecting permeability (Wira and Fahey, 
2004). Furthermore, the vagina is colonized by bacterial commensal species, which have a 
protective function against genital tract pathogens. Commensals such as the Lactobacillus species 
maintain vaginal acidity by metabolizing glycogen released by vaginal epithelial cells to lactic 
acid. Some Lactobacillus species also produce hydrogen peroxide, which is antimicrobial. 
Vaginal acidity (pH 3.5-5) probably plays a key role in determining the vaginal microbial flora 
and preventing ascending infection of pathogens that grow under more alkaline conditions 
(Hillier, 1999). Indeed, in vitro studies have demonstrated that this low pH prevents growth of 
C. trachomatis and may contribute to a reduction in the bacterial load delivered to the susceptible 
upper genital tract epithelium, although seminal plasma may buffer some of this effect 
(Mahmoud et al., 1995).  
When C. trachomatis EBs are able to pass through the mucosal barrier and establish infection, the 
innate immune effectors provide the next line of defense against the bacteria. The innate immune 
system recognizes microbial structures that are not normally found in the host. It relies on 
receptors that recognize conserved pathogen-associated molecular patterns (PAMPs) found in 
certain groups of microorganisms (Medzhitov and Janeway, 2000). The pattern recognition 
receptors (PRRs) of the host that recognize PAMPs are expressed on innate immune cells, 
including natural killer (NK) cells, monocytes/macrophages, neutrophils and dendritic cells 
(DCs), and epithelial cells. Toll-like receptors (TLRs) form a major group of PRRs that are 
important to initiate the innate immune responses to infection and serve as a link between innate 
and adaptive immunity. TLR2 and TLR4 are shown to be involved in antichlamydial host 
defense. Although chlamydial components such as lipopolysaccharide and heat shock protein 60 
are recognized by TLR4, the intact chlamydial bacteria stimulate innate immune cells 
independently of TLR4. No particular chlamydial molecule has been definitively proven as a 
TLR2 ligand, but there are several candidates (Joyee and Yang, 2008). TLR2 appears to 
colocalize with the intracellular chlamydial inclusion, suggesting that TLR2 is involved in 
signaling from this intracellular location. Examination of the outcomes of genital tract infection 
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with C. muridarum in wild-type mice and mice genetically deficient in TLR2 and TLR4 
confirmed a dominant role for TLR2, compared with TLR4, in the recognition and response to 
chlamydial infection. However, it should be noted that TLR2 and TLR4 signaling are also 
associated with immunopathology during chlamydial genital tract infection (Darville et al., 
2003). Furthermore, it has been suggested that TLR9 plays a role in modulating immune 
responses towards Th1 cellular responses in chlamydial infection (Joyee and Yang, 2008). There 
are also other PRRs that were found to recognize chlamydial PAMPs, such as CD14 (Bas et al., 
2008) or NOD1 (Nucleotide-binding oligomerization domain-containing protein 1) (Welter-Stahl 
et al., 2006; Buchholz and Stephens, 2008). 
Initial C. trachomatis infection of the genital tract epithelial cells causes a cascade of events 
leading to the increased production of pro-inflammatory cytokines and chemokines, including 
interleukin 1 (IL-1), IL-6, IL-8, granulocyte-macrophage colony stimulating factor (GM-CSF) 
and tumor necrosis factor alpha (TNF-α) (Rasmussen et al., 1997; Buchholz and Stephens, 2006). 
This induces an influx of innate immune cells such as NK cells, monocytes/macrophages, 
neutrophils and DCs. These cells then produce more cytokines such as interferon γ (IFN-γ) and 
TNF-α, which impede further chlamydial growth (Carey and Beagley, 2010). The cytokine IFN- 
γ is essential for optimal clearance of genital chlamydial infection (Cotter et al., 1997; Johansson 
et al., 1997a). This cytokine can have a direct physiological effect on chlamydial bacteria, as it 
can inhibit chlamydial intracellular growth through different mechanisms. IFN-γ induces 
tryptophan degradation by increasing host cell expression of the enzyme indoleamine 2,3-
dioxygenase. This is inhibitory for chlamydial growth since most Chlamydiaceae are unable to 
synthesize tryptophan (Kazar et al., 1971; Rothermel et al., 1983; Gupta et al., 1994). IFN-γ also 
induces the expression of inducible nitric oxide synthase (iNOS), which promotes the production 
of bactericidal nitric oxide free radicals (Chen et al., 1996; Igietseme et al., 1997). Furthermore, 
IFN-γ mediated iron deprivation has been suggested to control chlamydial infections (Igietseme 
et al., 1998; Freidank et al., 2001). In addition to its cytotoxic activities, IFN-γ also has an 
immunoregulatory role in chlamydial defense, by its ability to promote T helper (Th) 1-type 
protective immune responses, which, in turn, downregulate non-protective Th2-type responses. 
Moreover, IFN-γ increases the phagocytic activity of macrophages and thus promotes uptake and 
degradation of extracellular chlamydial EBs (Zhong and de la Maza, 1988). 
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Figure I-3: Immune response against C. trachomatis infection in the female genital tract. Innate, 
humoral and cell-mediated immunity act in concert to protect against infection (Hafner et al., 2013).  
 
In addition to secreting cytokines and chemokines, innate immune cells also possess other 
effector mechanisms for mediating innate immunity. Neutrophils and macrophages can eliminate 
bacteria by phagocytosis and subsequent destruction via the release of anti-microbial factors such 
as nitric oxide, superoxide anions and hydrogen peroxide (Wira et al., 2005; Beckett et al., 2012). 
Macrophages and DCs are professional antigen presenting cells (APCs). After internalization of 
pathogens through phagocytosis, they degrade them and present the antigens to T cells via major 
histocompatibility complex (MHC) receptors. This activates the T cells to initiate a cell-mediated 
and/or humoral immune response (Adams and Hamilton, 1984; Banchereau and Steinman, 1998; 
Vasilevsky et al., 2014). Mature DCs produce high levels of IL-12, which favors the 
development of IFN-γ producing Th1 cells (Macatonia et al., 1995; Cella et al., 1996). NK cells 
recognize and kill cells infected with intracellular bacteria, such as C. trachomatis, through 
cytotoxicity and secrete large amounts of IFN-γ (Hook et al., 2004, 2005). Natural killer T (NKT) 
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cells are a unique population of T lymphocytes that act in innate immune responses. These 
cytolytic lymphocytes are able to destroy infected cells without prior sensitization and can rapidly 
secrete large amounts of IFN-γ and/or IL-4 (Godfrey et al., 2000, 2005). These cytokines are 
important for the regulation of Th1 and Th2 responses, respectively (Mosmann and Coffman, 
1989), thus NKT cells are believed to be able to modulate immune responses (Godfrey et al., 
2005; Bendelac et al., 2007). Some studies suggested that NKT cells and NK cells may induce 
protective Th1 immunity, probably by modulating DC function (Joyee et al., 2010; Jiao et al., 
2011; Wang et al., 2012). 
 
6.2. Adaptive immunity 
An effective protective immune response to C. trachomatis requires not only innate immunity, 
the first line of defense against infection, but is highly dependent upon adaptive immunity. 
Adaptive immunity encompasses pathogen-specific defense mechanisms that can be divided into 
two major branches: humoral and cell-mediated immunity. 
 
6.2.1. Humoral immunity 
The role of humoral immune responses in protection against genital C. trachomatis infection is 
still a matter of debate. In women, the amount of IgA in cervical secretions was found to correlate 
inversely with the amount of C. trachomatis recovered from the cervix (Brunham et al., 1983). 
However, high titers of C. trachomatis-specific serum antibodies did not correlate with resolution 
of infection in women, but with increased severity of post-infection sequelae, such as tubal 
infertility (Punnonen et al., 1979). In the guinea pig model, used to study human genital 
chlamydial infections, antibodies are essential to control both primo-infection and re-infection 
with C. caviae (Rank et al., 1979; Rank and Barron, 1983b). In the C. muridarum mouse model, 
on the other hand, B cells are not required to eradicate a primo-infection, since the resolution of 
primo-infection in B cell deficient mice is equivalent to that of immunocompetent wild-type mice 
(Su et al., 1997; Johansson et al., 1997b). However, Morrison et al. (2000) demonstrated that B 
cell deficient mice depleted of CD4
+
 T cells are incapable of resolving re-infection with 
C. muridarum, whereas wild-type mice depleted of CD4
+
 T cells successfully clear re-infection, 
although the course of infection is slightly prolonged. This B cell mediated protection is due to 
antibody production because passive transfer of immune serum or Chlamydia-specific 
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monoclonal antibodies into B cell deficient mice deprived of CD4
+
 T cells rescues the ability of 
these mice to control re-infection (Morrison and Morrison, 2005). Therefore, the data obtained 
from the C. muridarum mouse model strongly support an important role for antibodies in 
resistance to chlamydial genital tract re-infection. How B cells and/or antibodies contribute to 
immunity to re-infection is not yet elucidated, but several mechanisms can be proposed. 
Antibodies can neutralize chlamydial infectivity and reduce genital tract colonization by blocking 
attachment of chlamydial EBs to epithelial cells (Morrison and Caldwell, 2002). In vitro studies 
have shown that antibodies to chlamydial MOMP can block infection via neutralization (Peeling 
et al., 1984; Zhang et al., 1987; Pal et al., 1997). Antibodies may also opsonize free chlamydial 
EBs or infected cells which enhances the uptake and destruction by professional phagocytes, as 
they can bind to the Fc part of antibodies with their Fc receptor. However, this mechanism is 
probably more important in preventing dissemination of chlamydial bacteria than in resolving 
infection (Morrison and Caldwell, 2002). Antibodies can also contribute to the resolution of 
intracellular chlamydial infection by an antibody-dependent cellular cytotoxicity (ADCC) 
mechanism. The binding of specific antibodies to chlamydial antigens expressed on the surface of 
infected cells could target these cells for destruction by macrophages or NK cells via Fc receptor-
dependent ADCC. Furthermore, in the case of Fc receptor-mediated uptake of chlamydial 
antigens into APCs, the antigen presentation to Th1 cells is enhanced (Moore et al., 2002). 
B cells can also participate in an antibody-independent manner in the secondary memory 
response. B cells are important APCs in the recall of memory Th cells and promote the clonal 
expansion of these antigen-specific cells (van Essen et al., 2000; Linton et al., 2000). 
 
6.2.2. Cell-mediated immunity 
Studies in experimental animal models have clearly established that cell-mediated immunity 
plays a crucial role in immune protection against genital C. trachomatis infection. It was 
demonstrated that nude mice, which lack T cells, are unable to control chlamydial infection and 
that adoptive transfer of Chlamydia-specific CD4
+
 or CD8
+
 T cells allows these mice to 
successfully control infection (Rank et al., 1985; Ramsey and Rank, 1991). Furthermore, both 
T cell subsets are detected at the site of C. trachomatis infection in humans and animal models 
(Van Voorhis et al., 1996; Kelly et al., 2000; Rank et al., 2000; Johansson and Lycke, 2001). In 
the C. muridarum mouse model, protection seems to be mediated by IFN-γ-producing CD4+ Th1 
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cells (Morrison and Caldwell, 2002). Gene knockout studies in mice have shown that mice 
lacking CD4
+
 T cells or IFN-γ are unable to control infection (Su and Caldwell, 1995; Johansson 
et al., 1997a; Wang et al., 1999; Morrison et al., 2000) and that immunity can be restored by 
adoptive transfer of C. muridarum-specific CD4
+
 Th1 cells, but not Th2 cells (Hawkins et al., 
2002). 
Chlamydia-specific CD4
+
 T cells are activated after recognition of chlamydial antigens that are 
presented on MHC class II molecules by APCs. Activated CD4
+
 T cells are important producers 
of effector cytokines. The Th1 subpopulation produces IFN-γ, which is essential for optimal 
clearance of genital chlamydial infection (Cotter et al., 1997; Johansson et al., 1997a; Perry et al., 
1997; Ito and Lyons, 1999). The Th2 cytokines, including IL-4, IL-5, IL-6, IL-10 and IL-13, on 
the other hand, do not appear to protect against chlamydial infection and may even indirectly 
enhance bacterial load by inhibiting the development of protective Th1 responses (Roan and 
Starnbach, 2008). Indeed, IL-10 has been associated with susceptibility to chlamydial infection 
and immunopathology (Igietseme et al., 2000; Mozzato-Chamay et al., 2000). In addition to 
cytokine production, CD4
+
 T cells are also crucial activators of B cells, CD8
+
 T cells and other 
inflammatory cells by contact-dependent or cytokine-mediated processes (Loomis and Starnbach, 
2002). Consequently, mice deficient in CD4
+
 T cells have defects in multiple arms of adaptive 
immunity. This may in part explain why mice deficient in CD4
+
 T cells are more susceptible to 
genital C. muridarum infection than mice lacking B cells or CD8
+
 T cells (Morrison et al., 1995; 
Roan and Starnbach, 2008).  
CD8
+
 T cells recognize Chlamydia-infected cells that present antigens in the context of MHC 
class I molecules (Igietseme et al., 1994; Starnbach et al., 1994; Beatty and Stephens, 1994). 
Only antigens that have access to the host cell cytoplasm can be processed and bound to MHC I 
molecules by infected cells. Chlamydiaceae remain confined to the inclusion throughout their 
replication cycle, but some chlamydial proteins have access to the host cell cytosol, including 
inclusion membrane proteins and substrates of the chlamydial type III secretion system (Loomis 
and Starnbach, 2002). Activated CD8
+
 T cells can directly kill infected cells by lysis and secrete 
effector cytokines, such as IFN-γ. In the C. muridarum mouse model, CD8+ T cells are not 
essential for clearance of infection as mice deficient in CD8
+
 T cells or cytolytic effector 
functions resolve infection as efficiently as wild-type mice (Morrison et al., 1995, 2000; Perry et 
al., 1999a). Nevertheless, some Chlamydia-specific CD8
+
 T cell lines are shown to confer a level 
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of protective immunity to naïve mice, but protection was relatively modest and mediated by IFN-
γ rather than by cellular cytotoxicity (Igietseme et al., 1994; Starnbach et al., 1994; Lampe et al., 
1998). Furthermore, it has been suggested that antigen-specific cytotoxic CD8
+
 T cells may 
contribute to Chlamydia-induced pathology as lysis of infected cells occurs generally late in the 
chlamydial replication cycle, when the majority of organisms have differentiated into infectious 
EBs (Morrison and Caldwell, 2002). Although CD8
+
 T cells are not critical for chlamydial 
elimination and may even contribute to chlamydial sequelae, they nonetheless may contribute to 
protection by IFN-γ secretion (Wizel et al.). 
It should be noted that most aspects of innate and adaptive immunity in the female genital tract 
vary with the release of ovarian steroid hormones over the menstrual cycle, including the 
secretion of protective factors, the levels of cytokines, the expression of TLR genes and the 
distribution of immune cells and antigen presentation in the genital tissues (Hafner et al., 2013). 
 
7. Animal models of Chlamydia trachomatis female genital tract infection 
Animal models are indispensable for the study of C. trachomatis infections and the development 
and evaluation of candidate vaccines. Various animal models have been developed, including 
mouse (Barron et al., 1981; Tuffrey and Taylor-Robinson, 1981), guinea pig (Mount et al., 1972, 
1973), non-human primate (Patton et al., 1983, 1987a), pig (Vanrompay et al., 2005), rat 
(Kaushic et al., 1998) and rabbit models (Patton et al., 1982). Here, the most commonly used 
animal models to study female genital tract infections with C. trachomatis will be reviewed, 
namely the mouse, guinea pig and non-human primate model. Additionally, the more recently 
developed pig model will be discussed.  
 
7.1. Mouse models 
Mice are the most commonly used animals to study genital chlamydial infections. The 
advantages of the mouse model are their small size, ease of handling, availability in sufficient 
amounts and low cost. Moreover, there are many well-characterized inbred and knockout mouse 
strains available (Vanrompay et al., 2006). The female mouse genital tract is susceptible to 
infection with both C. muridarum (Barron et al., 1981) and C. trachomatis (Tuffrey and Taylor-
Robinson, 1981), which has resulted in the establishment of two murine models: the 
C. trachomatis mouse model and the C. muridarum mouse model.  
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7.1.1. C. muridarum mouse model  
C. muridarum, previously known as C. trachomatis mouse pneumonitis biovar or MoPn, is a 
natural mouse pathogen that causes pneumonitis and was originally isolated from the lungs of 
mice (Nigg, 1942). Intravaginal inoculation of C. muridarum in mice results in a genital tract 
infection that closely resembles acute genital C. trachomatis infections in women (Barron et al., 
1981). The primary site of infection is the cervical epithelium. Subsequently, the infection 
ascends to the upper genital tract tissues (uterine horns and oviducts), which frequently leads to 
hydrosalpinx, fibrosis and infertility, which are also common post-infection sequelae in women 
(de la Maza et al., 1994; Morrison and Caldwell, 2002; Shah et al., 2005). Furthermore, a genital 
C. muridarum infection early in gestation can result in premature termination of murine 
pregnancy (Pal et al., 1999).  
Mice generally resolve a genital C. muridarum infection without antimicrobial therapy in 
approximately 4 weeks and develop long-lived adaptive immunity that partially protects against 
re-infection (Barron et al., 1981; Morrison et al., 1995). Primary infection with C. muridarum not 
only yields partial protection against re-infection with the homologous Chlamydia strain, but 
also, to a lesser degree, partially protects against heterotypic challenge with different 
C. trachomatis serovars. Mice that are re-infected have secondary infections of shorter duration 
and with fewer bacterial shedding than primary infection (Ramsey et al., 1999).  
The initial inflammatory response to a genital C. muridarum infection in mice is characterized by 
infiltration of myeloid cells in the genital tract tissues. Macrophages and lymphocytes, including 
B cells, CD4
+
 T cells and CD8
+
 T cells, infiltrate as infection resolves. CD4
+
 T cells predominate 
throughout the course of infection and form perivascular clusters that persist in the genital tract 
after resolution of infection (Morrison and Morrison, 2000). CD4
+
 T cells are essential for 
protective immunity in the C. muridarum mouse model (Ramsey and Rank, 1991; Igietseme et 
al., 1993). IFN-γ and IL-12, both Th1-type cytokines, also contribute to protection against 
infection (Rank et al., 1992; Cotter et al., 1997; Perry et al., 1997). However, the impact of IFN- 
γ on C. muridarum is not as powerful as it is on C. trachomatis (Morrison, 2000). CD8+ T cells 
are not required for resolution of primary infection or immunity to re-infection, but can contribute 
to protection via IFN-γ release (Igietseme et al., 1994). However, it was recently demonstrated 
that CD8
+
 T cell production of tumor necrosis factor alpha (TNF-α) promotes oviduct pathology 
following primary murine genital tract infection (Murthy et al., 2011). Antibodies and B cells are 
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also not necessary for eradication of primary infection (Ramsey et al., 1988; Su et al., 1997), but 
play an important role in resistance to chlamydial re-infection (Morrison et al., 2000). Moreover, 
Farris et al. (2010) showed that both CD4
+
 T cells and antibodies were required to induce an 
optimal protective immune response following major outer membrane protein (MOMP) 
vaccination. 
In the C. muridarum mouse model, the course and outcome of infection can vary depending on 
the mouse strain studied, the inoculating dose, the age of the animal and the hormone levels 
present. In general, C3H mouse strains show a more severe course of disease and a higher rate of 
infertility than other strains (de la Maza et al., 1994; Darville et al., 1997; Bernstein-Hanley et 
al., 2006). Maxion et al. (2004) showed that the infectious dose of C. muridarum affects the 
course of infection and the ascension of bacteria in the reproductive tract. Pal et al. (2001) 
demonstrated that young mice are more susceptible to genital C. muridarum infections than older 
animals. The oestrous cycle appears to play a significant role in the pathogenesis of infection. In 
a study of Pal et al. (1998), mice were less prone to develop an upper genital tract infection 
during the follicular phase than during the luteal phase. 
Usually, mice are infected by intravaginal challenge with C. muridarum. An alternative, 
infrequently used approach is to challenge the mice directly in the upper genital tract, mostly the 
ovarian bursa, which increases the incidence of pathology of these tissues (Swenson et al., 1983). 
The main concern with the latter approach is that it bypasses the natural route of infection 
(Swenson et al., 1983; Farris and Morrison, 2011). 
 
7.1.2. C. trachomatis mouse model  
As mentioned earlier, mice can also be genitally infected with human C. trachomatis serovars 
(Tuffrey and Taylor-Robinson, 1981). Intravaginal inoculation with C. trachomatis typically 
produces a mild genital tract infection that resolves relatively quickly and is mostly unable to 
ascend to the upper genital tract. A higher number of infectious units is required to establish 
infection with C. trachomatis than with C. muridarum. Additionally, the peak bacterial load is 
approximately 2 log scales lower and there is less genital tract inflammation in mice inoculated 
with human serovars than in those infected with C. muridarum (Ito et al., 1990; Darville et al., 
1997; Ramsey et al., 2000). In mice, experimental C. trachomatis infections cause post-infection 
sequelae, such as hydrosalpinx and infertility, only when high doses are inoculated directly into 
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the uterus, uterine horns or ovarian bursa (Tuffrey et al., 1986, 1990; Gondek et al., 2012; 
Carmichael et al., 2013), whereas infection by vaginal inoculation normally resolves without 
complications (Ito et al., 1990; Darville et al., 1997; Ramsey et al., 2000). However, Sturdevant 
et al. (2010) demonstrated that frameshift mutations in a single genetic locus (CT135) 
significantly change the in vivo pathogenicity of a human C. trachomatis strain for the female 
mouse genital tract. Intravaginal inoculation with a mutant of their C. trachomatis strain in innate 
immunity-deficient C3H/HeJ mice produced a naturally ascending infection which resulted in 
salpingitis. Their findings could contribute to the improvement of the C. trachomatis mouse 
model (Sturdevant et al., 2010). 
Studies examining the protective immune responses in the C. trachomatis mouse model have 
been contradictory. It has been demonstrated that strong adaptive immune responses are 
generated when mice are infected with C. trachomatis (Brunham et al., 2000; Brunham and Rey-
Ladino, 2005; Hafner et al., 2008), but it has also been shown that these infections can resolve in 
the absence of adaptive immunity (Tuffrey et al., 1982; Perry et al., 1999b), indicating that 
murine innate immune responses alone are able to eradicate the infection. Morrison et al. (2011) 
evaluated infection in female mice in the presence and absence of CD4
+
 T cells. In contrast to 
C. muridarum infection, C. trachomatis infection was unaltered in the absence of CD4
+
 T cells. 
Mice infected with C. trachomatis developed protective immunity to re-challenge, but unlike 
C. muridarum infection, optimum resistance required multiple infectious challenges, despite the 
generation of adaptive serum and local chlamydial specific immune responses (Morrison et al., 
2011). In contrast to intravaginal inoculation, intrauterine inoculation with C. trachomatis in mice 
results in a robust CD4
+
 T cell response that is sufficient but necessary to clear the infection. 
Moreover, it provides for protection against re-infection (Gondek et al., 2012). Ramsey et al. 
(1999) demonstrated that primary infection of mice with C. trachomatis serovar E may lead to 
partial protective immunity against challenge with homotypic or heterotypic human strains, as 
shown by reduced chlamydial shedding and a shortened infection course. However, homotypic 
secondary challenge with serovar E may also result in a significant rate of infertility, while 
heterotypic challenge with human serovars does not aggravate pathological outcome (Ramsey et 
al., 2000). 
In the C. trachomatis mouse model, a number of infection characteristics appear to differ 
between C. trachomatis strains (Ito et al., 1990; Carmichael et al., 2013). This may explain the 
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serovar prevalence among human clinical isolates, in particular for the most (serovars D and E) 
and least (serovars H and I) prevalent serovars (Ito et al., 1990). Like C. muridarum infection, 
C. trachomatis genital infection in mice is highly dependent on the mouse strain used, with C3H 
mice being more susceptible to infection than other strains (Tuffrey et al., 1986; Darville et al., 
1997; Ramsey et al., 2000; Lyons et al., 2005b). 
 
7.1.3. Comparison of the two mouse models 
In both murine models, mice are generally pretreated with progesterone in order to induce 
prolonged diestrus. This enhances initial infection rate of the genital epithelium as it increases the 
number of target cells available for chlamydial infection (Tuffrey and Taylor-Robinson, 1981). 
Yet, progesterone pretreatment alters the hormonal balance and the ensuing immunological state, 
making evaluation of any native hormonal contribution to the disease process impossible (Kita et 
al., 1989). However, the elimination of the variability of the estrous cycle and its potential effect 
on the infection is often desired in animal studies. Although progesterone pretreatment is 
frequently used in both models, it is not essential for infection of mice with C. muridarum, while 
the C. trachomatis mouse model is highly dependent on progesterone (Tuffrey and Taylor-
Robinson, 1981; Ramsey et al., 1999). 
There are remarkable differences in immunity and pathogenesis between the C. muridarum and 
C. trachomatis mouse model, but it is difficult to define which model best replicates chlamydial 
infection, pathogenesis and immunity in women (Morrison et al., 2011). First, a shortcoming of 
the C. muridarum model is that this Chlamydia species is not a naturally occurring human 
pathogen. Then again, the genomes of C. muridarum and C. trachomatis serovar D are 
remarkably similar in gene content and order, as well as in the presence of putative virulence 
factors (Stephens et al., 1998; Read et al., 2000; Belland et al., 2001). An important difference 
between both species is the presence of a tryptophan operon, which is present in the genome of 
C. trachomatis but not in C. muridarum (Perry et al., 1999b; Nelson et al., 2005). Human genital 
C. trachomatis strains encode a functional tryptophan synthase enzyme (trpRBA), which possibly 
uses exogenous indole supplied by cocolonizing microbes of the genital tract to evade IFN-γ 
mediated indole 2,3-dideoxygenase (IDO) expression and thus tryptophan starvation (Nelson et 
al., 2005). However, IFN-γ does not induce IDO production in mice, it induces GTPases, which 
might sensitize Chlamydia to tryptophan starvation, possibly by GTP depletion (Tietzel et al., 
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2009). Thus, GTPases are important endline effectors of an IFN-γ response in mice. However, 
Chlamydiaceae produce cytotoxins, which target GTPases and thus assist the bacterium in 
circumventing tryptophan starvation by GTP depletion (Nelson et al., 2005; Tietzel et al., 2009). 
Here, we can find another important difference between C. trachomatis and C. muridarum. 
C. trachomatis has a degraded cytotoxin, mostly non-functional, although differences in 
functionality at the serovar level have been described (Carlson et al., 2004). C. muridarum has 
three paralogous cytotoxin copies (Lo et al., 2012) and produces functional cytotoxins. Since 
C. muridarum and C. trachomatis show a difference in response to IFN-γ (Morrison, 2000), a 
cytokine which plays an important role in the early clearance of Chlamydia from the genital tract 
(Johansson et al., 1997a), both species will probably also differ in response to other cytokines. 
Therefore, it is argued that investigating cytokine profiles in the C. trachomatis mouse model is 
potentially more clinically relevant than in the C. muridarum model (Morre et al., 2000). Second, 
C. muridarum is much more virulent in mice than C. trachomatis. The developmental cycle of 
C. muridarum is more rapid, its duration being approximately half that of C. trachomatis, and 
C. muridarum is more prolific (Morre et al., 2000; Lyons et al., 2005a). However, the pathology 
of the upper genital tract of C. muridarum-infected mice is comparable to that of women with 
post-chlamydial infection sequelae (de la Maza et al., 1994; Shah et al., 2005). This similarity in 
pathogenesis and the strong adaptive immune response generated after infection make it a useful 
animal model for the study of Chlamydia pathogenesis and protective immunity (Morrison and 
Caldwell, 2002). But the C. muridarum model mimics only acute phases of human 
C. trachomatis infections, not the chronic phases responsible for disease in humans (Brunham 
and Rey-Ladino, 2005). Therefore, the appropriateness of the C. muridarum mouse model for the 
study of genital C. trachomatis infections in women has been questioned (Morre et al., 2000; 
Lyons et al., 2005a). Lyons et al. (2005a) argued that infection of mice with C. trachomatis 
mimics in many ways both the course and outcome of infection in most women: an asymptomatic 
and self-limiting infection that only rarely results in severe upper genital tract sequelae. However, 
the C. trachomatis mouse model also doesn‘t allow development of the chronic infections 
observed in humans (Coers et al., 2011) and upper genital tract pathology can hardly be produced 
when mice are vaginally infected with C. trachomatis (Ito et al., 1990; Darville et al., 1997; 
Ramsey et al., 2000). 
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7.2. Primate models: pig-tailed macaque 
Several species of non-human primates, including the marmoset (Johnson et al., 1980), grivet 
(Ripa et al., 1979), baboon (Thygeson and Mengert, 1936; Bell et al., 2011) and pig-tailed 
macaque (Patton et al., 1983, 1987a), have been used as potential models to study genital 
C. trachomatis infections. The frequently used pig-tailed macaque model, developed by Patton et 
al. (1983, 1987a), will be discussed here.  
The pig-tailed macaque (Macaca nemestrina) is a preferred primate model for genital chlamydial 
infections for following reasons. First, the anatomy and physiology of the female reproductive 
tract are similar to those in humans. Likewise women, they have a 28- to 30-day menstrual cycle 
and their vaginal microflora also closely resembles that of women (Patton et al., 1996, 2009). 
Second, pig-tailed macaques have a relatively quiet temperament and an ideal size, since they are 
large enough for most procedures but still manageable (Patton et al., 2009; Miyairi et al., 2010). 
Third, this macaque species is naturally susceptible to genital tract infection with human biovars 
of C. trachomatis and there is no need to pretreat the animals with for instance hormones to 
influence the infection (Patton et al., 2009).  
Patton et al. (1983, 1987a) developed two models in the pig-tailed macaque: an in situ model and 
a subcutaneous pocket model. In the in situ model, macaques are infected with C. trachomatis by 
cervical and/or intratubal inoculation to produce cervicitis and salpingitis (Patton et al., 1983, 
1990; Patton, 1985; Wolner-Hanssen et al., 1991). The experimentally induced chlamydial 
disease in macaques is highly similar to that in humans. Repeated C. trachomatis salpingeal 
infections were shown to cause extensive tubal scarring, chronic salpingitis and distal tubal 
obstruction, which is similar to the development of PID in women (Patton et al., 1987b). The in 
situ pig-tailed macaque model thus provides for an attractive animal model to study the 
pathogenesis and treatment of Chlamydia-induced PID (Patton et al., 1997, 2005).  
The subcutaneous pocket model is established by autotransplantation of salpingeal and/or 
endometrial tissues (Patton et al., 1987a, 1989). Briefly, segments of the oviducts (fimbria, 
ampulla, isthmus) and/or endometrium are removed, cut into small pieces and implanted 
subcutaneously into individual pockets made on the anterior abdominal wall of the macaque. The 
implants become vascularized and are surrounded by a connective tissue capsule. As many as 30 
pockets, well established and separated from each other, can easily be made on the abdomen of 
each animal. The transplanted tissues have been shown to be susceptible to infection with 
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C. trachomatis as indicated by re-isolation of the organism. Inoculation of the bacteria into the 
pockets produces acute infection similar to acute salpingitis or endometritis in macaques infected 
in the intact genital tract.  
In both the in situ and the pocket model, systemic and local antibody responses develop after 
infection (Patton et al., 1983, 1987a; Patton, 1985; Patton and Kuo, 1989). Van Voorhis et al. 
(1997) showed that, in both models, Th1-like cytokines were induced by single and repeated 
chlamydial infection of salpingeal tissues. The models were also similar with respect to 
histopathology, with a predominantly mononuclear infiltration mainly composed of CD8
+
 T cells 
and with lymphoid follicle formation. Both models showed evidence of progression to fibrosis. 
The similarity of their results validates the subcutaneous pocket model for the study of 
histopathology and immunopathology of C. trachomatis induced salpingitis.  
The advantage of the pocket model is that samples from a single macaque can be taken at 
multiple time points, which increases the yield of information from each macaque and conserves 
valuable animals (Van Voorhis et al., 1997). Moreover, sampling requires only minimal surgical 
intervention (Miyairi et al., 2010). Therefore, this model is ideal to study the kinetics of infection 
and the immune responses and to screen multiple antigens for vaccine development (Patton et al., 
1989). However, the intact reproductive tract and thus the in situ model are still necessary to 
investigate pathogenesis of PID and infertility. Also, the natural progression of chlamydial 
infections cannot be followed in the pocket model (Bell et al., 2011).  
Although macaques are a very good model for human chlamydial disease, the use of this model is 
not without limitations. There are ethical considerations as well as practical disadvantages (high 
costs, adequate facilities, expertise) inherent in primate models, which argue against the 
widespread use of this animal model (Coers et al., 2009; Bell et al., 2011). 
 
7.3. Guinea pig models 
Another model for chlamydial genital infections is the guinea pig infected with the C. caviae 
strain guinea pig inclusion conjunctivitis (GPIC). GPIC is a natural guinea pig pathogen which 
causes conjunctivitis (Murray, 1964). Experimental GPIC infection of the guinea pig  genital tract 
leads both in male and female subjects to an infection that closely resembles a genital 
C. trachomatis infection (Mount et al., 1972, 1973). GPIC mainly infects superficial epithelial 
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cells of the cervix (Barron et al., 1979), but infection frequently ascends to the endometrium and 
oviducts, which can result in endometritis and/or salpingitis (Rank and Sanders, 1992). 
An important advantage of this model is that the genital infection can be transmitted sexually 
(Mount et al., 1973). The sexually transmitted infective dose of Chlamydia in guinea pigs has 
even been determined (Rank et al., 2003). Moreover, perinatal transmission is possible and 
causes, likewise human C. trachomatis infections, conjunctivitis in newborn guinea pigs (Mount 
et al., 1972).  
Next, guinea pigs are a suitable animal model for the study of hormonal influences on genital 
chlamydial infection since their female reproductive system closely resembles that of humans. 
Female guinea pigs have a 15-17 day oestrus cycle, comparable to the 28-day menstrual cycle in 
humans. Also, female guinea pigs and humans both are spontaneous ovulators and have an 
actively secreting corpus luteum (Sisk, 1976; Alexander, 1979). To this respect, it was shown that 
estradiol, but not progesterone, makes guinea pigs more susceptible to chlamydial infections 
(Rank et al., 1982; Pasley et al., 1985). Human surveys show that estradiol has the same effect in 
women (Sweet et al., 1986; Agrawal et al., 2008).  
In guinea pigs, both humoral and cell-mediated immunity are required for resolution of infection 
and immunity to re-infection (Rank et al., 1979, 1989; Rank and Barron, 1983a). The immunity 
to re-infection that occurs in the animals is only short lasting, which is also analogous to humans 
(Rank et al., 1988). 
As already mentioned, the GPIC guinea pig model closely resembles disease following 
C. trachomatis infection in humans and is therefore suitable to evaluate potential vaccine 
candidates (Rank et al., 1990; Batteiger et al., 1993; Andrew et al., 2011).  
 
7.4. Pig model 
Vanrompay et al. (2005) evaluated the pig as a large animal model for studying C. trachomatis 
genital infections. There are several reasons for the selection of the pig as a model. First, pigs are 
physiologically and genetically closely related to humans (Bray et al., 2003; Tuggle et al., 2003). 
Second, it was shown that the majority of genes expressed in the major porcine female 
reproductive tissues are ubiquitously expressed in human genital tissues (Tuggle et al., 2003). 
Dawson et al. (2013) performed a comparative analysis of the porcine, murine and human 
immune systems. They found that approximately 80% of the examined parameters were more 
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similar between pigs and humans than between mice and humans. Third, pigs are naturally 
susceptible to infection with C. abortus, C. pecorum, C. psittaci and C. suis. The latter species is 
phylogenetically highly related to C. trachomatis. Finally, multiple samples of one tissue can be 
obtained because of their larger dimensions and pigs are practically and ethically more 
convenient for use as laboratory animals than non-human primates. However, using pigs as 
laboratory animals is more expensive and more complicated than using rodents, which limits the 
number of pigs per group. Therefore, the pig model is not appropriate for basic studies requiring 
large numbers of animals.  
Vanrompay et al. (2005) demonstrated that intravaginal inoculation of 16-week-old specific 
pathogen free (SPF) pigs with a 50% tissue culture infective dose (1 x 10
8
 cells) of 
C. trachomatis serovar E strain Bour or strain 468 can lead to an ascending infection. Both strains 
replicated in the superficial epithelial cervical and uterine layers, which are the specific target 
sites for a C. trachomatis genital infection in women. Inflammation and pathology occurred at the 
replication sites and the bacteria could trigger a humoral immune response (Vanrompay et al., 
2005). There was no need to pretreat the pigs with hormones to enhance the infection. Pigs do not 
have a real anestrous phase like that of mice, but have a period of ovarian quiescence from 13 
weeks of age until 26 weeks of age which can be considered as an anestrous condition. Therefore, 
their study demonstrated that pigs may be useful to study the pathology, pathogenesis and 
immune response of genital C. trachomatis infections. 
Schautteet et al. (2011b) validated the pig model for screening vaccine candidates against genital 
chlamydial infections. Two recombinant protein vaccines based on the Polymorphic membrane 
protein G (PmpG) or the Secretion and cellular translocation protein C (SctC) were tested, 
representing a promising and less promising candidate vaccine antigen, respectively. As 
expected, protective immunity against an experimental genital C. trachomatis infection was 
higher in PmpG-immunized pigs as compared to SctC-immunized pigs. 
The pig model was also successfully used to test a C. trachomatis DNA vaccine (Schautteet et 
al., 2011a, 2012). Mucosal C. trachomatis DNA vaccination induced significant protection 
against genital C. trachomatis challenge although the infection could not be eradicated. 
Intradermal immunization was significantly less efficient in protecting experimentally infected 
pigs. Protection of the pigs against infection was correlated with efficient T cell priming and 
significantly higher serum IgA titers following primo-vaccination. 
38 Chapter I 
Pigs experimentally infected with their natural pathogen C. suis are difficult to use as an animal 
model for human C. trachomatis infection as: 1) C. suis induces reproductive failure in sows, 
characterized by discrete vulval discharge and a decrease in conception rate following artificial 
insemination, rather than tubal infertility and PID, 2) we need more knowledge on the pathology 
and pathogenesis of genital C. suis infections in pigs. 
 
7.5. Conclusion 
None of the animal models used to study genital C. trachomatis infection perfectly mimics the 
anatomy, histology and endocrinology of the human reproductive system or the pathogenesis and 
immune responses occurring during a human genital C. trachomatis infection. Non-human 
primate models resemble the human disease most closely, but their use is complicated by ethical, 
financial and practical issues. Working with mice is comparatively simple and inexpensive, 
making them the most commonly used animals to study genital chamydial infections. However, 
results obtained in mouse studies cannot always straightforward be extrapolated to the human 
disease.  Guinea pig models have several advantages over the mouse models, such as the higher 
similarity of their female reproductive system to that of humans. Pigs are physiologically and 
genetically more closely related to humans than rodents and are practically and ethically more 
convenient for use as laboratory animals than non-human primates. Therefore, the pig model 
could be an intermediate animal model between rodents and non-human primates or even a 
substitute for the non-human primate models.  
As already mentioned, no single animal model for chlamydial genital infection can mimic exactly 
what occurs in humans, but each model reflects some aspects of human disease. Therefore, it is 
crucial to identify the most appropriate animal model for studying a specific aspect of genital 
C. trachomatis infection. Figure I-4 summarizes the advantages and disadvantages of the mouse, 
guinea pig, non-human primate and pig models to study female genital tract infection with 
C. trachomatis. The mouse is the preferred model for immunological studies because of the 
abundant availability of immunological reagents and knockout mouse strains. The pig-tailed 
macaque is an ideal model to study the pathogenesis and treatment of Chlamydia-induced PID. In 
theory, the pig-tailed macaque model is also appropriate for studying pathology, hormonal 
influences on infection and infection in the male genital tract. In practice, however, non-human 
primates are not suited for studies on the basic aspects of C. trachomatis infection. The guinea 
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pig is appropriate to investigate pathogenesis, pathology, effects of reproductive hormones on 
infection, infection of males and sexual transmission of infection. The pig model is also useful to 
study pathology and pathogenesis. Of course, the selection of the most appropriate animal model 
is mostly not straightforward and a detailed discussion on this topic is not the aim of this review. 
 
 
Figure I-4: Advantages and disadvantages of the mouse, guinea pig, nonhuman primate and pig 
models to study Chlamydia trachomatis female genital tract infection. 
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8. Nucleic acid vaccination 
8.1. General principle, advantages and disadvantages 
8.1.1. DNA vaccination 
DNA vaccination entails the delivery of plasmid DNA (pDNA) encoding a vaccine antigen to 
mammalian cells (Figure I-5). A DNA vaccine consists of a foreign gene of interest cloned into a 
eukaryotic expression vector. The vector contains all the information required to both propagate 
the plasmid in host strains of E. coli and express the desired gene in eukaryotic cells. An origin of 
replication and an antibiotic resistance gene allow the amplification and selection of plasmid 
DNA during the prokaryotic phase. The eukaryotic transcription unit contains a eukaryotic 
promoter. Viral promoters derived from cytomegalovirus (CMV) or Rous sarcoma virus (RSV) 
are often used as they provide high levels of gene expression in a wide range of host cells. 
Furthermore, a polyadenylation sequence is incorporated to ensure the stability of the transcribed 
mRNA (Shroff et al., 1999; Dunham, 2002).  
After delivery of the DNA vaccine to the host, the plasmid is taken up by host cells and 
transcribed to mRNA, from which the vaccine proteins are then translated. Since the antigens are 
produced within the host cells, the normal transcriptional and translational pathways of the host 
are used. As such, the expressed antigens have their authentic post-translational modifications 
and tertiary structure and, consequently, the conformational epitopes required for protection are 
effectively represented. The proteins are recognized as foreign by the host immune system and 
elicit an immune response. The exact mechanism by which DNA vaccines induce an immune 
response in the host is still disputed. Nevertheless, professional APCs, especially DCs, are shown 
to play a crucial role in the generation of immune responses by DNA vaccines. APCs may be 
primed either by direct transfection or indirectly by acquiring antigens shed by other transfected 
host cells and/or by phagocytosing apoptotic transfected cells. Activated APCs are able to 
stimulate both MHC class I and MHC class II restricted responses, eliciting cell-mediated as well 
as humoral immune responses (Dunham, 2002). 
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Figure I-5: Principle of DNA vaccination (Dufour, 2001) 
 
One of the main advantages of DNA vaccination compared to the more conventional vaccination 
methods is that the vaccine antigens are produced de novo by the host cells. Therefore, DNA 
vaccines mimic natural infection with viruses and intracellular bacterial pathogens and are able to 
stimulate both branches of the adaptive immune system. Thus, DNA vaccines act similarly to live 
attenuated vaccines, but are devoid of the risk of reversion to a virulent phenotype and adverse 
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side-effects encountered with these conventional vaccines (Shroff et al., 1999; van Drunen Littel-
van den Hurk et al., 2000; Héchard and Grépinet, 2004). Another advantage of DNA vaccines is 
the presence of immunostimulatory sequences within the plasmid DNA, which act as a natural 
adjuvant (Sato et al., 1996; Pisetsky, 1996). These sequences consist of unmethylated 
cytosinephosphate-guanosine (CpG) dinucleotides within the context of certain flanking bases 
(Krieg et al., 1995). The CpG motifs are recognized by the innate immune system of the host 
through TLR9 and preferentially stimulate Th1 cytokine production (Krieg et al., 1995; Sato et 
al., 1996). However, the exact contributions of immunostimulatory sequences to the efficacy of 
DNA vaccines should be further investigated as some sequences may be inhibitory in specific 
species or cell types (Shroff et al., 1999). Furthermore, multivalent DNA vaccines which contain 
several protective components from multiple pathogens can easily be created (van Drunen Littel-
van den Hurk et al., 2000). In addition, DNA vaccines are easy, rapid and cheap to produce, since 
they are amplified in bacterial cultures. The production process is readily scalable to meet the 
needs of a mass market. Moreover, DNA vaccines are well conserved and show greater stability 
at room temperature than conventional vaccines (Shroff et al., 1999; Dufour, 2001). Plasmid 
DNA can be successfully lyophilized, which enhances the stability, breaks the cold chain and 
makes DNA vaccines available on a global scale, in developed as well as developing countries 
(Shroff et al., 1999). Another advantage is that DNA vaccines are able to induce immune 
responses in neonates, even in the presence of maternal antibodies (Van Drunen Littel-van den 
Hurk et al., 1999; Van Loock et al., 2004). It was also shown that it is even possible to induce 
immunity in utero (Gerdts et al., 2000, 2002). This can be important to protect against infections 
that are transmitted before, during or after birth, such as chlamydial infections (Longbottom and 
Livingstone, 2006). 
Besides these numerous advantages, a number of concerns have been raised regarding possible 
adverse consequences of DNA vaccination. First, the plasmid DNA could integrate into the host 
genome. The random integration of foreign DNA could lead to the activation of oncogenes, 
inactivation of tumor suppressors or disruption of normal gene function and regulation. 
Furthermore, integration into stem or germ cells could lead to the propagation of foreign DNA 
into the offspring and subsequent generations (Shroff et al., 1999; van Drunen Littel-van den 
Hurk et al., 2000). However, the majority of studies in mice indicate that plasmid DNA does not 
integrate into the genome and it is thought that the risk of integration is far below the natural risk 
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of spontaneous mutations (Martin et al., 1999; van Drunen Littel-van den Hurk et al., 2000). 
Second, plasmid vectors used for DNA vaccination generally contain an antibiotic resistance 
gene for selection. This is clearly of concern given the potential for development of antibiotic 
resistance in pathogenic bacteria. This may be overcome by using alternative selectable markers 
(Dunham, 2002). A third concern is the potential for the development of antibodies to DNA, 
which could induce or exacerbate autoimmune diseases (Dunham, 2002). Fortunately, 
development of autoimmunity following DNA vaccination has not yet been demonstrated. 
Although anti-DNA antibodies have been identified in mice and humans, these antibodies were 
specific for bacteria and did not cross-react with mammalian DNA (Robertson and Pisetsky; van 
Drunen Littel-van den Hurk et al., 2000). Fourth, DNA vaccination could lead to immunological 
tolerance. Mor et al. (1996) have suggested that DNA immunization of young mice resulted in 
immune tolerance. However, subsequent studies have not substantiated this finding and indicate 
that the generation of immunological tolerance is not an issue for DNA vaccines (Shroff et al., 
1999; van Drunen Littel-van den Hurk et al., 2000). Lastly, it should be noted that DNA 
vaccination has been less effective in humans and large animals than in mice. This is likely due to 
the lower transfection and expression efficiency (Babiuk et al., 2003). Therefore, improving the 
delivery of plasmid DNA and the subsequent expression of proteins is crucial for developing 
effective DNA vaccines (Longbottom and Livingstone, 2006). 
 
8.1.2. mRNA vaccination 
Besides plasmid DNA, messenger RNA (mRNA) molecules encoding vaccine antigens can also 
be used for vaccination. In their simplest form, mRNA vaccines consist of the genetic 
information of the antigen of interest flanked by short 5´- and 3´-noncoding sequences, a cap 
structure (methyl-7-guanine followed by three phosphate groups) at the 5´-end and a poly-A tail at the 
3´-end (Geall et al., 2013). Messenger RNA can be produced by in vitro transcription of a 
linearized pDNA template. Therefore, the gene of interest is first cloned in a plasmid vector that 
contains an upstream bacteriophage promoter recognized by RNA polymerases, such as the T7, 
S6 or T3 promoter, a downstream poly-A sequence of at least 30 bases and a unique restriction 
site downstream the poly-A tail (Pascolo, 2008). Upon internalization of an mRNA vaccine in 
host cells, the mRNA is translated into the vaccine proteins by these cells. Like DNA vaccines, 
mRNA vaccines mimic natural infection by expressing antigens in situ after immunization and 
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are able to elicit cell-mediated as well as humoral immune responses (Geall et al., 2013). 
Moreover, mRNA can also act as a natural adjuvant since it can stimulate the innate defense 
system of the host through activation of TLRs (Tavernier et al., 2011). TLR7 and TLR8 
recognize single-stranded RNA, while TLR3 recognizes double-stranded RNA (Heil et al., 2004; 
Karikó et al., 2004; Scheel et al., 2005; Smits et al., 2008). 
Vaccination with mRNA has several advantages compared to DNA vaccination. First, mRNA 
vaccines are safer than DNA vaccines as mRNA cannot integrate into the host genome and the 
transfection remains transient (Tavernier et al., 2011). Messenger RNA is expressed during a 
controlled period of a few days while the expression of pDNA is uncontrolled, since its 
expression in mice can be transient or last for months. Therefore, long-term expression and its 
possible adverse effects, such as immunological tolerance, will not occur with mRNA vaccines 
(Pascolo, 2008). Furthermore, mRNA vaccines are relatively easy to engineer as there is no need 
to incorporate an efficient promoter and terminator into the transfection construct (Tavernier et 
al., 2011). Moreover, in contrast to pDNA vectors, mRNA molecules do not contain antibiotic 
resistance genes. Another important advantage is that mRNA does not need to enter the nucleus, 
since it is translated directly in the cytoplasm. In contrast, DNA vaccines must be delivered into 
and transcribed within the nucleus to transfect a cell. Thus, they must traverse two membrane 
barriers, namely the plasma and nuclear membrane. This could be particularly problematic in 
quiescent or slowly proliferating cells, where the nuclear membrane remains intact (Tavernier et 
al., 2011; Ulmer et al., 2012). Indeed, several studies have shown that microinjection of pDNA 
into the cytoplasm of non-dividing cells results in very low levels of gene expression, whereas 
direct intra-nuclear injection of the same amount of pDNA leads to efficient transfection 
(Capecchi, 1980; Mirzayans et al., 1992; Thorburn and Alberts, 1993; Zabner et al., 1995). 
Compared to DNA, mRNA is generally considered as a relatively unstable molecule, especially 
in the host cell cytoplasm which contains RNases. The hydroxyl group on the second carbon 
atom of the ribose sugar prevents the mRNA from adopting a stable double β-helix structure, 
which makes mRNA more susceptible to hydrolysis than pDNA. However, the stability and 
expression of mRNA vaccines can be increased by various modifications to the mRNA structure, 
as will be discussed later. Because of the relative instability of mRNA, its lifetime in host cells is 
limited and the production of the vaccine antigen lasts for a few days maximally (Tavernier et al., 
2011). Although this feature supports safety, it may go against efficacy. A sustained immune 
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response may require the persistence of the antigen (Kündig et al., 1996) and hence, mRNA 
vaccines may have to be applied frequently (Pascolo, 2004). However, the antigen expression 
following mRNA vaccination appears to peak and decay rapidly, which better mimics antigen 
expression during an acute infection and therefore may be more favorable to induction of 
antigen-specific immune responses (Ulmer et al., 2012). Indeed, it has been demonstrated that the 
capacity of mRNA to cause a boost in antigen expression is important for optimal vaccination 
(Ponsaerts et al., 2003; Gilboa and Vieweg, 2004).  
It is often assumed that mRNA vaccination would be too expensive to be feasible. However, the 
manufacturing of mRNA by in vitro transcription now seems achievable at reasonable cost and 
large scale. Surprisingly, it may be easier to produce large amounts of mRNA under good 
manufacturing practice (GMP) conditions than large amounts of plasmid DNA. When producing 
mRNA, the quality of the DNA is of no concern, as a DNase will destroy all DNA molecules 
after in vitro transcription. Furthermore, each DNA template can be transcribed several times. 
This means that a small amount of plasmid DNA is sufficient to obtain a larger amount of mRNA 
(Pascolo, 2004). Although mRNA vaccines are less easy to store than DNA vaccines, they are 
demonstrated to be not less stable than other conventional vaccines that require a cold chain 
(Jones et al., 2007). Moreover, preliminary studies indicated that lyophilization may be feasible 
to stabilize mRNA during storage (Jones et al., 2007; Petsch et al., 2012). 
 
8.2. Enhancing transfection efficiency 
The spontaneous uptake of naked nucleic acids by host cells is very inefficient. Therefore, 
different methods of nucleic acid delivery have been developed to provide protection from 
degradation and improve cellular uptake. These methods can be divided into two categories: viral 
and non-viral delivery systems. Viral vector-based delivery methods are generally considered as 
the most efficient means to deliver nucleic acids into cells, but have several safety issues and are 
expensive and time consuming to produce. Non-viral delivery methods include physical 
techniques such as gene gun delivery and electroporation, which can deliver nucleic acid 
vaccines intracellularly by physically disturbing the membrane barriers. In addition, synthetic 
gene carriers, such as cationic liposomes and cationic polymers, can be used to facilitate the entry 
of nucleic acid vaccines in host cells (Tavernier et al., 2011). Only the synthetic carrier systems 
will be discussed in more detail. 
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8.2.1. Cationic lipid based nucleic acid carriers 
Phospholipids are amphiphilic molecules that contain a hydrophilic polar head group and a 
hydrophobic hydrocarbon tail. When dispersed in an aqueous medium, these lipids form spherical 
bilayered structures, termed liposomes, with an internal aqueous phase which can be used to 
encapsulate small molecules, such as nucleic acids (Remaut et al., 2007). Cationic liposomes 
spontaneously interact with negatively charged nucleic acids through electrostatic interactions to 
form lipoplexes (Figure I-6A). These cationic lipoplexes have a positive surface charge, which 
facilitates the interaction with the negatively charged host cell membranes and thus enhances 
their cellular uptake (Labat-Moleur et al., 1996; Wasungu and Hoekstra, 2006; Li and Szoka, 
2007). Moreover, within the lipoplexes, the nucleic acids are protected from degradation by 
nucleases.  
Lipoplexes generally enter the host cells by endocytosis, whereafter they reside in endosomal 
vesicles. Subsequently, the lipoplexes have to escape from the endosomes to prevent degradation 
and deliver the nucleic acids to the required cell compartment. The endosomal escape of 
lipoplexes occurs by interaction between the cationic lipids of the liposomes and the anionic 
lipids of the endosomal membrane, which results in membrane fusion and release of the nucleic 
acids from the lipoplexes (Szoka et al., 1996; Zelphati and Szoka, 1996a, 1996b, 1997). Neutral 
helper lipids can be incorporated in the liposomes to facilitate escape from the endosomal 
compartment. The most common helper lipids are dioleoylphosphatidylethanolamine (DOPE) 
and cholesterol. These lipids are often used in an equimolar ratio with the cationic lipids 
(Litzinger and Huang, 1992; Li and Szoka, 2007). 
A wide variety of cationic lipids has been tested for their potential to complex and deliver nucleic 
acids into host cells. One of the most efficient and most commonly used cationic lipids is 
DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) which is generally mixed with the neutral 
lipid DOPE. Lipofectamine, a commercially available liposomal formulation, is another highly 
efficient transfection agent. Besides DOTAP and lipofectamine, many other cationic lipids have 
been used to prepare liposomes, such as stearylamine, DODAP (1,2-dioleoyl-3-
dimethylammonium-propane), DOTMA (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethyl-
ammoniumchloride), GL67 (Genzyme lipid 67),… 
As mentioned earlier, cationic lipoplexes have a positive surface charge. Therefore, they may 
interact with negatively charged serum proteins and non-target tissues, which can result in toxic 
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effects, reduced circulation times and lower transfection efficiency (Audouy et al., 2002). This 
problem can be partially overcome by coating the lipoplexes with a hydrophilic polymer such as 
polyethylene glycol (PEG) (Meyer et al., 1998). However, it was shown that the use of PEG 
negatively interferes with the release of the nucleic acids from the lipoplexes (Rejman et al., 
2004; Deshpande et al., 2004). 
 
                
Figure I-6: Complex formation. (A) Cationic liposomes spontaneously interact with negatively charged 
nucleic acids to form lipoplexes. (B) Polyplexes are formed by electrostatic interactions between cationic 
polymers and nucleic acids (Pack et al., 2005). 
 
8.2.2. Cationic polymer based nucleic acid carriers 
Cationic polymers spontaneously associate with nucleic acids through electrostatic interactions to 
form nanosized particles, termed polyplexes (Figure I-6B). As for lipoplexes, the positive charge 
of polyplexes improves their uptake in host cells by endocytosis. Moreover, the condensation of 
nucleic acids into polyplexes renders them less accessible to nucleases and facilitates their release 
from endosomes (De Smedt et al., 2000; Greenland and Letvin, 2007). Polyplexes generally 
escape from the endosomal compartments via the proton sponge mechanism (Godbey et al., 
1999; De Smedt et al., 2000; Bieber et al., 2002). Cationic polymers like polyethyleneimine 
(PEI) and dendrimers have an intrinsic endosomolytic activity, because their N-atoms are only 
partially protonated at physiological pH 7.4, but become extensively protonated upon 
acidification of the endosome. The buffering capacity of these polymers keeps the endosomal pH 
neutral, which causes more protons to be pumped in the endosomes, accompanied with an influx 
A B 
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of Cl
-
 ions. Consequently, the endosomes will swell due to water uptake, and eventually, they 
will rupture and release the polyplexes into the host cell cytosol (Remaut et al., 2007).  
Polyethyleneimine is probably the most commonly employed cationic polymer for nucleic acid 
delivery due to its strong compaction capacity and intrinsic endosomolytic activity, which result 
in a superior transfection efficiency (Boussif et al., 1995; Godbey et al., 1999). PEI is available in 
a linear (lPEI) and a branched (brPEI) form and in a wide variety of molecular weights. A higher 
molecular weight implies a higher ability to form compact and stable polyplexes and thus a 
higher transfection efficiency. However, the cytotoxicity of the polyplexes increases with 
increasing cationic density and molecular weight (Jeong et al., 2001; Lungwitz et al., 2005). 
Besides PEI, many other cationic polymers such as dendrimers, cationic polymethacrylates, 
cationic polypeptides and cationic polysaccharides like chitosan and cyclodextrin have been 
studied as nucleic acid carriers (Midoux and Monsigny; De Smedt et al., 2000; Funhoff et al., 
2004, 2005; Dufès et al., 2005).  
Many polymers are not biodegradable, which may lead to accumulation problems, especially in 
cases of repeat dosing. Recently, studies are focusing on biodegradable cationic polymers which 
can be degraded into less toxic low molecular weight products that are excreted by the kidneys 
(Lynn and Langer, 2000; Anderson et al., 2003). Like lipoplexes, cationic polyplexes are 
potentially toxic to host cells due to aspecific electrostatic interactions with cellular components. 
This can also be overcome by shielding the polyplexes with hydrophilic polymers (Meyer et al., 
1998; Remaut et al., 2007). 
 
8.3. Enhancing antigen expression 
8.3.1. DNA vaccination 
The expression of pDNA vaccine antigens can be optimized by modifying all the essential 
elements of the plasmid, including the promoter, the gene and the plasmid backbone (Babiuk et 
al., 2003).  
A strong promoter is essential for optimal antigen expression in mammalian cells. Galvin et al. 
(2000) have shown that the level of humoral and cell-mediated immunity induced by a DNA 
vaccine is directly correlated to the strength of the promoter. In general, viral promoters, such as 
those derived from cytomegalovirus, Rous sarcoma virus or simian virus 40 (SV40), have 
provided greater gene expression in vivo than other eukaryotic promoters. The strong CMV 
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promoter has frequently been shown to induce the highest level of antigen expression and 
immune responses when compared with other promoters (Garmory et al., 2003). Furthermore, it 
has been demonstrated that incorporation of the CMV intron A enhances the antigen expression 
(Chapman et al., 1991). The polyadenylation sequence included in the plasmid can also have 
significant effects on antigen expression (Garmory et al., 2003). 
The expression level of prokaryotic genes used in nucleic acid vaccination can be increased by 
the insertion of a Kozak sequence as prokaryotic genes do not possess these sequences. Kozak 
sequences (
-6
GCC(A/G)CCAUGG
+4
) flank the AUG initiator codon within most eukaryotic 
mRNA molecules and are important for initiation of translation since they increase the 
recognition of the start codon by ribosomes (Kozak, 1987, 1997). 
Many bacterial and viral genes used in nucleic acid vaccines have codon profiles that are 
suboptimal for mammalian translation, since the relative abundance of specific tRNAs and thus 
the codon preference is species-specific (Pascolo, 2008). In general, taxonomically close 
organisms use similar codons for their protein synthesis whereas taxonomically distant organisms 
utilize very different codons (Ikemura, 1982). The codon usage can be optimized to improve the 
translation of vaccine antigens in the host species. Therefore, the protein sequence of interest is 
converted into an optimal mRNA sequence using algorithms that take into account the precise 
codon usage of the host species. This virtual gene is then constructed in vitro using synthetic 
DNA oligonucleotides (Pascolo, 2008).   
It has been estimated that less than 1% of the plasmid DNA that successfully enters the 
cytoplasm of the host cells eventually enters the nucleus for transcription (Boutorine and Kostina, 
1993). The efficiency of DNA uptake across the nuclear membrane can be increased by targeting 
DNA vaccines to the nucleus with nuclear localization sequences (NLS). Therefore, DNA 
binding proteins with an existing or incorporated NLS can be used or the NLS can be covalently 
bound directly to the plasmid (Babiuk et al., 2003). However, NLS-mediated nuclear import of 
DNA in mammalian cells was only convincingly demonstrated for linear DNA (Zanta et al., 
1999; Ludtke et al., 1999), but not for plasmid DNA (Ciolina et al.; Sebestyén et al., 1998; 
Schwartz et al., 1999; Neves et al., 1999).  
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8.3.2. mRNA vaccination 
The expression and stability of mRNA vaccines can be enhanced by optimizing several features 
of the mRNA molecule.  
The cap structure and the poly-A tail are essential parts of the mRNA molecule and strongly 
influence the efficacy of the vaccine antigen expression and thereby the induction of an immune 
response (Gallie, 1991). During in vitro transcription, the cap structure can be attached to the 5´-
end of the mRNA molecule in two directions, with its 3´- or its 5´-side (Pasquinelli et al., 1995). 
However, only the 5´-5´ linkage leads to a translatable mRNA molecule, which means that only 
half of the in vitro synthesized mRNA molecules are functional. This can be solved by using an 
anti-reverse cap analogue (ARCA), a cap structure with a modification on the 3´-side. 
Consequently, this side cannot be used for the incorporation of the cap and only correctly capped 
mRNA molecules are generated (Jemielity et al.; Stepinski et al., 2001). The antigen expression 
of mRNA vaccines can also be increased by extending the poly-A tail to more than 100 residues, 
as it has been shown that mRNA expression positively correlates with poly-A tail length (Preiss 
et al., 1998; Elango et al., 2005; Mockey et al., 2006; Peng et al., 2008).  
Further optimization of the mRNA structure can be performed by replacing unstable non-coding 
sequences with non-coding sequences of stable mRNA molecules, such as α- and β-globin 
mRNA (Tavernier et al., 2011). In addition, as with DNA vaccines, the expression of mRNA 
vaccine antigens can be enhanced by incorporating a Kozak sequence and optimizing the codon 
usage. 
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Abstract 
The aim of the present study was to reveal the characteristic features of genital Chlamydia suis 
infection and re-infection in female pigs by studying the immune response, pathological changes, 
replication of chlamydial bacteria in the genital tract and excretion of viable bacteria. Pigs were 
intravaginally infected and re-infected with C. suis strain S45, the type strain of this species. We 
demonstrated that S45 is pathogenic for the female urogenital tract. Chlamydia replication 
occurred throughout the urogenital tract, causing inflammation and pathology. Furthermore, 
genital infection elicited both cellular and humoral immune responses. Compared to the primo-
infection of pigs with C. suis, re-infection was characterized by less severe macroscopic lesions 
and less chlamydial elementary bodies and inclusions in the urogenital tract. This indicates the 
development of a certain level of protection following the initial infection. Protective immunity 
against re-infection coincided with higher Chlamydia-specific IgG and IgA antibody titers in sera 
and vaginal secretions, higher proliferative responses of peripheral blood mononuclear cells 
(PBMC), higher percentages of blood B lymphocytes, monocytes and CD8
+
 T cells and 
upregulated production of IFN-γ and IL-10 by PBMC. 
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1. Introduction  
Chlamydia suis is widespread in commercial pig production and causes important economic 
losses (Schautteet et al., 2013). C. suis infections are associated with a variety of diseases 
including conjunctivitis (Rogers and Andersen, 1999), rhinitis (Rogers et al., 1996), pneumonia 
(Rogers et al., 1996; Reinhold et al., 2008), enteritis (Rogers and Andersen, 1996; Guscetti et al., 
2009), periparturient dysgalactiae syndrome (PDS) (Eggemann et al., 2000) and numerous 
reproductive disorders (Woollen et al., 1990; Schiller et al., 1997b; Eggemann et al., 2000; 
Kauffold et al., 2006a; Schautteet et al., 2013) such as abortion, mummification, perinatal and 
neonatal mortality, repeat breeding, vaginal discharge and endometritis in addition to orchitis, 
epididymitis and urethritis in boars (Sarma et al., 1983). C. suis has also been detected in the 
semen of boars, suggesting the possibility of venereal transmission during mating or artificial 
insemination (Kauffold et al., 2006b; Teankum et al., 2006; Schautteet et al., 2013). Furthermore, 
C. suis has frequently been identified in asymptomatic carriers (Hoelzle et al., 2000; Camenisch 
et al., 2004; Englund et al., 2012).  
Experimental infection of gnotobiotic and conventionally raised pigs with C. suis proved its 
pathogenic potential for the porcine respiratory system (Rogers et al., 1996; Sachse et al., 2004; 
Reinhold et al., 2008), gastrointestinal tract (Rogers and Andersen, 1996, 2000; Guscetti et al., 
2009) and eyes (Rogers and Andersen, 1999). In contrast, the exact role of C. suis in reproductive 
problems still has to be defined. To our knowledge, experimental genital tract infection of pigs 
with C. suis has never been performed before. Nevertheless, considering the possibility of 
venereal transmission, genital C. suis infections and re-infections are probably common in 
breeder sows, since they are mated or inseminated a minimum of twice a year and generally two 
to three inseminations per oestrus are carried out. In the present study, conventionally raised 
Chlamydia-negative pigs were intravaginally infected and/or re-infected with C. suis strain S45, 
the type strain of this species. The aim of this study was to reveal the characteristic features of a 
genital C. suis infection and re-infection in female pigs by studying the immune response, 
pathological changes, replication of chlamydiae in the genital tract and excretion of viable 
bacteria. 
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2. Materials and methods 
2.1. Chlamydia suis  
C. suis strain S45 (kindly donated by A. Andersen, National Animal Disease Center, USDA 
Agriculture Research Service, Ames, Iowa) was used to infect the pigs. This strain was isolated 
in the late 1960s from feces of an asymptomatic Austrian pig (Kolbl, 1969). The bacteria were 
grown in McCoy cells using standard techniques (Vanrompay et al., 1992). The 50% Tissue 
Culture Infective Dose (TCID50) was determined by the method of Spearman and Kaerber (Mayr 
et al., 1974). TCID50/ml is routinely used for titrating intracellular organisms like viruses in cell 
cultures and it correlates with IFU/ml as examined by Beeckman et al. (2009). 
 
2.2. Infection experiment 
Fifteen 9-week-old conventionally bred female pigs were randomly divided into three groups of 
five pigs. Antibodies against Chlamydiaceae were absent as determined by a C. suis ELISA using 
purified EBs of strain S45. Nasal, rectal and vaginal swabs did not contain chlamydial bacteria as 
determined by culture on McCoy cells. The animals were housed in isolation units and fed ad 
libitum with a commercial starting diet. At day 0, all pigs were anesthetized by intramuscular 
injection of Zoletil
®
 100 (Virbac Animal Health, Louvain La Neuve, Belgium) in 2% Xylazine-
M
®
 (VMD, Arendonk, Belgium). The control group and the infection group were inoculated with 
phosphate-buffered saline (PBS). The re-infection group was infected by intravaginal injection of 
1 x 10
7
 TCID50 of C. suis strain S45. Intravaginal inoculation was performed by inserting an 
artificial insemination pipette connected to a syringe into the vagina and injecting the bacterial 
suspension in 1ml PBS or injecting simply 1 ml PBS (controls). At day 56, pigs were 
anesthetized again, whereafter the control group was inoculated with PBS and the infection group 
and the re-infection group were infected intravaginally with C. suis strain S45 (1 x 10
7 
TCID50). 
All groups were euthanized at day 77 by intravenous injection of an overdose of pentobarbital (70 
mg/kg; Nembutal
®
, Ceva Santé Animale, Maassluis, the Netherlands) followed by 
exsanguination.  
Vaginal swabs in 2 ml Chlamydia transport medium for chlamydial isolation and in 2 ml PBS 
with protease inhibitor for mucosal antibody detection were collected weekly. Swabs were stored 
at -80°C until analysis. Blood for antibody detection was sampled from the jugular vein 
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(v. jugularis) weekly. Blood samples were stored overnight at room temperature and centrifuged 
(9300 × g, 20°C, 10 min) for serum collection. Sera were stored at -20°C until tested. At 
euthanasia, pigs were examined for gross lesions that were scored as none (0), slight (1), 
moderate (2) or severe (3). Samples of the spleen, liver, caecum, urethra, vagina, cervix, corpus 
uteri, uterine tubes, oviducts and ovaries were imbedded in methylcellulose medium, frozen in 
liquid nitrogen and stored at -80°C until preparation of cryostat tissue sections for localization 
and quantification of the infection. Samples from the same tissues were taken for histopathology. 
The experimental procedure was approved by the animal care and ethical committee of Ghent 
University (EC2012/078). 
 
2.3. Chlamydial antigen detection 
Vaginal swabs in Chlamydia transport medium were shaken for 1 h at 4°C, centrifuged and 
cultured in McCoy cells grown on 13 mm cover slips in Chlamydia Trac Bottles (International 
Medical, Brussels, Belgium) as described by Vanrompay et al. (1992). Additionally, cells were 
washed twice with 1 ml phosphate buffer supplemented with 0.003% DEAE-dextran before the 
inoculum was added to the cells. Chlamydial growth was monitored using the IMAGEN
TM
 direct 
immunofluorescence staining (Oxoid, Drongen, Belgium) at 6 days post inoculation. Cryostat 
tissue sections (5 µm) were also stained by use of the IMAGEN
TM 
immunofluorescence test. All 
slides were examined by immunofluorescence microscopy (BX41 Olympus, 600×). Positive cells 
were counted in five microscopic fields. The calculated mean was presented as a score ranging 
from 0 to 6. Score 0 indicated a negative result. Score 1 and 2 indicated 1 to 5 and 6 to 10 EBs 
per microscopic field in the absence of inclusions, respectively. Score 3 represented more than 10 
EBs and 1 inclusion-positive cell per microscopic field. Score 4, 5 and 6 indicated 1 to 5, 6 to 10 
and more than 10 inclusion-positive cells per microscopic field, respectively. 
 
2.4. Antibody responses 
Sera were heat inactivated at 56°C during 30 min and subsequently pretreated with kaolin to 
reduce background activity (Novak et al., 1993). Vaginal swabs in PBS with protease inhibitor 
were shaken for 1 h at room temperature and centrifuged. Isotype-specific serum and mucosal 
antibody titers were determined in an ELISA using purified S45 EBs as antigen. Maxisorp 96-
well microtiter plates were coated with purified C. suis strain S45 EBs (1 × 10
7
 TCID50 per well) 
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diluted in PBS. Plates were blocked overnight (4°C) with PBS supplemented with 5% bovine 
serum albumin (BSA). Serum and mucosal antibody titers were determined using twofold 
dilution series in dilution buffer (PBS + 3% BSA + 0.05% Tween
®
20), starting at a dilution of 
1:15. Antibody isotype titers were determined using monoclonal antibodies against swine IgA 
(mAb 27.8.1), IgG (mAb 23.3.1b) and IgM (mAb 28.4.1) (Van Zaane and Hulst, 1987) at a 
dilution of 1:15, 1:20 and 1:50, respectively, followed by an 1:5000 dilution of biotinylated anti-
mouse IgG (H+L) (Dako, Glostrup, Denmark). Subsequently, the plates were incubated with 
1:2500 diluted peroxidase-labeled streptavidin (Zymed Laboratories, San Francisco, USA). 
Finally, the substrate and chromogene ABTS (2, 2'-Azino-di(3-ethylbenzthiazoline-6-sulfonate); 
KPL, Maryland, USA) was added. Antibody titers were defined as the reciprocal of the highest 
dilution that gave an absorbance reading at 405 nm above the cut-off value (mean absorbance of 
seronegative pig serum + twice the standard deviation). Positive and negative control sera and 
mucosal secretions originated from a former experimental infection in pigs (Schautteet et al., 
2012). 
 
2.5. Proliferative responses of PBMC and MC 
At 7 and 10 days post infection or re-infection, peripheral blood mononuclear cells (PBMC) were 
isolated from heparinized blood samples collected from the jugular vein. Isolation of PBMC was 
performed by density gradient centrifugation (500 × g, 18°C, 25 min) on Lymphoprep
TM 
(Axis-
Shield, Oslo, Norway). After lysis of erythrocytes in ammonium chloride, the cells were washed 
and resuspended in leukocyte medium (RPMI-1640 (Life Technologies, Merelbeke, Belgium) 
supplemented with 5% heat-inactivated fetal calf serum (FCS) (Life Technologies), 5×10
−5
 M β-
mercaptoethanol (Life Technologies), 1% non-essential amino acids (Life Technologies), 1% 
sodium pyruvate (Life Technologies), 1% L-glutamine (Life Technologies), 1% penicillin-
streptomycin and 1% kanamycin). At euthanasia, monomorphonuclear cells (MC) were isolated 
from the spleen, the cervical lymph node (cervicalis superficialis) and the pelvic lymph nodes 
(iliaci mediales, iliaci laterales, sacrales and anorectales). Isolation of MC was performed by 
tearing the tissues apart, after the surrounding fat was removed. Subsequently, the erythrocytes 
were lysed with ammonium chloride. After centrifugation (270 × g, 4°C, 10 min), the cells were 
washed and resuspended in leukocyte medium without β-mercaptoethanol. PBMC or MC were 
grown in 96-well tissue culture plates at a concentration of 5 × 10
5
 cells/well. Proliferation was 
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tested by adding 10
5
 viable C. suis purified S45 EBs, 10 µg concanavalin A (ConA) (positive 
control) or medium (negative control) to the wells. Each condition was tested in duplicate. The 
cells were incubated at 37°C in a humidified atmosphere with 5% CO2. ConA- or antigen-
induced proliferation was measured by incorporation of 1 µCi/well of 
3
H-thymidine (Amersham 
ICN, Bucks, UK) during the last 16 h of culture, on day 3 and day 4, respectively. Cells were 
harvested onto glass fiber filter strips (Perkin Elmer, Life Science, Oosterhout, The Netherlands) 
with a cell harvester (Skatron, Liers, Norway). Radioactivity incorporated into the DNA was 
measured with a β-scintillation counter (Perkin Elmer). The stimulation index (SI) was defined as 
the ratio of the mean counts per minute of stimulated PBMC or MC versus the mean counts per 
minute of the negative control. 
 
2.6. Flow cytometric analysis 
PBMC and MC from the spleen, cervical and pelvic lymph nodes were isolated as described 
above. Flow cytometry was used to analyze the immune cell (sub)populations in the blood at 
different time points post infection and of the spleen, cervical and pelvic lymph nodes at 
euthanasia. T cell populations (CD3
+
CD4
+
CD8
-
, CD3
+
CD4
-
CD8
+
, CD3
+
CD4
+
CD8
+
, CD3
+
CD4
-
CD8
-
, T cells with a γδ T cell receptor), B cells (MHCII+CD21+, MHCII+IgM+), monocytes 
(MHCII
+
SWC3
+
), NK cells (CD3
-
CD4
-
CD8
+
) and plasmacytoid dendritic cells (pDC) (CD3
-
CD4
+
CD8
-
) were quantified. However, for the lymphoid tissues the CD3
-
CD4
+
CD8
-
 population 
does not exist entirely of pDC, but also contains an unknown lineage, presumably of myeloid 
origin (Mair et al., 2014). Based on the used markers, it was impossible to distinguish between 
both populations. PBMC and MC (10
6
 cells) were incubated for 20 minutes in staining buffer 
(RPMI-1640 + 1% heat-inactivated FCS) with optimal concentrations of mAbs (Table II-1). Cells 
stained with isotype-matched irrelevant mAbs were used to analyze aspecific binding. 
Subsequently, the cells were washed with staining buffer and incubated (20 min) with the 
appropriate isotype-specific Alexa-647-, FITC- or PE-conjugated antibodies (Life Technologies). 
Cells were washed with staining buffer and with PBS and were resuspended in PBS. Data were 
acquired on a FACSCanto flow cytometer (Beckton Dickinson, Erembodegem, Belgium) with a 
minimum event count of 50 000 and analyzed with FACSDiva® software. Doublets were 
excluded based on FSC-H/FSC-A and SSC-H/SSC-A plots. 
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Table II-1: Monoclonal antibodies used in flow cytometry. 
Specificity Clone Isotype Reference 
CD3 PTT3 IgG1 (Yang et al., 1996) 
CD4 74-12-4 IgG2b (Pescovitz et al., 1984) 
CD8α 11/295/33 IgG2a (Saalmüller et al., 1994) 
CD8β PG164A IgG2a (Saalmüller, 1996) 
CD21 BB6-11C9 IgG1 (Saalmüller, 1996) 
IgM 28.4.1 IgG1 (Van Zaane and Hulst, 1987) 
MHCII MSA3 IgG2a (Lunney et al., 1994) 
SWC3a 74-22-15 IgG1 (Pescovitz et al., 1984) 
TCR1-N4 (δ chain) PGBL22A IgG1 (Davis et al., 1998) 
 
2.7. Cytokine secretion by PBMC and MC 
PBMC and MC isolated from the spleen, pelvic lymph nodes and the cervicales superficiales 
dorsales lymph nodes were planted in 24-well microtiter plates at a concentration of 
10
7 
cells/well. Subsequently, the cells were stimulated by adding 10
5
 viable purified S45 EBs to 
each well. Supernatant was collected 16, 24, 48 and 72 h later. The concentration of IL-1β, IL-4, 
IL-6, IL-8, IL-10, IL-12p40, IFN-γ and TNF-α in the supernatant was determined using 
commercially available ELISA kits (DuoSet
®
 ELISA Development System, R&D Systems, 
Abingdon, UK). Assays were performed according to the manufacturer‘s guidelines.  
 
2.8. Histopathology 
Samples were fixed in 10% phosphate-buffered formalin, dehydrated and embedded in paraffin, 
sectioned at 5 µm and stained with haematoxylin and eosin. The samples were studied blindly. 
Slides were examined microscopically (Leitz). The microscopic findings were either graded 
(none (0), minimal (1), slight (2), moderate (3), marked (4) or severe (5) histological change) or 
indicated as present or absent without a grade.  
 
2.9. Statistical analysis 
Statistical analyses were performed using SPSS 22 and results for all groups were compared by 
use of the non-parametric Mann-Whitney U test. Results were considered significantly different 
if P<0.05. 
 
Experimental C. suis genital tract infection in pigs  59 
3. Results 
3.1. Macroscopic lesions 
The mean scores for macroscopic lesions, determined at necropsy, are presented in Table II-2. 
Macroscopic lesions were absent in all but one pig of the control group. One control animal had a 
severely inflamed vagina, cervix and uterus caused by an abnormal vaginal anatomy. Therefore, 
that animal was excluded from the experiment. All infected and re-infected animals showed gross 
pathology. The macroscopic lesions were generally more severe for the infection group than for 
the re-infection group. Four pigs (80%) of the infection group showed moderate to severe 
congestion of the genital tract (Figure II-1). The genital tract of the remaining pig (20%) of the 
infection group was slightly congested. In the re-infection group, all but one animal (80%) 
showed only slight congestion of the genital tract. In the other re-infected pig, a severely 
congested genital tract was noticed. In 60% of the pigs of the infection group, a large amount of 
clear watery exudate was present in almost the entire genital tract (Figure II-1), whereas only one 
animal (20%) of the re-infection group showed a moderate amount of watery exudate in the 
cervix. The pelvic lymph nodes were enlarged in 80% of the animals of both infected groups. 
Congestion of the pelvic lymph nodes could only be detected in four pigs (80%) of the infection 
group. Macroscopic lesions in the mesovarium and pelvic lymph nodes were significantly 
different between the groups. 
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Table II-2: Mean scores ± standard deviation (% of positive animals) for macroscopic lesions in the 
infection and the re-infection group at euthanasia*.  
Tissue Macroscopic  
lesion 
Infection  
group 
Re-infection  
group  
Vagina Congestion 0.0 ± 0.00 0.2 ± 0.45 (20) 
 Serous exudate 0.6 ± 1.34 (20) 0.0 ± 0.00 
Cervix Congestion 0.6 ± 1.34 (20) 0.2 ± 0.45 (20) 
 Serous exudate 1.0 ± 1.41 (40) 0.4 ± 0.89 (20) 
Uterus Congestion 0.8 ± 1.10 (40) 1.0 ± 1.22 (60) 
 Hypertrophy 0.6 ± 1.34 (20) 0.0 ± 0.00 
 Serous exudate 1.6 ± 1.52 (60) 0.0 ± 0.00 
Uterine tubes Congestion 1.2 ± 1.10 (60) 0.4 ± 0.55 (40) 
 Hypertrophy 0.6 ± 1.34 (20) 0.0 ± 0.00 
 Serous exudate 1.2 ± 1.64 (40) 0.0 ± 0.00 
Oviducts Serous exudate 0.6 ± 1.34 (20) 0.0 ± 0.00 
Ovaries Congestion 0.4 ± 0.89 (20) 0.0 ± 0.00 
Lig. Latum uteri Congestion 0.8 ± 0.84 (60) 0.4 ± 0.55 (40) 
Mesovarium Congestion 1.6 ± 1.34 (80)a
 
0.2 ± 0.45 (20) 
Mesosalpinx Congestion 1.4 ± 1.52 (60) 0.2 ± 0.45 (20) 
Spleen Congestion 0.4 ± 0.89 (20) 0.0 ± 0.00 
 Enlargement 0.0 ± 0.00 1.0 ± 1.41 (40) 
Liver Congestion 0.2 ± 0.45 (20) 0.0 ± 0.00 
Pelvic lymph nodes Congestion 1.6 ± 1.14 (80)a,c
 
0.0 ± 0.00
c 
 Enlargement 2.2 ± 1.3 (80)a
 
2.0 ± 1.22 (80)
b 
Cervical lymph node Enlargement 1.8 ± 1.64 (60) 0.4 ± 0.89 (20) 
* The mean score ± SD in the control group was 0.0 ± 0.00 for all tissues. 
a
 P < 0.05 for a comparison of 
the control group and the infection group. 
b
 P < 0.05 for a comparison of the control group and the re-
infection group. 
c
 P < 0.05 for a comparison of the infection group and the re-infection group. 
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Figure II-1: Macroscopic lesions in an animal from the infection group.  
(A) Congestion of the lig. latum uteri (arrow a) and the mesovarium and mesosalpinx (arrow b). A large 
amount of clear watery exudate was present in the lumen of the vagina, cervix, corpus uteri (arrow c) and 
uterine tubes. The uterine tubes were severely dilated by the presence of the exudate in their lumen (arrow 
d). (B) Congestion of the mesovarium and mesosalpinx (arrow e). Hyperemia of the uterine tube (arrow f). 
The mucosa of the uterine tube is congested and oedematous and serous exudate was present in the lumen 
(arrow g). 
 
3.2. Chlamydia suis vaginal excretion 
The presence of viable C. suis in vaginal swabs was examined using culture in McCoy cells. 
Figure II-2 shows the culture scores for vaginal swabs collected at different time points post 
infection. All swabs taken at day 0 of the experiment were Chlamydiaceae negative. Vaginal 
swab samples of the control group remained negative throughout the experiment. Vaginal C. suis 
shedding was detected in the infection group from day 59, three days after infection of those 
animals, onwards. In the re-infection group, C. suis excretion was consistently high from day 3 to 
day 28 post primo-infection. After 28 dpi, mean culture scores decreased gradually until re-
infection. Thereafter shedding was again consistently high. Before primo-infection of the 
infection group, the mean excretion scores of the re-infection group were statistically higher than 
those of the other groups. From day 59 onwards, vaginal shedding was significantly higher in the 
infection group and the re-infection group than in the control group. After primo-infection of the 
infection group, the mean culture scores of both infected groups did only differ statistically at day 
A
 
 
B
 
 
a
 
 
b 
c 
d 
e 
f 
g 
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66, when the infection group had the highest score, and at day 70, when the re-infection group 
had the highest score. 
 
Figure II-2: Mean scores ± standard deviation for vaginal C. suis shedding from 3 to 77 days post 
infection in the infection and the re-infection group. The mean score ± SD in the control group was 
0.0 ± 0.00 for all time points. 
a
 P < 0.05 for a comparison of the control group and the infection group. 
b 
P < 0.05 for a comparison of the control group and the re-infection group. 
c
 P < 0.05 for a comparison of 
the infection group and the re-infection group. 
 
3.3. Chlamydial antigen detection in the urogenital tract 
Table II-3 presents the mean scores for the presence of Chlamydiaceae in urogenital tissues 
collected at euthanasia, 21 days after infection or re-infection of the infection group and the re-
infection group, respectively. All tissue samples from the non-infected pigs were negative, as 
were the spleen, the liver and the caecum of both infected groups. An ascending chlamydial 
infection occurred in all pigs of the infection group and in 4 of 5 pigs of the re-infection group, as 
chlamydial EBs and/or intracellular inclusions were detected in the upper genital tract of those 
animals. Intracellular chlamydial inclusions, indicating the presence of replicating chlamydiae, 
were detected in the urethra (20%), vagina (40%), cervix (60%), right uterine horn (20%), 
oviducts (20%) and ovaries (40%) of the infection group. In the re-infection group, chlamydial 
replication could only be observed in the urethra of one pig (20%), the vagina of two pigs (40%) 
and the right oviduct of one pig (20%). Overall, more chlamydial EBs and inclusions, 
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demonstrated by higher mean scores, occurred in the urogenital tract of the infection group than 
of the re-infection group. Statistical analysis revealed significant differences between the mean 
scores of the right uterine horn and the left oviduct of both infected groups. Furthermore, mean 
scores for the presence of Chlamydiaceae in the vagina, right uterine horn, left oviduct and right 
ovary of the infection group were statistically higher than for the control group. In the re-
infection group, the level of Chlamydia replication in the vagina and the urethra was significantly 
higher than in the non-infected pigs.  
 
Table II-3: Mean scores ± standard deviation for the presence of C. suis in urogenital tissues of the 
infection and the re-infection group at euthanasia*. 
Tissue Infection 
group 
Re-infection 
group 
Vagina 1.80 ± 1.10a
 
2.00 ± 1.41
b 
Cervix 2.00 ± 1.87 0.40 ± 0.55 
Corpus uteri 0.80 ± 0.45 0.20 ± 0.45 
Uterine horn R 1.40 ± 0.89a,c
 
0.40 ± 0.55
c 
Uterine horn L 0.20 ± 0.45 0.40 ± 0.55 
Oviduct R 0.80 ± 1.30 0.80 ± 1.30 
Oviduct L 1.40 ± 0.89a,c
 
0.50 ± 0.58
c 
Ovary R 1.60 ± 1.34a
 
0.20 ± 0.45 
Ovary L 0.80 ± 1.30 0.00 ± 0.00 
Urethra 1.20 ± 1.30 1.20 ± 1.10b
 
* The mean score ± SD in the control group was 0.00 ± 0.00 for all tissues. 
a
 P < 0.05 for a comparison of 
the control group and the infection group. 
b
 P < 0.05 for a comparison of the control group and the re-
infection group. 
c
 P < 0.05 for a comparison of the infection group and the re-infection group. 
 
3.4. Antibody responses 
The C. suis S45-specific IgM, IgG and IgA antibody titers in serum (Table II-4) and vaginal swab 
samples (Table II-5) were determined following primo- and re-infection. The control pigs had no 
chlamydial antibodies in both serum and vaginal secretion throughout the experiment. Before 
infection, no serum or vaginal antibodies were detected in the animals of the infection and the re-
infection group. Primo-infection induced IgM and IgG, but no IgA antibodies in serum and 
vaginal secretion. C. suis S45-specific serum IgM and IgG were observed from 7 days post 
primo-infection onwards and mean titers peaked at 14 or 21 dpi. Vaginal antichlamydial IgM and 
IgG antibodies appeared at 14 and at 14 and 21 days post primo-infection, respectively. Seven 
days after re-infection, mean C. suis-specific serum IgM and IgG titers had increased again and 
they kept on rising towards euthanasia. Antichlamydial mucosal IgM and IgG antibodies were 
detected from 7 to 14 and from 7 to 21 days post re-infection, respectively. Moreover, C. suis-
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specific serum and vaginal IgA antibodies appeared from 14 days following re-infection onwards. 
Compared to the antibody responses after primo-infection, re-infection with C. suis S45 induced 
lower IgM antibody titers and higher antichlamydial IgG and IgA titers, which is illustrative for a 
secondary antibody response. 
 
Table II-4: Mean C. suis S45-specific IgM, IgG and IgA serum titers of the infection (I) and the re-
infection (R) group ± standard deviation*. 
Dpi Procedure Serum IgM Serum IgG Serum IgA 
 
 
Infection 
group 
Re-infection 
group 
Infection 
group 
Re-infection 
group 
Re-
infection 
group 
0 Infection R  0 ± 0.00 0 ± 0.00 0 ± 0.00 0 ± 0.00 0 ± 0.00 
7  0 ± 0.00c
 
30 ± 0.00
b,c 0 ± 0.00
c 
48 ± 16.43
b,c 0 ± 0.00 
14  0 ± 0.00c 168 ± 98.59b,c 0 ± 0.00
c 
240 ± 0.00
b,c 0 ± 0.00 
21  0 ± 0.00c 60 ± 0.00b,c 0 ± 0.00
c 
144 ± 90.99
b,c 0 ± 0.00 
28  0 ± 0.00 0 ± 0.00 0 ± 0.00
c 
36 ± 13.42
b,c 0 ± 0.00 
35  0 ± 0.00 0 ± 0.00 0 ± 0.00
c 
48 ± 16.43
b,c 0 ± 0.00 
42  0 ± 0.00 0 ± 0.00 0 ± 0.00
c 
36 ± 13.42
b,c 0 ± 0.00 
49  0 ± 0.00 0 ± 0.00 0 ± 0.00
c 
54 ± 39.12
b,c 0 ± 0.00 
56 Infection I & R  0 ± 0.00 0 ± 0.00 0 ± 0.00c
 
48 ± 16.43
b,c 0 ± 0.00 
63  30 ± 0.00a
 
30 ± 0.00
b 
45 ± 21.21
a,c 
264 ± 131.45
b,c 0 ± 0.00 
70  216 ± 53.67a,c
 
42 ± 16.43
b,c 
120 ± 0.00
a,c 
336 ± 131.45
b,c 
30 ± 0.00
b,c 
77 Euthanasia 72 ± 26.83a
 
60 ± 0.00
b 
195 ± 178.12
a,c 
816 ± 321.99
b,c 
60 ± 0.00
b,c 
* The mean IgM, IgG and IgA serum antibody titers ± SD in the control group and the mean IgA serum 
titers ± SD in the infection group were 0 ± 0.00 for all time points. 
a
 P < 0.05 for a comparison of the 
control group and the infection group. 
b
 P < 0.05 for a comparison of the control group and the re-
infection group. 
c
 P < 0.05 for a comparison of the infection group and the re-infection group. 
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Table II-5: Mean C. suis S45-specific IgM, IgG and IgA mucosal (vaginal) titers of the infection (I) 
and the re-infection (R) group ± standard deviation*. 
Dpi Procedure Mucosal IgM Mucosal IgG Mucosal IgA 
  Infection 
group 
Re-infection 
group 
Infection 
group 
Re-infection 
group 
Re-infection 
group 
0 Infection R 0 ± 0.00 0 ± 0.00 0 ± 0.00 0 ± 0.00 0 ± 0.00 
7  0 ± 0.00 0 ± 0.00 0 ± 0.00 0 ± 0.00 0 ± 0.00 
14  0 ± 0.00c 60 ± 0.00b,c 0 ± 0.00c
 
54 ± 13.42
b,c 
0 ± 0.00 
21  0 ± 0.00 0 ± 0.00 0 ± 0.00c
 
30 ± 0.00
b,c 
0 ± 0.00 
28 - 49  0 ± 0.00 0 ± 0.00 0 ± 0.00 0 ± 0.00 0 ± 0.00 
56 Infection I & R 0 ± 0.00 0 ± 0.00 0 ± 0.00 0 ± 0.00 0 ± 0.00 
63  0 ± 0.00c
 
30 ± 0.00
b,c 
0 ± 0.00
c 
48 ± 16.43
b,c 
0 ± 0.00 
70  48 ± 16.43a,c
 
24 ± 13.42
b,c 
60 ± 0.00
a,c 
96 ± 32.86
b,c 
24 ± 13.42
b,c 
77 Euthanasia 0 ± 0.00 0 ± 0.00 96 ± 32.86a,c 48 ± 16.43b,c
 
30 ± 0.00
b,c 
* The mean IgM, IgG and IgA mucosal antibody titers ± SD in the control group and the mean IgA 
mucosal titers ± SD in the infection group were 0 ± 0.00 for all time points. 
a
 P < 0.05 for a comparison of 
the control group and the infection group. 
b
 P < 0.05 for a comparison of the control group and the re-
infection group. 
c
 P < 0.05 for a comparison of the infection group and the re-infection group. 
 
3.5. Proliferative responses of PBMC and MC 
Proliferative responses of PBMC to C. suis strain S45 were determined 7 and 10 days post primo-
infection of the re-infection group, and again at day 63 and day 66, 7 and 10 days post infection 
or re-infection of the infection group and the re-infection group, respectively. At day 7 and 10, 
the proliferative activities of PBMC of all groups were statistically the same (data not shown). At 
day 63, the mean stimulation index (SI ± SD) of the PBMC for the control group, the infection 
group and the re-infection group were 2.03 ± 1.42, 2.15 ± 1.23 and 8.80 ± 5.46, respectively. The 
PBMC of the re-infection group showed significantly higher proliferative responses than the 
PBMC of the other groups. At day 66, the mean SI ± SD of the PBMC for the control, the 
infection and the re-infection group were 7.42 ± 2.87, 2.24 ± 1.35 and 7.29 ± 3.39. The 
proliferative activity of PBMC of the infection group was statistically lower than for the control 
group and the re-infection group. However, at day 66, the PBMC of the control group showed 
significantly higher proliferative responses to the positive control ConA, a T cell mitogen, than 
the PBMC of the other groups (data not shown). This indicates that the PBMC of the control 
group had a higher proliferative capacity than the other groups at that time and explains the high 
SI following stimulation with C. suis for the control group. At euthanasia, proliferative responses 
of MC from the spleen, cervical and pelvic lymph nodes were statistically the same for all groups 
(data not shown). 
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3.6. Immune cell populations 
Blood immune cell populations were analyzed by flow cytometry at 7 and 10 days post primo-
infection of the re-infection group and again at day 63 and day 66, 7 and 10 days post infection or 
re-infection of the infection group and the re-infection group, respectively (Table II-6 and Figure 
II-3). Seven days post primo-infection of the re-infection group, the infected animals had a 
significantly lower mean percentage of CD4
+
 T cells than the non-infected animals. At day 10, a 
significantly lower percentage of T cells was noticed in the re-infection group than in the 
infection group. At day 63, the re-infected animals had significantly higher mean percentages of 
T cells, B cells and monocytes, but a significantly lower mean percentage of pDC as compared to 
the control group or the infection group. Within total T cells, significantly less CD4
+
CD8
-
 T cells 
were present in the re-infection group than in the infection group. At day 66, the re-infection 
group had significantly higher percentages of B cells and CD4
-
CD8
+
 T cells. At that time, a 
significantly lower percentage of monocytes was detected in the infection group than in the other 
groups. Furthermore, immune cell populations in the spleen, cervical and pelvic lymph nodes 
were analyzed at euthanasia (Table II-6 and Figure II-3). For the spleen, the mean percentage of 
T cells was significantly lower in the re-infection group than in the other groups and within total 
T cells significantly less CD4
+
CD8
+
 and CD4
-
CD8
+
 T cells and significantly more CD4
+
CD8
-
 T 
cells were present in the re-infection group. Moreover, the re-infection group had significantly 
lower mean percentages of B cells and monocytes in the spleen as compared to the control group, 
but a significantly higher percentage of CD3
-
CD4
+
CD8
-
 spleen MC, which contain pDC, than the 
other groups. The mean percentage of NK cells in the spleen was significantly higher for the 
infection group. For the cervical lymph nodes, significantly higher mean percentages of 
CD4
+
CD8
-
 T cells, B cells and monocytes, besides a significantly lower mean percentage of 
CD3
-
CD4
+
CD8
-
 MC, containing pDC, were noticed in the non-infected animals. For the pelvic 
lymph nodes, the control pigs had significantly higher mean percentages of γδ T cells, IgM+ B 
cells and monocytes. The mean percentage of NK cells was significantly higher for the infection 
group than for the re-infected animals. Within total T cells, significantly more CD4
-
CD8
+
 T cells 
were detected in the re-infection group than in the other groups. 
 
 Table II-6: Mean percentage ± standard deviation of different immune cell populations within PBMC, isolated at 7 and 10 days post 
infection or re-infection, and in spleen, cervical and pelvic lymph nodes at euthanasia. 
a,b,c
 For each time point or tissue, means with different superscripts within a column are significantly different (P<0.05). ♯ C: control group; 
I: infection group; R: re-infection group. * Total T cells: CD3
+
; γδ T cells: CD8β- TCR1-N4+; Mature B cells: MHCII+ CD21+; IgM+ B cells 
(immature and mature naive B cells): MHCII
+ 
IgM
+
; Monocytes: MHCII
+
 SWC3
+
; NK cells: CD3
-
 CD4
-
 CD8
+
; pDC (plasmacytoid dendritic 
cells): CD3
-
 CD4
+
 CD8
-
. ** For the lymphoid tissues the CD3
-
CD4
+
CD8
-
 population does not exist entirely of pDC, but also contains an unknown 
lineage, presumably of myeloid origin. 
 Group ♯ Total  
T cells *
 
γδ T cells *
 
Mature 
B cells *
 
IgM
+ 
B cells *
 
Monocytes*
 
NK cells * pDC **
 
PBMC 
Day 7 
(7 dpi 1 R) 
C 46.40 ± 5.23 17.60 ± 3.70 11.40 ± 6.92 12.10 ± 7.24 1.63 ± 0.38 10.5 ± 4.59 0.43 ± 0.21 
I 47.38 ± 5.87 17.50 ± 4.23 11.40 ± 4.60 10.96 ± 2.95 1.72 ± 1.45 11.16 ± 3.49 0.38 ± 0.16 
R 46.46 ± 10.72 18.56 ± 5.10 10.10 ± 2.84 11.20 ± 2.30 1.38 ± 0.19 11.64 ± 4.72 0.26 ± 0.13 
PBMC 
Day 10  
(10 dpi 1 R) 
C 47.25 ± 5.79 19.70 ± 3.93 12.03 ± 5.71 12.73 ± 6.18 2.20 ± 0.76 6.63 ± 2.93 0.58 ± 0.17 
I 52.02 ± 6.43a
 
17.54 ± 6.36 10.70 ± 4.77 10.54 ± 5.98 2.06 ± 0.80 11.66 ± 6.00 0.46 ± 0.28 
R 42.53 ± 4.86b
 
21.75 ± 7.07 15.53 ± 2.76 16.53 ± 2.64 1.93 ± 0.56 6.78 ± 3.04 0.40 ± 0.14 
PBMC 
Day 63 
(7 dpi 1 I; 7 dpi 2 R) 
C 45.23 ± 11.23 25.50 ± 5.20 4.35 ± 2.41a
 
4.05 ± 2.20
a 
1.08 ± 0.60
a 
4.35 ± 2.37 1.28 ± 0.75a
 
I 32.48 ± 19.11a
 
25.00 ± 9.40 4.56 ± 4.96 4.00 ± 4.62 1.14 ± 1.29 4.32 ± 0.98 1.64 ± 0.87 
R 59.98 ± 9.02b
 
30.83 ± 7.65 7.86 ± 2.42b
 
9.10 ± 2.30
b 
2.28 ± 0.38
b 
5.44 ± 3.40 0.46 ± 0.19b
 
PBMC 
Day 66 
(10 dpi 1 I; 10 dpi 2 R) 
C 62.50 ± 5.13 31.83 ± 5.99 5.68 ± 1.79a
 
6.30 ± 1.99
a 
2.10 ± 0.48
a 
2.75 ± 1.34 0.88 ± 0.56 
I 55.92 ± 11.01 24.90 ± 3.43 4.80 ± 3.14a
 
4.54 ± 2.81
a 
0.68 ± 0.81
b 
5.52 ± 2.38 0.78 ± 0.43 
R 55.50 ± 4.63 29.58 ± 7.03 13.66 ± 2.01b
 
13.38 ± 2.28
b 
1.94 ± 0.40
a 
4.03 ± 2.48 0.50 ± 0.08 
Spleen 
Day 77 
(21 dpi 1 I; 21 dpi 2 R) 
C 55.75 ± 4.40a
 
29.33 ± 9.67 10.90 ± 3.10a
 
9.38 ± 2.71
a 
8.48 ± 1.54
a 
4.78 ± 2.59 4.25 ± 1.22a
 
I 59.65 ± 4.78a
 
26.45 ± 3.00 7.88 ± 4.27 6.72 ± 3.82 5.30 ± 3.57 7.93 ± 2.93a
 
4.35 ± 1.11
a 
R 25.66 ± 12.26b
 
24.46 ± 6.47 4.54 ± 1.96b
 
4.56 ± 2.25
b 
3.36 ± 1.82
b 
3.28 ± 0.73
b 
6.66 ± 1.29
b 
Cervical LN  
Day 77 
(21 dpi 1 I; 21 dpi 2 R) 
C 48.18 ± 9.81 17.78 ± 9.58 20.43 ± 9.53a
 
17.55 ± 8.27
a 
2.13 ± 1.05
a 
1.20 ± 0.94 0.20 ± 0.08a
 
I 26.47 ± 19.44 11.30 ± 6.35 0.40 ± 0.36b
 
0.17 ± 0.15
b 
0.53 ± 0.42
b 
6.83 ± 5.24 2.00 ± 2.08b
 
R 21.73 ± 25.17 9.27 ± 7.42 0.33 ± 0.32b
 
0.07 ± 0.12
b 
0.60 ± 0.53 3.70 ± 3.32 1.23 ± 0.35b
 
Pelvic LN  
Day 77 
(21 dpi 1 I; 21 dpi 2 R) 
C 35.58 ± 13.77 18.98 ± 3.81a
 
15.85 ± 7.10 18.1 ± 5.99a
 
4.10 ± 1.68
a 
2.83 ± 1.23 1.35 ± 0.81 
I 39.36 ± 15.28 14.92 ± 2.90b
 
14.66 ± 6.33 8.00 ± 1.29b
 
2.20 ± 0.60
b 
3.96 ± 1.53
a 
1.14 ± 0.51 
R 33.86 ± 18.49 11.24 ± 4.58b
 
7.88 ± 4.38 6.08 ± 2.60b
 
2.16 ± 1.57 1.56 ± 0.46b
 
1.02 ± 0.36 
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Figure II-3: Mean percentage of different subpopulations within total T cells (CD3
+
) in the blood, 
isolated at 7 and 10 days post infection or re-infection, and in spleen, cervical and pelvic lymph 
nodes at euthanasia. T cells were divided into four subpopulations based on the expression of CD4 and 
CD8. 
a,b,c
 For each time point or tissue, different letters within a data series are significantly different 
(P<0.05). C: control group; I: infection group; R: re-infection group. 
 
3.7. Cytokine secretion by PBMC and MC 
Results for cytokine detection at 16 h and 72 h post stimulation are presented in Table II-7 and 
Table II-8. Data of cytokine production at 24 h and 48 h post stimulation are not shown, since the 
results were either without statistical differences between the groups or with statistical 
differences similar to these observed at 72 h post stimulation. Compared to the amount of 
cytokines produced at 16 h following stimulation, PBMC and MC had produced generally more 
IFN-γ, TNF-α, IL-6 and IL-10 and less IL-1β at 72 h after stimulation. Only the data of cytokine 
secretion at 72 h post stimulation are discussed in detail.  
At 7 dpi, the PBMC of the re-infection group produced significantly more TNF-α, IL-1β, IL-6 
and IL-12p40 than the PBMC of the other groups. At day 10, cytokine production by PBMC was 
statistically the same for all groups. At day 63, seven days post infection or re-infection of the 
infection group and the re-infection group, respectively, the mean concentrations of IFN-γ, TNF-
α, IL-1β, IL-6, IL-10 and IL-12p40 for the re-infection group were significantly higher than the 
concentrations produced by the PBMC of the other groups. At day 66, the PBMC of the re-
infected animals had produced significantly more TNF-α, IL-1β, IL-6 and IL-10 than the PBMC 
of the other animals. Furthermore, significantly more IL-8 and IL-12p40 was produced by the 
blood mononuclear cells from the re-infection group when compared to the infection group. For 
a
b a b a a
b
a
b b
a
b a a
b
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a b
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the infection group, mean IL-1β and IL-10 concentrations in PBMC culture media were 
significantly lower than for the control group.  
At euthanasia, spleen MC of the infection group had produced significantly less IFN-γ, TNF-α, 
IL-1β, IL-6, IL-8 and IL-12p40 than MC of the other groups. The production of TNF-α, IL-6 and 
IL-8 by cervical lymph node MC was significantly higher for the control animals than for the 
infection or the re-infection group. Mean IL-6 amounts produced by MC isolated from the pelvic 
lymph nodes were significantly higher for the control group than for both infected groups. The 
MC from pelvic lymph nodes of the infection group produced significantly less IL-4 than the MC 
of the control group. 
 
  
Table II-7: Mean cytokine concentration (pg/ml) ± standard deviation in culture medium of PBMC, isolated at 7 and 10 days post infection 
or re-infection, and of spleen, pelvic and cervical lymph node MC at euthanasia, measured at 16 h post stimulation with C. suis S45. 
 Group* IFN-γ TNF-α IL-1β IL-4 IL-6 IL-8 IL-10 IL-12p40 
PBMC 
Day 7 
(7 dpi 1 R) 
C 14.9 ± 18.6 209.2 ± 241.5
a 
6775.7 ± 3002.1
a 
134.7 ± 72.8 351.6 ± 333.8
a 
23508.0 ± 12568.8 606.7 ± 142.9 387.5 ± 90.5
a
 
I 61.3 ± 60.0 242.0 ± 105.0
a
 8035.1 ± 2768.7 107.9 ± 68.3 408.3 ± 211.9
a
 32039.6 ± 10677.3 554.3 ± 83.2 383.4 ± 94.7
a
 
R 1916.1 ± 1326.0 781.8 ± 458.0
b
 11309.1 ± 2917.9
b
 120.1 ± 125.2 1241.4 ± 728.5
b
 30800.6 ± 11017.7 994.7 ± 476.8 719.8 ± 157.8
b
 
          
PBMC 
Day 10 
(10 dpi 1 R) 
C 100.3 ± 193.0 668.0 ± 1132.5 5532.0 ± 2827.4 107.7 ± 41.3 377.4 ± 648.7 19573.9 ± 15280.0 642.7 ± 392.8 424.4 ± 96.2 
I 57.5 ± 70.2 419.1 ± 458.1 4731.6 ± 2143.3 103.1 ± 17.9 415.1 ± 296.9 16866.9 ± 9817.5 621.8 ± 171.5 458.5 ± 238.3 
R 272.4 ± 263.2 668.7 ± 411.1 6940.0 ± 3052.6 120.6 ± 32.5 642.5 ± 479.6 25847.5 ± 10291.6 742.7 ± 160.2 617.6 ± 172.8 
          
PBMC 
Day 63 
(7 dpi 1 I; 
 7 dpi 2 R) 
C 0.0 ± 0.0 103.9 ± 89.4
a
 4231.3 ± 4012.4 103.7 ± 14.7 2.2 ± 4.4 4916.9 ± 3535.5
a 
197.5 ± 81.4 170.5 ± 94.9 
I 0.0 ± 0.0 87.4 ± 65.6
a
 1474.2 ± 1159.7
a
 100.9 ± 36.6 634.6 ± 1419.0 3347.2 ± 3873.3
a
 99.8 ± 13.5
a
 98.2 ± 63.7
a 
R 0.0 ± 0.0 5681.7 ± 10372.4
b
 8196.4 ± 3841.0
b
 97.1 ± 10.2 304.4 ± 629.5 19118.0 ± 8398.9
b
 247.3 ± 140.1
b
 188.8 ± 65.6
b 
          
PBMC 
Day 66 
(10 dpi 1 I; 
 10 dpi 2 R) 
C 0.0 ± 0.0 56.8 ± 9.4
a
 1397.5 ± 530.8
a
 170.0 ± 52.8 0.0 ± 0.0 2640.6 ± 1518.5 127.2 ± 30.7 95.3 ± 76.4 
I 0.0 ± 0.0 49.4 ± 20.4
a
 741.0 ± 276.7
b
 145.6 ± 109.5 71.4 ± 159.7 1527.4 ± 875.4 135.6 ± 28.7 181.3 ± 112.3 
R 30.8 ± 56.9 331.5 ± 245.6
b
 2518.0 ± 1581.9
a
 114.5 ± 45.2 9.0 ± 20.2 4695.8 ± 4504.7 161.3 ± 12.0 266.4 ± 272.0 
          
Spleen 
Day 77 
(21 dpi 1 I; 
 21 dpi 2 R) 
C 1585.6 ± 1033.0 7068.9 ± 11641.1 10898.8 ± 1108.4
a
 104.7 ± 64.8 841.3 ± 246.2
a 
41453.5 ± 11189.7 387.1 ± 127.7 3448.9 ± 2025.0 
I 551.7 ± 542.9 805.9 ± 831.1
a
 3853.2 ± 2459.6
b
 83.5 ± 54.3 187.5 ± 195.5
b
 23832.8 ± 18335.3 221.5 ± 116.8 1394.1 ± 1012.0
a 
R 1905.7 ± 1797.5 9447.4 ± 14963.6
b
 7944.7 ± 1934.9
c
 80.7 ± 40.8 606.8 ± 405.2 32227.5 ± 12894.8 297.0 ± 148.0 4204.8 ± 2096.9
b 
          
Cervical LN 
Day 77 
(21 dpi 1 I; 
 21 dpi 2 R) 
C 89.8 ± 179.7 50.0 ± 27.4 439.7 ± 322.0 81.6 ± 14.0 2.2 ± 4.4 2074.8 ± 1458.9 101.1 ± 28.8 291.1 ± 107.9
a 
I 21.5 ± 37.3 26.2 ± 6.7 117.5 ± 144.2 77.8 ± 17.6 0.0 ± 0.0 269.6 ± 112.2 73.3 ± 22.3 88.9 ± 124.0 
R 0.0 ± 0.0 25.4 ± 11.3 35.1 ± 44.7 78.8 ± 28.2 0.0 ± 0.0 1001.4 ± 901.2 78.1 ± 34.2 55.4 ± 52.9
b 
          
Pelvic LN 
Day 77 
(21 dpi 1 I; 
 21 dpi 2 R) 
C 0.0 ±  0.0 88.0 ± 45.8 343.1 ± 80.7 96.0 ± 45.0 0.0 ± 0.0 1431.0 ± 360.3 205.0 ± 77.8 746.0 ± 169.0 
I 6.9 ± 15.4 87.0 ± 63.7 302.1 ± 331.0 94.6 ± 30.8 0.0 ± 0.0 1319.9 ± 1040.2 172.9 ± 54.4 621.8 ± 274.4 
R 3.5 ± 7.8 94.2 ± 55.7 157.8 ± 180.8 56.1 ± 18.6 0.0 ± 0.0 847.1 ± 686.0 130.1 ± 47.4 515.9 ± 294.0 
a,b,c
 For each time point or tissue, means with a different superscript within a column are significantly different (p < 0.05). * C: control group; 
I: infection group; R: re-infection group 
 
 
 
  
Table II-8: Mean cytokine concentration (pg/ml) ± standard deviation in culture medium of PBMC, isolated at 7 and 10 days post infection 
or re-infection, and of spleen, pelvic and cervical lymph node MC at euthanasia, measured at 72 h post stimulation with C. suis S45.  
 Group* IFN-γ TNF-α IL-1β IL-4 IL-6 IL-8 IL-10 IL-12p40 
PBMC 
Day 7 
(7 dpi 1 R) 
C 98.3 ± 99.2 627.8 ± 659.7
a
 4457.8 ± 1581.5
a
 139.5 ± 31.0
a 
611.6 ± 1039.7
a 
26444.8 ± 5082.7 757.9 ± 341.6 414.2 ± 159.7
a
 
I 126.0 ± 157.3 855.3 ± 375.2
a
 7941.3 ± 3412.2 111.0 ± 6.5
b
 1336.7 ± 1309.2 22123.4 ± 5898.8 787.4 ± 325.6 392.2 ± 118.9
a
 
R 2100.4 ± 1873.3 9288.1 ± 11716.4
b
 10353.4 ± 3454.7
b
 116.0 ± 45.3 3201.7 ± 2077.6
b
 30837.7 ± 14239.3 1138.9 ± 602.3 806.6 ± 192.4
b
 
          
PBMC 
Day 10 
(10 dpi 1 R) 
C 828.0 ± 1510.3 795.7 ± 1213.2 2980.8 ± 2345.0 67.5 ± 22.6 460.0 ± 920.0 14506.5 ± 11370.7 664.6 ± 434.3 368.2 ± 92.0 
I 500.0 ± 518.1 683.2 ± 334.9 4761.5 ± 2852.7 109.9 ± 58.4 501.3 ± 554.3 15131.6 ± 2542.2 714.8 ± 203.7 383.5 ± 251.1 
R 1713.0 ± 2204.0 961.6 ± 893.2 5100.2 ± 3593.4 109.1 ± 51.5 1689.8 ± 1641.5 20478.8 ± 8615.2 1112.6 ± 358.5 428.5 ± 154.9 
          
PBMC 
Day 63 
(7 dpi 1 I; 
7 dpi 2 R) 
C 0.0 ± 0.0
a 
162.4 ± 198.0
a
 339.4 ± 256.6
a
 153.2 ± 51.5 64.9 ± 101.0
a 
11829.5 ± 10910.1 174.1 ± 55.7
a
 129.1 ± 69.9
a 
I 0.0 ± 0.0
a
 221.0 ± 137.6
a
 300.2 ± 322.0
a
 153.9 ± 55.1 192.8 ± 264.0
a
 7553.1 ± 5451.8 145.3 ± 66.4
a
 110.3 ± 9.5
a
 
R 100.1 ± 80.3
b
 42189.2 ± 33858.1
b
 10025.3 ± 1628.5
b
 145.0 ± 81.5 2835.5 ± 988.4
b
 14127.9 ± 5192.9 547.2 ± 232.3
b
 300.2 ± 106.5
b
 
          
PBMC 
Day 66 
(10 dpi 1 I; 
10 dpi 2 R) 
C 43.0 ± 86.1 1070.0 ± 1193.1
a
 1363.9 ± 956.9
a
 73.8 ± 20.6 1050.9 ± 1144.3
a 
20822.3 ± 14899.6 214.8 ± 104.0
a 
180.6 ± 75.7 
I 72.9 ± 124.3 185.4 ± 74.2
a
 267.1 ± 168.8
b
 55.9 ± 12.6 0.2 ± 0.4
a
 8341.6 ± 6800.7
a
 82.6 ± 45.9
b
 90.1 ± 82.0
a
 
R 2.8 ± 6.3 40175.6 ± 66573.5
b
 12831.1 ± 1533.1
c
 48.3 ± 15.8 5440.6 ± 1152.9
b
 20828.7 ± 5075.0
b
 390.7 ± 81.9
c
 340.4 ± 196.8
b
 
          
Spleen 
Day 77 
(21 dpi 1 I; 
21 dpi 2 R) 
C 3924.4 ± 957.5
a 
7260.2 ± 8443.7
a
 3298.3 ± 630.8
a
 148.0 ± 81.7 2934.4 ± 842.2
a 
26199.6 ± 9525.2
a 
1086.8 ± 488.7 5458.1 ± 3593.8
a
 
I 1560.1 ± 1373.9
b
 1061.1 ± 1055.8
b
 1018.9 ± 645.4
b
 67.5 ± 35.9 479.2 ± 315.1
b
 6762.8 ± 2120.6
b
 619.8 ± 447.6 2203.8 ± 1311.0
b
 
R 5684.7 ± 2240.9
a
 3937.4 ± 3914.0
a
 2089.9 ± 872.9
a
 89.4 ± 36.3 2211.3 ± 961.1
a
 32102.3 ± 23143.1
a
 1035.2 ± 301.8 7853.9 ± 2388.3
a
 
          
Cervical LN 
Day 77 
(21 dpi 1 I; 
21 dpi 2 R) 
C 660.9 ± 539.9 718.7 ± 493.4
a
 679.7 ± 479.5 97.2 ± 65.3 251.4 ± 196.6
a 
12858.2 ± 6186.6
a 
229.8 ± 77.2 1598.2 ± 860.2 
I 186.8 ± 151.4 173.0 ± 148.2 119.7 ± 52.3 62.4 ± 57.5 0.0 ± 0.0
b
 1562.2 ± 562.7
b
 122.8 ± 32.4 627.0 ± 639.5 
R 14.5 ± 25.0 62.5 ± 32.8
b
 98.60 ± 83.57 121.0 ± 18.2 0.0 ± 0.0
b
 5496.8 ± 8220.2 124.4 ± 52.1 660.5 ± 503.0 
          
Pelvic LN 
Day 77 
(21 dpi 1 I; 
21 dpi 2 R) 
C 1191.9 ± 789.5 980.2 ± 405.6 506.6 ± 250.2 92.8 ± 21.4
a 
270.1 ± 291.2
a 
15994.2 ± 8742.3 446.5 ± 129.0 2098.6 ± 888.0 
I 1070.2 ± 1239.9 706.0 ± 380.6 283.7 ± 149.0 60.4 ± 8.1
b
 5.2 ± 11.7
b
 3453.7 ± 2027.7 373.4 ± 286.1 1752.8 ± 1009.5 
R 1193.4 ± 902.9 1007.1 ± 364.3 176.4 ± 163.6 103.1 ± 1.3 0.0 ± 0.0
b
 6748.2 ± 5004.3 406.9 ± 161.5 1698.4 ± 840.3 
a,b,c
 For each time point or tissue, means with a different superscript within a column are significantly different (p < 0.05). * C: control group; 
I: infection group; R: re-infection group 
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3.8. Histopathology 
An overview of the mean scores of the histopathological lesions found in the urogenital tract of 
the pigs at euthanasia is presented in Table II-9. Histopathological findings consisted of: (a) 
intraluminal proteinaceous fluid; (b) the presence of a superficial layer of exfoliated (epithelial) 
cells and/or inflammatory cells: cells and debris laying on the surface of the epithelium; 
(c) interepithelial inflammatory cells, thus indicating the presence of migrating lymphocytes or 
polymorphonuclear cells in the epithelium; (d) degeneration (vacuolation) and/or apoptosis (cell 
death) of epithelial cells; (e) infiltration of inflammatory cells in the lamina propria with 
infiltration of the connective tissue layer beneath the epithelium with polymorphonuclear cells 
(pmc), a feature of more acute  inflammation, or with mononuclear cells (mnc) (lymphocytes 
and/or plasma cells), a feature of more subacute to chronic inflammation; (f) oedema in the 
lamina propria: presence of loosely arranged fibers in the connective tissue and/or eosinophilic 
fluid between the fibers; (g) infiltration of inflammatory cells (pmc or mnc) in the muscular layer, 
(h) or in the serosa. In the corpus uteri, both uterine horns and the right oviduct mononuclear 
inflammatory cells increased slightly in the mucosa with infection with C. suis S45 (infection 
group) and even more when animals were re-infected (re-infection group). The inflammatory 
cells in the infection group were more periglandularly clustered in the deep mucosa, whereas in 
the re-infection group the inflammation was more diffusely present throughout the mucosa. No 
lesions were noted in both ovaries and the lesions observed in the left oviduct, the cervix, the 
vagina and the urethra did not differ statistically between the different groups. In the liver of two 
pigs of the re-infection group slight to moderate, focal to multifocal granulomatous 
inflammations within the portal areas were noticed. The same animals presented also minimal to 
slight diffuse follicular hyperplasia in the spleen, a feature of immunological stimulation. The 
spleen and liver samples from the remaining pigs and all caecum samples showed no 
histopathological changes. 
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Table II-9: Mean scores ± standard deviations for histopathological findings
#
. 
 
Tissue 
 
Histopathological findings 
Control 
group 
Infection  
group 
Re-infection  
group 
Vagina Exfoliation * 0.5 ± 1.00 0.2 ± 0.45 0.0 ± 0.00 
 Interepithelial inflammatory cells 0.0 ± 0.00 0.4 ± 0.55 0.2 ± 0.45 
 Degeneration and/or apoptosis of epithelial cells 0.0 ± 0.00 0.4 ± 0.55 0.4 ± 0.55 
 Infiltration of mnc in the lamina propria 1.5 ± 0.58 1.4 ± 0.55 1.2 ± 0.45 
Cervix Interepithelial inflammatory cells 1.0 ± 0.82 0.8 ± 0.84 1.2 ± 0.84 
 Degeneration and/or apoptosis of epithelial cells 0.0 ± 0.00 0.2 ± 0.45 0.0 ± 0.00 
 Infiltration of mnc in the lamina propria 2.0 ± 0.82 1.4 ± 0.55 1.8 ± 0.84 
Corpus Interepithelial inflammatory cells 1.0 ± 0.00  1.2 ± 0.45 1.2 ± 0.45 
uteri Degeneration and/or apoptosis of epithelial cells 0.3 ± 0.50 0.2 ± 0.45 0.0 ± 0.00 
 Infiltration of mnc in the lamina propria 1.0 ± 0.00b
 
1.2 ± 1.30 2.0 ± 0.71b
 
 Oedema lamina propria 2.3 ± 0.96 1.8 ± 1.30 1.4 ± 1.34 
Uterine Exfoliation * 0.0 ± 0.00 0.0 ± 0.00 0.4 ± 0.89 
horn R Interepithelial inflammatory cells 1.3 ± 0.50 1.2 ± 0.45 1.2 ± 0.45  
 Degeneration and/or apoptosis of epithelial cells 0.3 ± 0.50 0.4 ± 0.55 0.0 ± 0.00 
 Infiltration of mnc in the lamina propria 1.3 ± 0.50b
 
2.2 ± 1.10 2.6 ± 0.55b
 
 Oedema lamina propria 1.5 ± 0.58 1.6 ± 1.34 1.2 ± 1.30 
Uterine Exfoliation * 0.0 ± 0.00 0.4 ± 0.89 0.0 ± 0.00 
horn L Interepithelial inflammatory cells 1.8 ± 0.50 1.8 ± 0.45 1.2 ± 0.45  
 Degeneration and/or apoptosis of epithelial cells 0.3 ± 0.50 0.8 ± 0.45 0.8 ± 0.45 
 Infiltration of mnc in the lamina propria 1.3 ± 0.50b
 
2.2 ± 1.10 2.4 ± 0.55b
 
 Oedema lamina propria 1.0 ± 0.82 1.4 ± 0.55 1.0 ± 0.00 
Oviduct  Intraluminal proteinaceous fluid 4 of 4 4 of 5 4 of 5 
R Exfoliation * 0.5 ± 0.58 0.0 ± 0.00 0.0 ± 0.00 
 Infiltration of mnc in the lamina propria 1.0 ± 0.00b
 
1.4 ± 0.55
c 
2.2 ± 0.45
b,c 
Oviduct  Intraluminal proteinaceous fluid 1 of 4 1 of 5 2 of 5 
L Exfoliation * 0.3 ± 0.50 0.2 ± 0.45 0.4 ± 0.55 
 Interepithelial inflammatory cells 0.0 ± 0.00 0.4 ± 0.55 0.6 ± 0.55 
 Infiltration of pmc in the lamina propria 0.3 ± 0.50 0.0 ± 0.00 0.0 ± 0.00 
 Infiltration of mnc in the lamina propria 1.3 ± 0.50 1.4 ± 0.89 1.4 ± 0.55 
Urethra Interepithelial inflammatory cells 0.3 ± 0.50 0.2 ± 0.45 0.0 ± 0.00 
 Infiltration of mnc in the lamina propria 1.0 ± 0.00 0.8 ± 1.30 1.4 ± 1.52 
#
 The mean scores ± SD for the histopathological parameters which are not shown in the table, were 
0.0 ± 0.00 for the three groups. * Superficial layer of exfoliated (epithelial) cells and/or inflammatory 
cells. pmc: polymorphonuclear inflammatory cells; mnc: mononuclear inflammatory cells. 
a
 P < 0.05 for 
a comparison of the control group and the infection group. 
b
 P < 0.05 for a comparison of the control 
group and the re-infection group. 
c
 P < 0.05 for a comparison of the infection group and the re-infection 
group. 
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4. Discussion 
Genital C. suis infections are likely to be transmitted venereally, since these bacteria have been 
detected in the semen of boars (Kauffold et al., 2006b; Teankum et al., 2006; Schautteet et al., 
2013). However, non-sexual transmission cannot be ruled out, for instance by fecal 
contamination of the vagina. In fact, C. suis has been commonly detected in the gastrointestinal 
tract of pigs (Schiller et al., 1997a), and in most of the cases it is associated with subclinical 
infections. Therefore, the gastrointestinal tract could serve as a reservoir for chlamydial genital 
tract infection (Yeruva et al., 2013). In this study, female pigs were successfully infected in the 
genital tract with C. suis strain S45, which was isolated from feces of an asymptomatic pig. This 
indeed suggests that persistent intestinal C. suis infections are able to cause pathology in the 
genital tract of pigs. 
In the present study, all infected animals showed gross pathology at necropsy. However, the pigs 
that were infected once had significantly more severe lesions than the re-infected animals. 
Moreover, more chlamydial EBs and inclusions were found in the urogenital tract of the infection 
group than in the re-infected pigs. For the infection group, chlamydial replication occurred 
throughout the urogenital tract and even in the ovaries, whereas for the re-infection group, 
inclusions were scarce. This indicates that a certain level of protection against re-infection was 
developed following primo-infection. This presumption is in accordance with human 
epidemiologic studies suggesting that prior genital infection with Chlamydia trachomatis, which 
is phylogenetically highly related to C. suis, confers some short term protection against re-
infection (Barnes et al., 1986; Rietmeijer et al., 2002). Moreover, in all evaluated animal models 
of genital chlamydial infection, including the mouse (Barron et al., 1984), guinea pig (Rank et 
al., 1988) and macaque (Wolner-Hanssen et al., 1991), it has been demonstrated that at least 
partial immunity to re-infection develops. Nevertheless, vaginal inoculation with C. suis resulted 
in an ascending infection in both groups. Likewise, C. trachomatis was able to ascend in the 
genital tract of pigs after intravaginal inoculation (Vanrompay et al., 2005). No chlamydial 
bacteria were detected outside the urogenital tract. With the exception of the lymphogranuloma 
venereum strains, C. trachomatis also does not disseminate beyond the urogenital tract (Morrison 
and Caldwell, 2002). 
Infection of the female porcine genital tract with C. suis resulted microscopically in a slight 
increase of mononuclear inflammatory cells in the mucosa of the corpus uteri, both uterine horns 
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and the right oviduct. Surprisingly, this histopathological finding was even more prominent when 
animals were re-infected, which is not in accordance with the less severe macroscopic lesions and 
the lower mean scores for the presence of chlamydial bacteria observed in this group. However, 
these mononuclear cells, including lymphocytes and plasma cells, may indicate the mobilization 
of memory cells in response to re-infection and can contribute to protective immunity against 
infection. In the future, we will include immunohistochemistry to obtain in situ information on 
the cells contributing to this partial protection. Schautteet et al. (2011b) also observed that 
protection against gross lesions was correlated with a higher infiltration of mononuclear 
inflammatory cells in the genital tract mucosa of pigs intravaginally infected with C. trachomatis. 
Vaginal chlamydial excretion was observed in all infected animals from three days post infection 
onwards. There were no differences noticed between shedding after primo-infection and re-
infection. Interestingly, vaginal excretion started to decrease gradually at four weeks post primo-
infection and one out of five animals stopped shedding chlamydial bacteria at 56 days post 
infection. Since the animals were infected again at that moment, we could not determine whether 
the pigs were able to resolve a genital C. suis infection spontaneously after a certain period of 
time. Also, it would have been interesting to follow up the animals for a longer period than three 
weeks post re-infection in order to assess whether chlamydial excretion stops earlier post re-
infection than post primo-infection.  
Primo-infection with C. suis induced antichlamydial IgM and IgG, but no IgA antibodies in sera 
and vaginal secretions. Compared to the antibody responses after primo-infection, re-infection 
with C. suis resulted in lower IgM antibody titers and higher IgG and IgA titers in sera and 
genital secretions, which is illustrative for a secondary antibody response. Furthermore, re-
infection was, in contrast to primo-infection, able to induce C. suis-specific proliferation of 
PBMC after 7 and 10 days, which indicates the mobilization of memory cells in response to re-
infection. Re-infection was associated with a shift to more B cells, monocytes and CD4
-
CD8
+
 T 
cells, but less pDC and CD4
+
CD8
-
 T cells within PBMC. However, the immune responses 
detected in the blood do not necessarily reflect the immune responses induced at the local site of 
infection. Again, immunohistochemistry might assist in determining the local responses. The 
shifts in immune cell populations from the spleen, cervical and pelvic lymph nodes are 
presumably not resulting from C. suis-specific MC since their proliferative responses were not 
statistically different between groups.  
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Primary genital C. suis infection of the re-infection group (nine-week-old pigs) resulted in 
increased secretion of TNF-α, IL-1β, IL-6 and IL-12p40 by PBMC, whereas primo-infection of 
the infection group (seventeen-week-old animals) decreased the IL-1β, IL-8 and IL-10 secretion 
by PBMC. This discrepancy could be due to age differences between both groups at the moment 
of the primo-infection. In pigs, various aspects of the immune system change with age such as the 
level of NK cells, which was shown to be higher in younger pigs (Sutherland et al., 2005; Talker 
et al., 2013). Since NK cells produce cytokines like TNF-α, this can explain the higher cytokine 
production following primo-infection at nine weeks of age. Furthermore, it was demonstrated that 
neonatal porcine blood DCs were more responsive to stimulation with toll-like receptor ligands 
than adult porcine blood DCs, since they showed higher expression levels of cytokines and 
chemokines following stimulation (Auray et al., 2013). After re-infection, higher concentrations 
of IFN-γ and IL-10 were produced by PBMC, next to higher amounts of the cytokines 
upregulated after primo-infection.  
Our data suggest that antibody producing B cells, mononuclear phagocytes, CD8
+
 T cells, and 
IFN-γ may contribute to protection against a genital C. suis infection. The role of IL-10 is less 
clear. Antibodies, and especially mucosal antibodies, albeit not considered as crucial, may 
contribute to protection by neutralization and opsonization of extracellular Chlamydia. Indeed, 
antibodies clearly play an important role in resistance to genital C. muridarum re-infection in 
mice (Morrison and Morrison, 2005). Moreover, mucosal antichlamydial IgA antibodies have 
been associated with the resolution of C. muridarum and C. trachomatis infection in mice and 
women, respectively (Brunham et al., 1983; Morrison et al., 1995). The Th1-type cytokine IFN-γ 
was also shown to be essential for the resolution of C. muridarum infection (Cotter et al., 1997; 
Perry et al., 1997). IFN-γ produced by NK cells, CD4+ Th1 cells and CD8+ cytotoxic T cells is 
known to up-regulate and/or induce expression of major histocompatibility complex (MHC) class 
I and II molecules on a number of cells, including antigen presenting cells. In addition, IFN-γ 
favours immunoglobulin class switching to the IgG2a isotype and activation of cytotoxic 
T lymphocytes, which induce apoptosis in infected cells. IL-10, as the main anti-inflammatory 
cytokine, plays important roles in immune-homeostasis after microbe elimination (Hakimi et al., 
2014). IL-10 expression results in an inhibition of antigen presentation and MHCII expression on 
the surface of infected cells. However, as an anti-inflammatory cytokine, it also deactivates 
macrophages and interferes with the Th1 response through inhibition of the NF-B pathway 
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(Moore et al., 2001). Interestingly, Moore-Connors et al. (2014) showed that C. muridarum 
induces a novel CD43
-
CD1d
hi
CD5
+
 IL-10-producing regulatory B cell population (Bregs) during 
a genital infection in mice. These IL-10 producing B cells displayed bona fide regulatory Breg 
activity by potently suppressing IFN- production in vitro in an IL-10-dependent manner. We do 
not know if these IL-10 producing CD43
-
CD1d
hi
CD5
+
 Bregs do exist in the pig and if they can be 
induced by C. suis, but it could be a possible explanation for our observation that CD4
+
 Th1 cells, 
which are generally considered as crucial immune effectors in antichlamydial immunity, were 
less dominantly present. 
In conclusion, we demonstrated that C. suis strain S45 is pathogenic for the female porcine 
urogenital tract. Chlamydial replication occurred throughout the urogenital tract, causing 
inflammation and pathology. Furthermore, genital infection elicited both cellular and humoral 
immune responses. Compared to the primo-infection of pigs with C. suis, re-infection was 
characterized by less severe macroscopic lesions and significantly less chlamydial EBs and 
inclusions in the urogenital tract. This indicates the development of a certain degree of protection 
following the initial infection. Protective immunity against re-infection coincided with higher 
antichlamydial IgG and IgA antibody titers in sera and vaginal secretions, higher proliferative 
responses of peripheral blood mononuclear cells (PBMC), higher percentages of blood B 
lymphocytes, monocytes and CD8
+
 T cells and upregulated production of IFN-γ and IL-10 by 
PBMC. 
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Abstract 
The present study aims to obtain more knowledge about female genital tract infection and re-
infection with Chlamydia trachomatis serovar L2c, the most recently discovered 
lymphogranuloma venereum serovar, by using a pig model. Intravaginal inoculation of pigs with 
this bacterium resulted in an infection that was confined to the urogenital tract, where 
inflammation and pathology were caused. Re-infection resulted in more severe gross pathology 
than primo-infection and chlamydial colonization of the urogenital tract was similar for primo-
infected and re-infected pigs. This indicates that primo-infection failed to induce protective 
immune responses against re-infection. Indeed, the proliferative responses of mononuclear cells 
from blood and lymphoid tissues to C. trachomatis strain L2c were never statistically different 
among groups, suggesting that C. trachomatis-specific lymphocytes were not generated 
following infection or re-infection. Nevertheless, antichlamydial antibodies were elicited in sera 
and vaginal secretions after primo-infection and re-infection clearly resulted in a secondary 
systemic and mucosal antibody response. Apparently, the induced antibody response could not 
even partially protect the pigs against re-infection.  
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1. Introduction 
Chlamydia trachomatis is an obligate intracellular bacterial pathogen that infects annually over 
100 million individuals (WHO, 2012). C. trachomatis comprises two biovars: the trachoma 
biovar which includes ocular and urogenital strains and the lymphogranuloma venereum (LGV) 
biovar (Moulder, 1984; Batteiger, 1996). The two biovars are serologically subdivided into 
serovars based on the major outer membrane protein (MOMP) (Everett et al., 1999). The ocular 
serovars A, B, Ba and C are primarily associated with trachoma, the leading cause of preventable 
blindness in developing countries (WHO, 2008). The urogenital (D-K, Da, Ia and Ja) and LGV 
(L1-L3, L2a, L2b and L2c) serovars cause sexually transmitted infections. Urogenital infection 
with serovars D to K, including Da, Ia and Ja, can result in cervicitis, urethritis and post-infection 
complications such as pelvic inflammatory disease, ectopic pregnancy, infertility, chronic pelvic 
pain, epididymitis and infant pneumonia. The LGV serovars cause a more invasive disease called 
lymphogranuloma venereum. After transiently infecting epithelial cells, these serovars penetrate 
into the submucosal tissues to infect macrophages and monocytes and consequently spread to 
regional draining lymph nodes (Schachter, 1999). The disease usually manifests as acute inguinal 
lymphadenitis with abscess formation (inguinal syndrome) following urogenital inoculation, 
whereas anorectal entrance of the bacteria can lead to acute hemorrhagic proctitis (anorectal 
syndrome) (Perine and Stamm, 1998; Mabey and Peeling, 2002). Without treatment, persistent 
infections with chronic inflammation arise, resulting in strictures and fistulas of the involved 
region, which can eventually result in serious complications such as genital elephantiasis, 
esthiomene and the frozen pelvis syndrome with infertility (Aggarwal et al., 2002; Gupta et al., 
2006). 
LGV is endemic in parts of Africa, South-East Asia, South America and the Caribbean, while it 
is considered a rare disease in developed countries (Viravan et al., 1996; Behets et al., 1999; 
Mabey and Peeling, 2002). However, since 2003 LGV outbreaks among men who have sex with 
men (MSM) have been reported in Europe (Götz and Nieuwenhuis, 2004; Plettenberg et al., 
2004; von Holstein et al., 2004; Nieuwenhuis et al., 2004; Vall Mayans et al., 2005; Berglund et 
al., 2005; Liassine et al., 2005), North America (Kropp and Wong, 2005; Ahdoot et al., 2006) 
and Australia (Morton et al., 2006). Almost all infected men suffered from severe proctitis, 
characterized by anorectal pain, haemopurulent discharge and rectal bleeding, whereas genital 
and inguinal symptoms were rare. Remarkably, a high proportion of LGV patients was also 
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infected with HIV (Rönn and Ward, 2011). The vast majority of infections was caused by serovar 
L2b, which was first identified in patients from Amsterdam (Spaargaren et al., 2005). Recently, a 
new LGV serovar, called L2c, was isolated from an MSM with severe hemorrhagic proctitis. 
This hypervirulent serovar appeared to be a recombinant of C. trachomatis serovars L2 and D 
(Somboonna et al., 2011). The extent of dissemination of serovar L2c within the MSM 
community still has to be investigated (de Vries et al., 2014). In industrialized countries, LGV is 
very uncommon in women, although a few female patients with cervicitis or without symptoms 
have been described (De Munain et al., 2008; Gomes et al., 2009). Recently, the first case of 
C. trachomatis L2b proctitis in a woman was reported (Peuchant et al., 2011). Furthermore, 
Verweij et al. (2012) described the first urogenital L2b infection in a female patient with bubonic 
LGV. Considering the ongoing outbreaks, the disease has probably spread to bisexual men and 
subsequently to heterosexual women.  Therefore, more LGV infections in women are expected in 
the near future (Verweij et al., 2012).  
The current study investigates the pathogenesis, pathology and immune response of a urogenital 
C. trachomatis serovar L2c infection and re-infection in a pig model. Vanrompay et al. (2005) 
demonstrated that pigs are a suitable animal model to study female genital tract infection with 
C. trachomatis. Pigs are immunologically, genetically and physiologically more closely related to 
humans than rodents and are ethically and practically more convenient than primates.  
 
2. Materials and Methods 
2.1. Chlamydia trachomatis strain 
C. trachomatis strain L2c was isolated from the rectal mucosa of a male who had a history of sex 
with men and suffered from severe hemorrhagic proctitis (Somboonna et al., 2011). The bacteria 
were propagated in cycloheximide-treated McCoy cells using standard procedures (Vanrompay et 
al., 1992) and the tissue culture infective dose (TCID50) of the C. trachomatis stock was 
determined by the method of Spearman and Kaerber (Mayr et al., 1974).  
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2.2. Animals 
Fifteen 9-week-old conventionally bred female pigs were randomly assigned to three groups of 
five pigs, each housed in separate isolation units. The animals were fed ad libitum with a 
commercial starting diet. The pigs were seronegative for antibodies against Chlamydiaceae as 
determined by ELISA. Nasal, rectal and vaginal swabs did not contain chlamydial bacteria as 
determined by culture on McCoy cells.  
 
2.3. Experimental infection and euthanasia 
Table III-1 shows the design of the experiment. On day 0, when pigs were 9 weeks old, all 
groups were anesthetized by intramuscular injection of Zoletil
®
 100 (Virbac Animal Health, 
Louvain La Neuve, Belgium) in 2% Xylazine-M
®
 (VMD, Arendonk, Belgium). The control 
group and the infection group were inoculated intravaginally with phosphate-buffered saline 
(PBS). The re-infection group was infected by intravaginal injection of 1 x 10
7
 TCID50 of 
C. trachomatis strain L2c. Intravaginal inoculation was performed by inserting an artificial 
insemination pipette connected to a syringe into the vagina and injecting 1 ml PBS or 1ml of the 
bacterial suspension in PBS. On day 56, the 17-week-old pigs were anesthetized again. 
Subsequently, the control group was inoculated with PBS, whereas the infection group and the 
re-infection group were infected intravaginally with C. trachomatis strain L2c (1 x 10
7 
TCID50). 
At day 77, when pigs were 21 weeks old, all animals were euthanized by intravenous injection of 
an overdose of pentobarbital (70 mg/kg; Nembutal
®
, Ceva Santé Animale, Maassluis, the 
Netherlands) followed by exsanguination. All animal procedures were in accordance with the 
guidelines of the animal care and ethical committee of Ghent University. 
 
Table III-1: Experimental design 
Group (n) Day 0 Day 56 Day 77 
Control (5) Mock infection (PBS) Mock infection (PBS) Euthanasia 
Infection (5) Mock infection (PBS) Primo-infection (10
7
 TCID50) Euthanasia 
Re-infection (5) Primo-infection (10
7
 TCID50) Re-infection (10
7
 TCID50) Euthanasia 
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2.4. Sample collection and processing 
Vaginal swab samples in 2 ml sucrose-phosphate transport medium (2-SP) for chlamydial 
isolation as well as in 2 ml PBS with protease inhibitor for mucosal antibody detection were 
collected weekly. These samples were stored at -80°C until tested. Additionally, blood samples 
(v. jugularis) for antibody detection were taken weekly. Blood was stored overnight at room 
temperature and centrifuged (9300 × g, 20°C, 10 min) to collect serum. Sera were stored at -20°C 
until analysis. Peripheral blood mononuclear cells (PBMC) were isolated at 7 and 10 days post 
infection or re-infection to determine their proliferative responses and immune cell 
subpopulations.  
At euthanasia, pigs were examined for gross lesions that were scored as none (0), slight (1), 
moderate (2) or severe (3). Monomorphonuclear cells (MC) from the spleen, the cervical lymph 
node (lymphonodulus cervicalis superficialis) and the pelvic lymph nodes (the lymphonoduli 
iliaci mediales, the lymphonoduli iliaci laterales, the lymphonoduli sacrales and the 
lymphonoduli anorectales) were collected to analyze the proliferative responses and immune cell 
subpopulations. Samples of the spleen, liver, pelvic lymph nodes, caecum, urethra, vagina, 
cervix, corpus uteri, uterine tubes, oviducts and ovaries were imbedded in methylcellulose 
medium, frozen in liquid nitrogen and stored at -80°C until preparation of cryostat tissue sections 
for the detection of C. trachomatis antigen. Samples from the same tissues were fixed in 10% 
phosphate-buffered formalin for histopathology.  
 
2.5. C. trachomatis detection in swabs and tissue sections 
Vaginal swabs in 2-SP were shaken for 1 h at 4°C, centrifuged and cultured in McCoy cells 
grown on 13 mm cover slips in Chlamydia Trac Bottles (International Medical, Brussels, 
Belgium) using standard techniques (Vanrompay et al., 1992). Before the inoculum was added to 
the cells, they were washed twice with 1 ml phosphate buffer supplemented with 0.003% DEAE-
dextran. Chlamydial growth was analyzed using the Mikrotrak direct immunofluorescence 
staining (Kordia, Leiden, The Netherlands) at 6 days post inoculation. Cryostat tissue sections 
(5 µm) were also stained by use of the Mikrotrak immunofluorescence test. All slides were 
examined by immunofluorescence microscopy (BX41 Olympus, 600×). C. trachomatis positive 
cells were counted in five randomly selected microscopic fields. A score ranging from 0 to 6 was 
given for each swab or tissue section. Score 0 indicated that there were no C. trachomatis 
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positive cells. Score 1 and 2 indicated a mean of 1 to 5 and 6 to 10 EBs per microscopic field in 
the absence of inclusions, respectively. Score 3 represented more than 10 EBs and 1 inclusion-
positive cell per microscopic field. Score 4, 5 and 6 indicated 1 to 5, 6 to 10 and more than 10 
inclusion-positive cells per microscopic field, respectively. 
 
2.6. Histopathology 
Tissue samples were fixed in 10% phosphate-buffered formalin, dehydrated and embedded in 
paraffin, sectioned at 5 µm and stained with haematoxylin and eosin. Slides were examined 
blindly by a veterinary pathologist. The microscopic findings were either graded (none (0), 
minimal (1), slight (2), moderate (3), marked (4) or severe (5) histological change) or indicated as 
present or absent without a grade.  
 
2.7. Serum and mucosal antibody analysis 
Sera were heat inactivated at 56°C during 30 min and subsequently pretreated with kaolin to 
reduce background signals in ELISA (Novak et al., 1993). Vaginal swabs in PBS with protease 
inhibitor were shaken for 1 h at room temperature. Isotype-specific serum and mucosal antibody 
titers were determined using a C. trachomatis L2c ELISA. Briefly, Maxisorp 96-well microtiter 
plates were coated with purified C. trachomatis strain L2c EBs diluted in PBS. Plates were 
blocked overnight with PBS supplemented with 5% bovine serum albumin (BSA) at 4°C. 
Antibody titers were determined using twofold dilution series in dilution buffer (PBS + 3% BSA 
+ 0.05% Tween
®
20), starting at a dilution of 1:15. Serum and swab samples from a previous 
experimental infection in pigs (Schautteet et al., 2012) were used as positive and negative 
controls. Antibody isotype titers were analyzed using monoclonal antibodies against swine IgA 
(mAb 27.8.1), IgG (mAb 23.3.1b) and IgM (mAb 28.4.1) (Van Zaane and Hulst, 1987) at a 
dilution of 1:15, 1:20 and 1:50, respectively, followed by an 1:5000 dilution of biotinylated anti-
mouse IgG (H+L) (Dako, Glostrup, Denmark). Subsequently, the plates were incubated with 
1:2500 diluted peroxidase-labeled streptavidin (Zymed Laboratories, San Francisco, USA). 
Finally, the substrate and chromogene ABTS (2, 2'-Azino-di(3-ethylbenzthiazoline-6-sulfonate); 
KPL, Maryland, USA) was added. Antibody titers were defined as the inverse of the highest 
sample dilution giving an absorbance value at 405 nm above the cut-off value (mean absorbance 
of seronegative pig serum at a dilution of 1:15 + twice the standard deviation).  
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2.8. PBMC and MC proliferation assay 
At 7 and 10 days post infection or re-infection, PBMC were isolated from heparinized blood 
samples collected from the jugular vein by density gradient centrifugation (500 × g, 18°C, 
25 min) on Lymphoprep
TM 
(Axis-Shield, Oslo, Norway). Subsequently, the erythrocytes were 
lysed with ammonium chloride. After centrifugation (270 × g, 4°C, 10 min), the cells were 
washed and resuspended in leukocyte medium (RPMI-1640 (Life Technologies, Merelbeke, 
Belgium) supplemented with 5% heat-inactivated FCS (Life Technologies), 5×10
−5
 M β-
mercaptoethanol (Life Technologies), 1% non-essential amino acids (Life Technologies), 
1% sodium pyruvate (Life Technologies), 1% L-glutamine (Life Technologies), 1% penicillin-
streptomycin and 1% kanamycin). At euthanasia, monomorphonuclear cells (MC) were isolated 
from the spleen, the cervical lymph node (cervicalis superficialis) and the pelvic lymph nodes 
(iliaci mediales, iliaci laterales, sacrales and anorectales). Isolation of MC was performed by 
mincing the tissues, after removal of the surrounding fat. Erythrocytes were lysed with NH4Cl 
solution and the cells were washed and subsequently resuspended in leukocyte medium without 
β-mercaptoethanol. PBMC or MC were placed in 96-well tissue culture plates at a concentration 
of 5 × 10
5
 cells per well. Proliferative responses were tested by adding 10
5
 C. trachomatis 
purified L2c EBs, 10 µg concanavalin A (ConA) (positive control) or medium (negative control) 
to the wells. Each condition was tested in duplicate. The cells were incubated at 37°C in a 
humidified atmosphere with 5% CO2. ConA- or antigen-induced proliferation was measured by 
incorporation of 1 µCi/well of 
3
H-thymidine (Amersham ICN, Bucks, UK) for the last 16 h of a 
3-day or 4-day culture period, respectively. Cells were harvested onto glass fiber filter strips 
(Perkin Elmer, Life Science, Oosterhout, The Netherlands) with a cell harvester (Skatron, Liers, 
Norway) and radioactivity was measured with a β-scintillation counter (Perkin Elmer). As a 
measure of proliferative response, stimulation indices (SI) were calculated as the ratio of the 
mean counts per minute of stimulated PBMC or MC versus the mean counts per minute of the 
negative control. 
 
2.9. Flow cytometric analysis of immune cell subpopulations 
The immune cell subpopulations in the blood, the spleen, the cervical and pelvic lymph nodes 
were examined by flow cytometry. T cell populations (CD3
+
CD4
+
CD8
-
, CD3
+
CD4
-
CD8
+
, 
CD3
+
CD4
+
CD8
+
, CD3
+
CD4
-
CD8
-
, T cells with a γδ T cell receptor), B cells (MHCII+CD21+, 
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MHCII
+
IgM
+
), monocytes (MHCII
+
SWC3
+
), NK cells (CD3
-
CD4
-
CD8
+
) and plasmacytoid 
dendritic cells (pDC) (CD3
-
CD4
+
CD8
-
) were analyzed. For the lymphoid tissues the CD3
-
CD4
+
CD8
-
 population does not exist entirely of pDC, but also contains an unknown lineage, 
presumably of myeloid origin (Mair et al., 2014). It was impossible to distinguish between both 
populations based on the used markers. PBMC and MC (10
6
 cells) were incubated for 20 minutes 
at 4°C in staining buffer (RPMI-1640 + 1% heat-inactivated FCS) with optimal concentrations of 
monoclonal antibodies (Table III-2). Cells stained with isotype-matched irrelevant mAbs were 
used as a negative control. After incubation, the cells were washed with staining buffer and 
stained with the appropriate isotype-specific Alexa-647-, FITC- or PE-conjugated antibodies 
(Life Technologies) for 20 min at 4°C. Cells were washed twice and resuspended in PBS. Data 
were acquired on a FACSCanto flow cytometer (Beckton Dickinson, Erembodegem, Belgium) 
with a minimum event count of 50 000 and analyzed with FACSDiva® software. Doublets were 
excluded based on FSC-H/FSC-A and SSC-H/SSC-A plots. 
 
Table III-2: Overview of the monoclonal antibodies used in flow cytometry. 
Specificity Clone Isotype Reference 
CD3 PTT3 IgG1 (Yang et al., 1996) 
CD4 74-12-4 IgG2b (Pescovitz et al., 1984) 
CD8α 11/295/33 IgG2a (Saalmüller et al., 1994) 
CD8β PG164A IgG2a (Saalmüller, 1996) 
CD21 BB6-11C9 IgG1 (Saalmüller, 1996) 
IgM 28.4.1 IgG1 (Van Zaane and Hulst, 1987) 
MHCII MSA3 IgG2a (Lunney et al., 1994) 
SWC3a 74-22-15 IgG1 (Pescovitz et al., 1984) 
TCR1-N4 (δ chain) PGBL22A IgG1 (Davis et al., 1998) 
 
2.10. Statistical analysis 
Statistical analyses were performed using SPSS 22. The non-parametric Mann-Whitney U test 
was used to analyze differences between two groups. Results were considered significantly 
different if P<0.05. 
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3. Results 
3.1. Gross lesions  
Table III-3 shows the median scores for gross lesions in the infection and the re-infection group, 
determined at necropsy. Gross lesions were absent in all pigs of the control group. Gross 
pathology was generally more severe for the re-infection group than for the infection group, 
especially in the urogenital tract. All re-infected pigs showed congestion of the urogenital tract 
(Figure III-1A,B,C), while only three pigs (60%) of the infection group had a congested 
urogenital tract. A significantly higher congestion of the uterus, uterine tubes, ligamentum latum 
uteri, mesovarium and urethra was noticed in the re-infection group than in the control and/or the 
infection group. A large amount of clear watery exudate was present in almost the entire genital 
tract of 40% of the pigs of both infected groups and in the uterus of one animal (20%) of the re-
infection group (Figure III-1A,C). The liver of two re-infected pigs (40%) was moderately 
congested, whereas the liver was normal in all animals of the infection group. Gross pathology 
was detected in the spleen of three pigs (60%) of the infection group and four pigs (80%) of the 
re-infection group (Figure III-1D). The pelvic lymph nodes were moderately to severely enlarged 
in all animals of both infected groups. Furthermore, moderate to severe congestion of the pelvic 
lymph nodes was detected in 80% of the pigs of both infected groups (Figure III-1E). Gross 
lesions in the pelvic lymph nodes were significantly different between the control group and both 
infected groups. 
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Table III-3: Gross lesions detected at euthanasia in the infection and the re-infection group*.  
  Median score (range, % of positive animals) in: 
Tissue 
Macroscopic 
lesion 
Infection group Re-infection group 
Vagina Congestion 0 (0-2, 20) 0 (0-2, 40) 
 Serous exudate 0 (0-3, 40) 0 (0-3, 40) 
Cervix Congestion 0 (0-2, 20) 0 (0-0, 0) 
 Serous exudate 0 (0-3, 40) 0 (0-3, 40) 
Uterus Congestion 0 (0-1, 20)
c 
1 (1-3, 100)
b,c 
 Hypertrophy 0 (0-2, 20) 0 (0-1, 20) 
 Serous exudate 0 (0-3, 40) 3 (0-3, 60)
b 
Uterine tubes Congestion 0 (0-1, 40)
c 
1 (1-3, 100)
b,c 
 Serous exudate 0 (0-3, 40) 0 (0-3, 40) 
Oviducts Serous exudate 0 (0-2, 20) 0 (0-2, 40) 
 Dilated 0 (0-2, 20) 2 (0-2, 80)
b 
Lig. latum uteri Congestion 1 (0-2, 60) 2 (0-3, 80)
b 
Mesovarium Congestion 2 (0-3, 60) 2 (0-3, 80)
b 
Urethra Congestion 0 (0-3, 40) 3 (1-3, 100)
b 
Spleen Congestion 0 (0-2, 20) 0 (0-3, 40) 
 Enlargement 0 (0-0, 0) 0 (0-3, 20) 
 red pulp expansion 0 (0-0, 0) 0 (0-2, 20) 
 white pulp expansion 0 (0-3, 40) 0 (0-2, 40) 
Liver Congestion 0 (0-0, 0) 0 (0-2, 40) 
Pelvic lymph nodes Congestion 2 (0-3, 80)
a 
3 (0-3, 80)
b 
 Enlargement 2 (2-3, 100)
a 
3 (2-3, 100)
b 
* The median score (range) in the control group was 0 (0-0) for all tissues. 
a
 P < 0.05 for a comparison of 
the control group and the infection group. 
b
 P < 0.05 for a comparison of the control group and the re-
infection group. 
c
 P < 0.05 for a comparison of the infection group and the re-infection group. 
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Figure III-1: Gross lesions in the re-infection group. (A) The oviducts were dilated by the presence of 
serous exudate in their lumen (arrow a). Hyperemia of the mesovarium and mesosalpinx (arrow b). 
(B) Hyperemia of the lig. latum uteri (arrow c), the mesovarium and mesosalpinx (arrow d) and the 
uterine tubes (arrow e). (C) Hyperemia of the cervical mucosa (arrow f). A large amount of serous exudate 
was detected in the lumen of the vagina, cervix, corpus uteri and uterine tubes. Note the severely dilated 
uterine tube (arrow g). (D) The spleen is enlarged, hemorrhagic (arrow h) and shows expansion of the red 
pulp (arrow i). (E) Enlarged and hemorrhagic pelvic lymph nodes. 
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3.2. Chlamydia trachomatis vaginal excretion 
Vaginal swabs were examined for the presence of viable C. trachomatis using culture in McCoy 
cells. Median culture scores for vaginal swabs of the infection and the re-infection group, 
collected at different time points post infection, are presented in Table III-4. All vaginal swab 
samples of the control group were Chlamydiaceae negative, as were the swabs of the other pigs 
taken before primo-infection. The infection group vaginally excreted C. trachomatis from day 59, 
three days after primo-infection of this group, onwards. In the re-infection group, vaginal 
C. trachomatis shedding was consistently high from day 3 to day 49 post primo-infection and 
was slightly decreased at day 56 and day 59. Median culture scores were again consistently high 
from seven days post re-infection (day 63) onwards. From day 3 to day 56, vaginal shedding in 
the re-infection group was significantly higher than in the control group and the infection group, 
which was not yet infected at these time points. After primo-infection of the infection group, the 
median excretion scores of the infection group and the re-infection group did not differ 
statistically from each other, but were significantly higher than those of the control group. 
 
Table III-4: Vaginal C. trachomatis shedding from 0 to 77 days post infection (dpi) in the infection 
and the re-infection group*.  
 Median score (range) in: 
dpi Infection group Re-infection group 
0 0 (0-0) 0 (0-0) 
3 0 (0-0)
c 
3 (1-3)
b,c 
7 0 (0-0)
c
 3 (3-4)
b,c
 
10 0 (0-0)
c
 3 (1-3)
b,c
 
14 0 (0-0)
c
 3 (3-3)
b,c
 
21 0 (0-0)
c 
3 (3-4)
b,c
 
28 0 (0-0)
c 
3 (3-4)
b,c
 
35 0 (0-0)
c 
3 (3-3)
b,c
 
42 0 (0-0)
c 
3 (2-3)
b,c
 
49 0 (0-0)
c 
3 (1-3)
b,c
 
56 0 (0-0)
c 
1 (0-3)
b,c
 
59 3 (3-3)
a 
1 (1-3)
b 
63 3 (1-3)
a
 3 (1-3)
b
 
66 3 (3-3)
a
 3 (1-3)
b
 
70 3 (3-3)
a
 3 (3-3)
b
 
77 3 (3-3)
a
 3 (1-3)
b
 
* The median score (range) in the control group was 0 (0-0) for all time points. 
a
 P < 0.05 for a 
comparison of the control group and the infection group. 
b
 P < 0.05 for a comparison of the control group 
and the re-infection group. 
c
 P < 0.05 for a comparison of the infection group and the re-infection group. 
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3.3. C. trachomatis detection in tissue sections 
Table III-5 shows the median scores for the presence of C. trachomatis in tissues of the infection 
and the re-infection group at euthanasia. All tissue samples from the control group were negative.  
C. trachomatis was neither detected in the caecum, the spleen, the liver and the pelvic lymph 
nodes of both infected groups. Chlamydial EBs and intracellular inclusions, containing 
replicating chlamydiae, were detected in both the lower and upper genital tract tissues of all pigs 
of the infection and the re-infection group. Thus, an ascending C. trachomatis infection occurred 
in all pigs of both infected groups. Furthermore, chlamydial replication was observed in the 
urethra of three pigs (60%) of the infection group and two pigs (40%) of the re-infection group. 
The urethra of the remaining infected animals contained only EBs, except for the urethra of one 
pig of the re-infection group, which was negative. For all urogenital tissues, median scores were 
significantly higher for the infection and the re-infection group than for the control group. 
Statistical analysis revealed no significant differences between the median scores of both infected 
groups.  
 
Table III-5: Presence of C. trachomatis in tissues of the infection and the re-infection group at 
euthanasia*. 
 Median score (range) in: 
Tissue Infection group Re-infection group 
Vagina 3 (3-4)
a 
3 (1-3)
b
 
Cervix 3 (3-4)
a 
3 (3-3)
b
 
Corpus uteri 3 (2-4)
a 
3 (3-4)
b
 
Uterine horn R 3 (3-4)
a 
3 (1-4)
b
 
Uterine horn L 3 (3-4)
a 
3 (3-5)
b
 
Oviduct R 3 (3-3)
a
 3 (3-4)
b
 
Oviduct L 3 (3-4)
a
 3 (1-4)
b
 
Ovary R 3 (3-3)
a
 3 (0-4)
b
 
Ovary L 3 (3-3)
a
 3 (1-4)
b
 
Urethra 3 (1-4)
a
 1 (0-3)
b
 
* The median score (range) in the control group was 0 (0-0) for all tissues. 
a
 P < 0.05 for a comparison of 
the control group and the infection group. 
b
 P < 0.05 for a comparison of the control group and the re-
infection group. 
c
 P < 0.05 for a comparison of the infection group and the re-infection group. 
 
3.4. Histopathology  
The median scores of the histopathological lesions detected in the urogenital tract of the pigs are 
presented in Table III-6. Statistical differences among groups were only present in the cervix, the 
corpus uteri, the uterine horns and the urethra. In the cervix and the uterine horns interepithelial 
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inflammatory cells had increased slightly in the mucosa of the infection group (Figure III-2B). 
Furthermore, epithelial vacuolation was noted in the cervix, corpus uteri and uterine horns of the 
infection group (Figure III-2B,C). This vacuolation was to a lesser extent also present when 
animals were re-infected. The significantly higher median score for epithelial vacuolation in the 
urethra of the re-infection group was due to the absence of the mucosa in some samples and the 
high value in one animal.  In the oviducts, exfoliated epithelial cells and proteinaceous fluid were 
observed only in both infected groups, however with low incidence and/or severity. The lesions 
noticed in the oviducts and the vagina were not statistically different among groups. No 
histopathological lesions were observed in the ovaries. In the liver of one or two animals of each 
group minimal to slight focal to multifocal mononuclear inflammations within the parenchyma or 
portal areas were noted. This lesion is considered to be a background lesion, frequently observed 
and unrelated to the experimental infection. The liver samples from the other pigs and all spleen, 
caecum and pelvic lymph node samples showed no microscopic lesions. 
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Table III-6: Histopathological findings in the urogenital tract at euthanasia*. 
  Median score (range) in: 
 
Tissue 
 
Histopathological findings
# 
Control 
group 
Infection  
group 
Re-infection  
group 
Vagina Interepithelial inflammatory cells 0 (0-0) 0 (0-1) 0 (0-0) 
 Infiltration of pmc in the lamina propria 0 (0-0) 0 (0-1) 0 (0-0) 
 Infiltration of mnc in the lamina propria 1 (1-2) 0 (0-2) 0 (0-1) 
Cervix Interepithelial inflammatory cells 0 (0-1)a
 
2 (1-4)
a,c 
0 (0-2)
c 
 Degeneration and/or apoptosis of epithelial cells 0 (0-0)a
 
1 (0-2)
a 
0 (0-2) 
 Infiltration of pmc in the lamina propria 0 (0-0) 0 (0-1) 0 (0-0) 
 Infiltration of mnc in the lamina propria 0 (0-2) 2 (0-3) 1 (0-3) 
 Oedema lamina propria 0 (0-0) 0 (0-0) 0 (0-1) 
Corpus Interepithelial inflammatory cells 1 (0-2) 1 (0-2) 0 (0-2) 
uteri Degeneration and/or apoptosis of epithelial cells 0 (0-1)a
 
3 (0-3)
a 
1 (0-2) 
 Infiltration of mnc in the lamina propria 1 (1-2) 2 (1-2) 1 (1-2) 
 Oedema lamina propria 0 (0-1) 0 (0-1) 2 (0-2) 
Uterine Interepithelial inflammatory cells 1 (1-2) 2 (1-3) 1 (1-1) 
Horn R Degeneration and/or apoptosis of epithelial cells 0 (0-0)a
 
2 (1-3)
a 
1 (0-2) 
 Infiltration of mnc in the lamina propria 2 (1-2) 2 (1-3) 1 (1-2) 
 Oedema lamina propria 1 (0-1) 1 (0-1) 1 (0-3) 
Uterine Exfoliation  0 (0-1) 0 (0-0) 0 (0-0) 
Horn L Interepithelial inflammatory cells 1 (0-2) 2 (1-3) 1 (1-2) 
 Degeneration and/or apoptosis of epithelial cells 0 (0-1)a,b
 
2 (1-4)
a 
1 (1-2)
b 
 Infiltration of pmc in the lamina propria 0 (0-0) 0 (0-0) 0 (0-1) 
 Infiltration of mnc in the lamina propria 2 (1-3) 2 (1-2) 1 (0-2) 
 Oedema lamina propria 1 (0-1) 1 (0-1) 1 (0-3) 
Oviduct   Intraluminal proteinaceous fluid 0 of 5 2 of 5 0 of 5 
R Exfoliation  0 (0-0) 1 (0-3) 0 (0-0) 
 Infiltration of mnc in the lamina propria 1 (0-2) 0 (0-1) 0 (0-2) 
Oviduct  Intraluminal proteinaceous fluid 1 of 5 0 of 5 1 of 5 
L Infiltration of mnc in the lamina propria 1 (0-3) 1 (0-2) 2 (0-2) 
Urethra Degeneration and/or apoptosis of epithelial cells 0 (0-0)b
 
0 (0-2) 2,5 (1-4)b
 
 Infiltration of mnc in the lamina propria 0 (0-1) 0 (0-3) 0 (0-0) 
* The median score (range) for the histopathological parameters which are not shown in the table, were 
0 (0-0) for the three groups. 
#
 Exfoliation: superficial layer of exfoliated (epithelial) cells and/or 
inflammatory cells; pmc: polymorphonuclear inflammatory cells; mnc: mononuclear inflammatory cells. 
a
 P < 0.05 for a comparison of the control group and the infection group. 
b
 P < 0.05 for a comparison of 
the control group and the re-infection group. 
c
 P < 0.05 for a comparison of the infection group and the re-
infection group. 
 
Genital C. trachomatis L2c infection in the pig model 95 
 
Figure III-2: Photomicrographs of uterine horn tissue sections stained with hematoxylin and eosin. 
Original magnification ×10 (A, C) or ×40 (B). (A) Minimal lymphocytic infiltration in the lamina propria 
(arrow a) of a control animal. (B and C) Inflammation of the uterine horns of an animal of the infection 
group. Note the interepithelial lymphocytic infiltration (arrow b), the vacuolation of the epithelium 
(arrow c), the oedema in the lamina propria (arrow d) and the lymphocytic infiltration in the lamina 
propria (arrow e). 
 
3.5. Serum and mucosal antibody responses 
Tables III-7 and III-8 show the C. trachomatis L2c-specific IgM, IgG and IgA antibody titers in 
sera and vaginal secretions collected at different time points post infection or re-infection. 
Chlamydial antibodies were never detected in the serum and vaginal swab samples of the control 
pigs. The pigs of the infection and the re-infection group neither had serum or vaginal 
C. trachomatis-specific antibodies before they were infected. Serum IgM, IgG and IgA 
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antibodies were elicited from 7 days post primo-infection onwards and peak titers were reached 
at 14 or 21 dpi. Antichlamydial IgM and IgA were observed in serum samples until 21 and 28 
days post primo-infection, respectively. Serum IgG antibodies, on the other hand, remained 
detectable throughout the experiment in most pigs. C. trachomatis L2c-specific serum IgM, IgG 
and IgA titers increased again following re-infection. Serum IgA titers reached peak levels early 
after re-infection (7 days), whereas serum IgM and IgG titers continued to increase until the end 
of the experiment. Vaginal secretions were positive for antichlamydial IgM, IgG and IgA from 14 
to 21, 14 to 28 and 7 to 21 days post primo-infection, respectively. Mucosal antibodies appeared 
again from 7 (IgM and IgG) or 14 (IgA) days post re-infection onwards. Re-infection clearly 
resulted in a secondary systemic and mucosal antibody response, with significantly lower IgM 
titers and significantly higher IgG and IgA titers than following primo-infection.  
 
  
Table III-7: C. trachomatis L2c-specific IgM, IgG and IgA serum antibody titers of the infection (I) and the re-infection (R) group*. 
  Median titer (range) for: 
  Serum IgM Serum IgG Serum IgA 
Dpi Procedure 
Infection 
group 
Re-infection 
group 
Infection 
group 
Re-infection 
group 
Infection 
group 
Re-infection 
group 
0 Infection R 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
7  0 (0-0)c
 
60 (30-60)
b,c 
0 (0-0)
c 
60 (30-60)
b,c 
0 (0-0) 0 (0-15) 
14  0 (0-0)c
 
480 (120-480)
b,c 0 (0-0)c 240 (120-240)b,c 0 (0-0)c 60 (60-60)b,c 
21  0 (0-0)c
 
240 (60-240)
b,c 0 (0-0)c 120 (60-120)b,c 0 (0-0)c 30 (30-60)b,c 
28  0 (0-0) 0 (0-0) 0 (0-0)c 30 (30-60)b,c 0 (0-0)c 30 (15-30)b,c 
35  0 (0-0) 0 (0-0) 0 (0-0) 0 (0-30) 0 (0-0) 0 (0-0) 
42  0 (0-0) 0 (0-0) 0 (0-0)c 30 (0-30)b,c 0 (0-0) 0 (0-0) 
49  0 (0-0) 0 (0-0) 0 (0-0)c 30 (0-60)b,c 0 (0-0) 0 (0-0) 
56 Infection I & R 0 (0-0) 0 (0-0) 0 (0-0)c 30 (0-60)b,c 0 (0-0) 0 (0-0) 
63  60 (30-60)a
 
30 (30-60)
b 
30 (30-60)
a,c 120 (60-240)b,c 0 (0-15)c 120 (60-120)b,c 
70  480 (120-480)a,c
 
60 (30-60)
b,c 
120 (120-240)
a,c 480 (120-480)b,c 15 (15-15)a,c 30 (30-30)b,c 
77 Euthanasia 120 (60-120)a
 
60 (60-120)
b 
240 (240-480)
a,c 960 (480-1920)b,c 30 (30-30)a,c 15 (15-15)b,c 
* The median IgM, IgG and IgA serum antibody titers (range) in the control group were 0 (0-0) for all time points. 
a
 P < 0.05 for a comparison of 
the control group and the infection group. 
b
 P < 0.05 for a comparison of the control group and the re-infection group. 
c
 P < 0.05 for a comparison 
of the infection group and the re-infection group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table III-8: C. trachomatis L2c-specific IgM, IgG and IgA vaginal secretion antibody titers of the infection (I) and the re-infection (R) 
group*. 
  Median titer (range) for: 
  Mucosal IgM Musocal IgG Mucosal IgA 
Dpi Procedure 
Infection 
group 
Re-infection 
group 
Infection 
group 
Re-infection 
group 
Infection 
group 
Re-infection 
group 
0 Infection R 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
7  0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)c
 
15 (0-30)
b,c 
14  0 (0-0)c
 
60 (30-60)
b,c 
0 (0-0)
c 
60 (30-60)
b,c 0 (0-0)c
 
15 (0-15)
b,c 
21  0 (0-0)c
 
30 (15-30)
b,c 0 (0-0)c
 
120 (30-120)
b,c 0 (0-0) 0 (0-0) 
28  0 (0-0) 0 (0-0) 0 (0-0)c
 
15 (0-30)
b,c 0 (0-0) 0 (0-0) 
35  0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
42  0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
49  0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
56 Infection I & R 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
63  0 (0-0)c
 
30 (30-30)
b,c 0 (0-0)c
 
60 (30-60)
b,c 0 (0-0) 0 (0-0) 
70  60 (60-60)a,c 15 (0-30)b,c 60 (30-60)a,c 120 (120-120)b,c 15 (0-15)a,c 30 (30-30)b,c 
77 Euthanasia 0 (0-30) 0 (0-0) 120 (60-120)a,c 60 (60-60)b,c 0 (0-15)c
 
30 (30-60)
b,c 
* The median IgM, IgG and IgA mucosal antibody titers (range) in the control group were 0 (0-0) for all time points. 
a
 P < 0.05 for a comparison of 
the control group and the infection group. 
b
 P < 0.05 for a comparison of the control group and the re-infection group. 
c
 P < 0.05 for a comparison 
of the infection group and the re-infection group. 
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3.6. PBMC and MC proliferation 
At 7 and 10 days post primo-infection or re-infection, proliferative responses of PBMC to 
C. trachomatis strain L2c were measured. Furthermore, proliferation of spleen, cervical and 
pelvic lymph node MC was determined at euthanasia. Surprisingly, the proliferative activities of 
PBMC and MC were never statistically different among groups (data not shown). The 
proliferative responses to ConA were always positive indicating the viability of the cells and the 
functionality of the assay. 
 
3.7. Immune cell subpopulations 
Flow cytometry was used to identify blood immune cell subpopulations at 7 and 10 days post 
primo-infection or re-infection (Table III-9 and Figure III-3). Seven days after primo-infection of 
the re-infection group, the median percentage of NK cells was significantly higher for the re-
infection group than for the infection group. Three days later, the re-infection group had 
significantly higher median percentages of T cells, γδ T cells and NK cells than the non-infected 
animals. At day 63, 7 days after primo-infection of the infection group and re-infection of the re-
infection group, a significantly higher median percentage of γδ T cells was noticed in both 
infected groups than in the control group. Within total T cells, significantly less CD4
-
CD8
+
 T 
cells were detected in the re-infection group than in the control group. Moreover, the re-infected 
animals had significantly lower median percentages of B cells and monocytes than the other 
groups. At day 66, the re-infection group had significantly lower median percentages of T cells 
and IgM
+
 B cells, but a significantly higher median percentage of pDC than the other groups. At 
that time, the median percentages of T cells and γδ T cells were significantly higher for the 
infection group than for the control group. Furthermore, significantly lower median percentages 
of mature B cells and monocytes were observed in both infected groups than in the control group. 
At euthanasia, immune cell populations in the spleen, cervical and pelvic lymph nodes were also 
determined using flow cytometry (Table III-9 and Figure III-3). For the spleen, significantly 
higher median percentages of CD4
+
CD8
-
 T cells and CD3
-
CD4
+
CD8
-
 MC, containing pDC, 
besides a significantly lower median percentage of total T cells were detected in the non-infected 
animals. The re-infection group had a significantly higher median percentage of NK cells in the 
spleen than the control group. Furthermore, a significantly lower percentage of monocytes was 
present in the spleen of the infection group as compared to the other groups. For the cervical 
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lymph nodes, significantly lower median percentages of CD4
-
CD8
+
 T cells and mature B cells 
were noticed in the infection group than in the control and the re-infection group, respectively. 
For the pelvic lymph nodes, the re-infected pigs had a significantly lower median percentage of 
B cells and a significantly higher median percentage of NK cells. Within total T cells, 
significantly more CD4
-
CD8
-
 T cells were observed in both infected groups than in the control 
group. 
 
 
Figure III-3: Median percentage of different subpopulations within total T cells (CD3
+
), isolated at 7 
and 10 days post infection or re-infection, and in spleen, cervical and pelvic lymph nodes at 
euthanasia. T cells were divided into four subpopulations based on the expression of CD4 and CD8. 
a,b,c 
For each time point or tissue, different letters within a data series are significantly different (P < 0.05). 
C: control group; I: infection group; R: re-infection group. 
a b
a b b
a
b a b
0%
20%
40%
60%
80%
100%
C I R C I R C I R C I R C I R C I R C I R
Day 7 Day 10 Day 63 Day 66 Spleen Cervical LN Pelvic LN
CD4+ CD8- CD4+ CD8+ CD4- CD8- CD4- CD8+
  
Table III-9: Different immune cell populations within PBMC isolated at 7 and 10 days post infection or re-infection, and in spleen, cervical 
and pelvic lymph nodes at euthanasia. 
♯
 C: control group; I: infection group; R: re-infection group. * Total T cells: CD3
+
; γδ T cells: CD8β- TCR1-N4+; Mature B cells: MHCII+ CD21+; 
IgM
+
 B cells (immature and mature naive B cells): MHCII
+ 
IgM
+
; Monocytes: MHCII
+
 SWC3
+
; NK cells: CD3
-
 CD4
-
 CD8
+
; pDC (plasmacytoid 
dendritic cells): CD3
-
 CD4
+
 CD8
-
. ** For the lymphoid tissues the CD3
-
CD4
+
CD8
-
 population does not exist entirely of pDC, but also contains an 
unknown lineage, presumably of myeloid origin. 
a
 P < 0.05 for a comparison of the control group and the infection group. 
b
 P < 0.05 for a 
comparison of the control group and the re-infection group. 
c
 P < 0.05 for a comparison of the infection group and the re-infection group. 
 
 
  Median percentage (range) of: 
 Group
♯
 Total  
T cells *
 
γδ T cells * Mature 
B cells *
 
IgM
+
 
B cells *
 
Monocytes*
 
NK cells * pDC
 
**
 
PBMC 
Day 7 
(7 dpi 1 R) 
C 29.0 (18.7-35.6) 11.4 (9.7-13.7) 10.0 (1.7-12.3) 12.1 (1.7-14.0) 1.2 (1.0-1.4)
a 
3.7 (1.7-6.9) 0.7 (0.5-1.4) 
I 36.0 (18.5-50.8) 16.0 (8.4-26.1) 3.8 (1.5-9.0) 3.4 (1.3-8.2) 0.6 (0.2-0.9)
a 
3.0 (2.0-3.1)
c 
0.9 (0.6-1.6) 
R 33.5 (19.5-40.0) 11.5 (7.8-16.2) 6.8 (3.7-9.6) 6.4 (1.3-9.1) 0.5 (0.3-1.6) 6.0 (4.4-7.0)
c 
1.1 (0.8-1.1) 
PBMC 
Day 10  
(10 dpi 1 R) 
C 13.1 (7.9-17.2)
b 
10.8 (8.7-12.1)
b 
3.1 (1.6-9.6) 3.3 (1.1-6.0) 0.4 (0.3-1.4) 3.5 (1.8-5.2)
b 
1.1 (0.5-1.6) 
I 13.1 (8.0-17.8)
c 
9.7 (8.4-19.9) 3.8 (2.2-7.0) 4.2 (1.1-9.5) 0.4 (0.1-0.9) 3.4 (2.0-4.1)
c 
1.5 (1.0-1.8) 
R 41.6 (22.2-51.5)
b,c 
16.4 (16-19.4)
b 
3.9 (2.4-10.7) 3.8 (2.0-13.4) 0.3 (0.1-1.5) 6.0 (4.2-7.0)
b,c 
1.3 (0.4-2.8) 
PBMC 
Day 63 
(7 dpi 1 I; 7 dpi 2 R) 
C 33.4 (13.3-52.2) 16.8 (7.0-19.7)
a,b 
5.6 (2.3-6.8)
b
 4.1 (2.1-6.8)
b
 0.9 (0.3-1.3)
b
 2.2 (0.5-3.0) 0.6 (0.5-1.3) 
I 45.2 (14.5-66.2) 27.1 (13.6-37.2)
a 
6.2 (2.6-10.6)
c
 5.5 (1.6-10.4)
c
 1.2 (0.2-2.3) 2.1 (1.8-2.6) 0.6 (0.4-1.2) 
R 17.7 (9.1-20.6) 23.1 (18.0-28.3)
b 
1.9 (1.5-2.6)
b,c
 1.7 (1.3-2.4)
b,c
 0.3 (0.2-0.4)
b
 2.5 (1.0-3.1) 0.8 (0.5-1.1) 
PBMC 
Day 66 
(10 dpi 1 I; 10 dpi 2 R) 
C 41.5 (30.9-51.2)
a,b 
20.3 (16.0-21.8)
a 
7.7 (4.1-14.2)
a,b
 6.4 (4.4-10.0)
b
 1.0 (0.6-2.3)
a,b
 2.4 (1.7-3.6) 0.8 (0.6-0.9)
a,b 
I 54.3 (49.5-71.8)
a,c 
24.4 (20.4-39.2)
a 
4.3 (2.3-5.9)
a
 5.0 (2.8-5.5)
c
 0.5 (0.3-0.9)
a,c
 2.1 (1.6-3.5) 0.7 (0.4-0.9)
a,c 
R 12.9 (9.4-17.5)
b,c 
25.9 (17.2-28.6) 2.7 (1.5-3.0)
b
 2.5 (1.1-3.9)
b,c
 0.2 (0.2-0.3)
b,c 
2.4 (1.3-3.6) 1.6 (0.9-1.8)
b,c 
Spleen 
Day 77 
(21 dpi 1 I; 21 dpi 2 R) 
C 33.4 (19.4-47.1)
a 
9.8 (5.9-15.2) 7.2 (1.6-32.7) 6.7 (1.4-29.0) 5.7 (2.6-25.3)
a
 6.2 (2.4-8.2)
b 
2.8 (2.0-6.9)
a,b 
I 46.3 (37.1-55.4)
a 
13.8 (9.6-18.3) 2.6 (1.8-6.0) 2.8 (1.2-6.0) 2.0 (1.4-2.4)
a,c
 9.5 (5.7-14.5) 1.0 (0.5-2.1)
a 
R 44.0 (33.5-50.0) 14.5 (11.0-20.7) 5.1 (4.3-5.8) 3.9 (3.6-4.9) 4.4 (3.0-4.8)
c
 16.0 (8.1-20.9)
b 
1.8 (1.1-2.4)
b 
Cervical LN  
Day 77 
(21 dpi 1 I; 21 dpi 2 R) 
C 54.3 (30.3-57.2) 13.1 (7.7-22.6) 13.4 (10.0-21.1) 13.1 (10.1-20.6) 9.7 (7.1-13) 2.6 (2.3-4.7) 1.6 (0.5-3.7) 
I 44.4 (39.7-60.1) 20.0 (13.4-30.1) 9.6 (5.7-21.2)
c 
7.4 (4.7-20.6) 5.9 (3.5-16.2) 2.0 (1.8-3.9) 3.8 (0.9-5.3) 
R 44.8 (35.4-66.2) 12.7 (10.5-22.2) 17 (11.9-33.2)
c 
13.6 (9.8-23.0) 10.3 (6.5-16.8) 3.5 (3.0-8.5) 1.2 (0.9-7.1) 
Pelvic LN  
Day 77 
(21 dpi 1 I; 21 dpi 2 R) 
C 47.6 (44.8-58.9) 12.6 (9.7-18.5) 11.7 (10.3-14.8)
b 
11.2 (9.1-15.2)
b 
6.3 (2.4-9.3) 4.1 (3.8-4.2)
b 
0.6 (0.3-1.9) 
I 45.0 (38.4-61.2) 18.4 (12.4-22.4) 12.0 (4.3-16.4) 11.7 (3.2-13.8) 4.4 (3.3-6.3) 3.4 (2.4-5.0)
c 
0.7 (0.3-3.7) 
R 51.2 (41.4-53.6) 18.3 (15.1-23.8) 7.7 (6.4-9.1)
b 
6.8 (4.9-8.3)
b
 4.9 (4.1-6.3) 6.6 (6.2-8.0)
b,c 
1.5 (0.6-2.0) 
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4. Discussion 
Since 2003, an ongoing outbreak of lymphogranuloma venereum has been observed among men 
who have sex with men in developed countries (Götz and Nieuwenhuis, 2004; Plettenberg et al., 
2004; von Holstein et al., 2004; Nieuwenhuis et al., 2004; Vall Mayans et al., 2005; Berglund et 
al., 2005; Kropp and Wong, 2005; Liassine et al., 2005; Ahdoot et al., 2006; Morton et al., 
2006). In these countries, LGV is rarely found in women, but this may change in the near future 
by dissemination of the disease to bisexual men and subsequently to women (Verweij et al., 
2012). Women are more prone to develop serious complications, since LGV infections remain 
more often asymptomatic, and therefore untreated, in women (Stary and Stary, 2008). The 
present study aims to obtain more knowledge about female genital tract infection and re-infection 
with C. trachomatis serovar L2c, the most recently discovered LGV serovar, by using a pig 
model.  
At necropsy, gross pathology was generally more severe for the re-infected pigs than for the 
animals which were infected only once. In women, repeated urogenital C. trachomatis infections 
are also associated with an elevated risk of pathological damage resulting in reproductive 
complications, such as pelvic inflammatory disease, ectopic pregnancy and infertility (Westrom 
et al., 1992; Kimani et al., 1996; Hillis et al., 1997; Bakken et al., 2007; Ness et al., 2008). 
Similar levels of C. trachomatis EBs and intracellular inclusions were detected in the lower and 
upper genital tract tissues of the infection and the re-infection group. This indicates that following 
re-infection C. trachomatis L2c could colonize the urogenital tract as efficiently as following 
primo-infection, and therefore that primo-infection failed to induce protective immune responses 
against re-infection. Nevertheless, several epidemiologic studies indicate that protective 
immunity to re-infection, albeit only partial, develops in humans following prior genital infection 
with C. trachomatis (Barnes et al., 1986; Katz et al., 1987; Brunham et al., 1996; Rietmeijer et 
al., 2002; Gomes et al., 2006a; Batteiger et al., 2010) and this is consistent with the findings from 
animal model experiments (Barron et al., 1984; Rank et al., 1988; Wolner-Hanssen et al., 1991).  
The infection was confined to the urogenital tract, since no chlamydial bacteria were found in the 
caecum, spleen, liver and pelvic lymph node samples of the infected animals. This is in 
accordance with the symptoms observed in the patient from which serovar L2c was isolated 
(Somboonna et al., 2011). The patient suffered from a severe localized mucosal disease, namely 
hemorrhagic proctitis, but did not show an inguinal syndrome, indicating that the bacteria had not 
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spread to the inguinal lymph nodes. This lack of dissemination to regional lymph nodes was 
likely due to the presence of a functional cytotoxin, which may also enable innate immune 
evasion. The toxin gene was presumably acquired from serovar D, since it lacks in the known 
LGV genome sequences (Somboonna et al., 2011). Infection of the female porcine genital tract 
with C. trachomatis serovar L2c resulted only in minor microscopic lesions, in particular 
interepithelial inflammatory cells and epithelial vacuolation. This is in contrast with a previous 
study describing genital tract infection of female pigs with two C. trachomatis serovar E strains 
(Vanrompay et al., 2005). Remarkably, histopathological changes were more prominent in the 
genital tissues of the infection group than the re-infection group, which is opposed to the gross 
pathology noticed in both groups. Immunohistochemistry could provide more detailed 
information on the cells involved in the microscopic lesions and therefore will be performed 
during future experiments. 
All infected animals vaginally excreted C. trachomatis from three days post infection onwards. 
Prior infection had no influence on vaginal chlamydial shedding, since similar excretion levels 
were observed after primo-infection and re-infection. Vaginal excretion was consistently high 
until 49 days post primo-infection and was only slightly decreased at day 56, indicating that the 
pigs had not yet resolved the chlamydial infection after 8 weeks. In humans, C. trachomatis 
infection can last several months before spontaneous clearance (Parks et al., 1997; Golden et al., 
2000; Joyner et al., 2002). In some patients infected with LGV serovars, the bacteria could still 
be isolated many years after the primo-infection (McCormack et al., 1979; Dan et al., 1980). 
Antichlamydial IgM, IgG and IgA antibodies were elicited in sera and vaginal secretions 
following primo-infection with C. trachomatis L2c. Re-infection clearly resulted in a secondary 
systemic and mucosal antibody response, with significantly lower IgM titers and significantly 
higher IgG and IgA titers than following primo-infection. However, the induced antibody 
response apparently could not even partially protect the pigs against re-infection. The importance 
of antibodies in immunity to C. trachomatis is still disputed. In women, the amount of IgA in 
cervical secretions was found to correlate inversely with the amount of C. trachomatis recovered 
from the cervix (Brunham et al., 1983). However, high titers of C. trachomatis-specific serum 
antibodies were not associated with resolution of infection in women, but with increased severity 
of post-infection complications (Punnonen et al., 1979). In mice, antibodies are not needed to 
resolve a primary genital C. muridarum infection (Su et al., 1997), but contribute to protection 
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against re-infection (Morrison and Morrison, 2005). In the guinea pig model, antibodies play an 
important role in immunity to both primo-infection and re-infection with Chlamydia caviae 
(Rank et al., 1979; Rank and Barron, 1983b). Interestingly, it was shown that C. trachomatis 
strains of the LGV biovar are more resistant to neutralization by immune sera than strains of the 
trachoma biovar (Peterson et al., 1990). 
The proliferative responses of PBMC and MC to C. trachomatis strain L2c were never 
statistically different among groups, suggesting that C. trachomatis-specific lymphocytes were 
not generated following infection or re-infection. However, antichlamydial antibodies were 
detected, which implies that C. trachomatis-specific B lymphocytes must have been created at a 
certain point. Simultaneously with the proliferation assays, the immune cell subpopulations 
within PBMC and lymphoid tissue MC were analyzed. The observed differences in percentages 
of B and T lymphocytes among groups are considered irrelevant, since no C. trachomatis-
specific lymphocytes appeared to be present at the examined time points. Furthermore, the 
differences in percentages of monocytes, NK cells and pDC between groups were sometimes 
inconsistent. Primo-infection of the re-infection group resulted in a significant increase of NK-
cells in the blood, whereas this was not the case following primo-infection of the infection group. 
However, both the spleen and the pelvic lymph nodes of the re-infected animals contained 
significantly higher percentages of NK cells three weeks post re-infection. NK cells are an 
important component of the innate immune response, which can help control chlamydial 
infections by secreting IFN-γ (Tseng and Rank, 1998). Moreover, it was shown that human NK 
cells are able to lyse epithelial cells infected with C. trachomatis (Hook et al., 2004). 
Nevertheless, an effective protective immune response to genital C. trachomatis infections is 
highly dependent on specific CD4
+
 T-helper Type 1 cells (Ramsey and Rank, 1991; Igietseme et 
al., 1993; Su and Caldwell, 1995), but also on IFN-γ (Cotter et al., 1997; Perry et al., 1997). The 
apparent lack of C. trachomatis-specific T cells following infection or re-infection in the present 
study can explain why the pigs were not even partially protected against re-infection. However, 
the immune responses detected in the blood, the spleen and the cervical and pelvic lymph nodes 
do not necessarily mirror the immune responses elicited at the local site of infection. It would be 
interesting to perform immunohistochemical analysis of genital tract tissues as this could provide 
more information about the local immune response following infection or re-infection. 
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In conclusion, intravaginal inoculation of pigs with Chlamydia trachomatis serovar L2c resulted 
in an infection that was confined to the urogenital tract, where inflammation and pathology were 
caused. Re-infection resulted in more severe gross pathology than primo-infection and 
chlamydial colonization of the urogenital tract was similar for primo-infected and re-infected 
pigs. This indicates that primo-infection failed to induce protective immune responses against re-
infection. Indeed, no C. trachomatis-specific lymphocytes could be detected in the blood and the 
lymphoid tissues following infection or re-infection. However, the cellular immune responses 
need to be further investigated for instance by performing immunohistochemical analysis of the 
infected urogenital tissues. Nevertheless, antichlamydial antibodies were elicited in sera and 
vaginal secretions after primo-infection and re-infection clearly resulted in a secondary systemic 
and mucosal antibody response. Apparently, the induced antibody response could not even 
partially protect the pigs against re-infection.  
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Abstract  
The human pathogen Chlamydia trachomatis is worldwide the leading cause of bacterial sexually 
transmitted disease. Nasal or vaginal nucleic acid vaccination is a promising strategy for 
controlling genital C. trachomatis infections. Since naked nucleic acids are generally not 
efficiently taken up by cells, they are often complexed with carriers that facilitate their 
intracellular delivery. In the current study, we screened a variety of commonly used non-viral 
gene delivery carriers for their ability to transfect newborn pig tracheal cells. The effect of 
aerosolization on the physicochemical properties and transfection efficiency of the complexes 
was also evaluated in vitro. Both mRNA and pDNA containing lipofectamine and ADM70 
complexes showed promise for protein expression in vitro, before and after aerosolization. 
Subsequently, a pilot experiment was performed in which these complexes were aerosolized in 
the vaginal tract of pigs. In vivo, only lipofectamine/pDNA complexes resulted in high protein 
expression levels 24 h following aerosolization. As aerosolization was an easy and effective 
method to deliver complexes to the vaginal tract of pigs, we believe this application technique 
has future potential for both vaginal and perhaps nasal vaccination using non-viral gene delivery 
vectors.  
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1. Introduction 
The human pathogen Chlamydia trachomatis is worldwide the leading cause of bacterial sexually 
transmitted disease, with over 100 million new infections each year (WHO, 2012). This 
bacterium typically infects the mucosal epithelium in the endocervix of women and the urethra of 
men, leading to cervicitis and urethritis, respectively. However, genital tract infections with 
C. trachomatis remain largely subclinical in approximately 70% of women and 50% of men and 
therefore often go undiagnosed (Peipert, 2003; Brunham and Rey-Ladino, 2005). If left untreated, 
these infections can progress to pelvic inflammatory disease in women and epididymo-orchitis 
and prostatitis in men (Manavi, 2006; Cunningham and Beagley, 2008). In women, pelvic 
inflammatory disease may lead to severe reproductive complications including tubal factor 
infertility, ectopic pregnancy and chronic pelvic pain (Westrom et al., 1992; Haggerty et al., 
2010). In addition, genital C. trachomatis infection facilitates the transmission of HIV (Plummer 
et al., 1991) and might be a risk factor for the development of cervical carcinoma (Koskela et al., 
2000; Samoff et al., 2005). Uncomplicated chlamydial infections can be treated effectively with 
antibiotics, such as azithromycin and doxycycline. However, once infection and pathology are 
established, treatment may not prevent complications. Moreover, due to the asymptomatic nature 
of C. trachomatis genital tract infection, the spread of infection cannot be successfully controlled 
by treating only the individuals with clinical symptoms.  
Vaccination is considered as the most effective approach to control genital C. trachomatis 
infection (Stagg, 1998). An ideal vaccine should generate long-lasting and sterilizing immunity 
while avoiding immunopathology. However, a vaccine that prevents ascending infection and 
reduces shedding would already have a major economic and social benefit (Hafner et al., 2008). 
A successful C. trachomatis vaccine will need to induce strong local immunity at the site of 
bacterial entry, which is the vaginal mucosa for women (Holmgren and Czerkinsky, 2005; 
Kanazawa et al., 2009). The vaginal immunization route has been used effectively for inducing 
local immune responses in the female genital tract (Wassén et al., 1996; Holmgren and 
Czerkinsky, 2005; Kanazawa et al., 2009). Moreover, nasal immunization can also give rise to a 
strong mucosal immune response in the genital tract (Johansson et al., 2001).  
Non-viral gene delivery systems carrying plasmid DNA (pDNA) or messenger RNA (mRNA) 
show potential for vaccination purposes. While pDNA has to reach the nucleus of the target cells 
to induce protein expression, mRNA can directly be translated in the cytoplasm to the 
110 Chapter IV 
 
corresponding protein. This is an advantage as the nuclear barrier, which is one of the most 
difficult intracellular barriers to cross, is avoided in mRNA delivery (Symens et al., 2012b). 
mRNA, however, is more easily degraded in living cells, generally leading to a shorter time 
frame of gene expression when compared to pDNA (Tavernier et al., 2011). In general, non-viral 
gene delivery systems are cationic lipids or cationic polymers which spontaneously form 
complexes when mixed with negatively charged nucleic acids. The ideal delivery system should 
protect the nucleic acids against degradation, facilitate cellular uptake (mostly through 
endocytosis) and escape the endosomal compartment to deliver the nucleic acids to the cytoplasm 
(mRNA) or the nucleus (pDNA) of the cells (Remaut et al., 2007). Lipofectamine and JetPEI are 
the most commonly used commercially available lipid-based and polymer-based carriers, 
respectively. Each newly developed carrier is usually compared to at least one of these positive 
controls.  
In previous research, we showed that polycationic amphiphilic cyclodextrins show potential for 
the efficient delivery of mRNA to liver cells (Symens et al., 2012a). In this study, we were 
interested if these cyclodextrins were also efficient in delivering pDNA and mRNA to newborn 
pig tracheal (NPTr) cells, as a representative epithelial cell line for porcine vaginal tissue since a 
porcine vaginal epithelial cell line is not yet established. Before going to in vivo evaluation of 
non-viral gene delivery carriers, we performed in vitro cell assays to identify the most suitable 
gene delivery carriers. The effect of aerosolization on the physicochemical properties and 
transfection efficiency of the complexes was also evaluated in vitro. Then, selected complexes 
were used to perform a pilot experiment in which the non-viral gene delivery complexes were 
aerosolized in the vaginal tract of pigs.  
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2. Materials and methods 
2.1. Carriers 
The lipid based commercial carrier Lipofectamine
®
2000 was purchased from Invitrogen 
(Merelbeke, Belgium). The polymer-based commercial carrier JetPEI (22 kDa linear PEI) was 
obtained from Polyplus Transfection (Leuven, Belgium). DOTAP chloride salt was purchased 
from Avanti Polar Lipids (Alabaster, AL, USA) and DOPE from Lipoid GmbH (Ludwigshafen, 
Germany). The GL67-liposomes were a kind gift of Dr. Seng Cheng (Genzyme Corporation, 
Framingham, MA, USA). They were ex tempore prepared by adding 2.667 ml of RNAse-free 
water to vials containing 4 μmol GL67, 8 μmol DOPE and 0.2 μmol 1,2-Dimyristoyl-sn-glycero-
3-phosphoethanolamine linked to 5 kDa polyethylene glycol (DMPE-PEG5000). The 
cyclodextrin ADM70 was synthesized as described elsewhere (Symens et al., 2012a). 2 kDa and 
25 kDa brPEI were purchased from Sigma-Aldrich (Bornem, Belgium). 
 
2.2. pDNA and mRNA production 
Different plasmids were used: pgWIZ-GFP encoding green fluorescent protein (GFP) 
(GeneTherapy Systems, San Diego, California), pGL-4 encoding luciferase (Promega, Leiden, 
The Netherlands), pGEM4Z-EGFP-A64 for in vitro transcription of eGFP mRNA, and pBlue-
Luc-A50 for in vitro transcription of luciferase mRNA. Heat-competent E. coli transformed with 
the plasmids were grown in LB medium with appropriate antibiotics at 37 °C for 20 h. Plasmids 
were purified with the Qiafilter Plasmid Giga Kit (Qiagen
®
, Venlo, The Netherlands) according 
to the manufacturer‘s instructions. Capped and polyadenylated mRNA was produced by in vitro 
transcription, after purification of the pGEM4Z-EGFP-A64 or pBlue-Luc-A50 plasmid using a 
QIAquick PCR purification kit (Qiagen
®
). Purified plasmids were linearized using SpeI and DraI 
restriction enzymes, respectively, and subsequently used as templates for the in vitro transcription 
reaction using a T7 mMessage mMachine kit (Ambion
®
, Merelbeke, Belgium). mRNAs were 
purified by DNase I digestion, LiCl precipitation and a 70% ethanol wash. The produced 
luciferase mRNA (Luc mRNA) and eGFP mRNA were stored at -80°C at a concentration of 
1 µg/µl. 
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2.3. Complex preparation and characterization 
All dilutions of pDNA, mRNA and carriers were made in Hepes Buffer. Equal volumes of pDNA 
or mRNA (0.1 µg/µl) were mixed with carrier solutions to obtain the desired N/P ratio (for 
polyplexes), +/- charge ratio (for lipoplexes) or molar ratio (for GL67 complexes). After 30 min 
of incubation, 10 µl of each complex solution was diluted to a final volume of 800 µl to perform 
size and zeta potential measurements using a NanoZS Zetasizer (Malvern Instruments, Hoeilaart, 
Belgium).  
 
2.4. In vitro transfections 
In vitro transfections were performed in NPTr cells (Istituto Zooprofilattico Sperimentale, 
Brescia, Italy) (Ferrari et al., 2003) cultured in Dulbecco's modified Eagle‘s medium (DMEM) 
with high glucose and pyruvate (Gibco
®
, Merelbeke, Belgium) containing 10% heat-inactivated 
FCS (Hyclone/Perbio
®
), 2% vancomycin (Eli Lilly, Brussels, Belgium), 1% streptomycin 
(Sigma-Aldrich, Bornem, Belgium), 1% sodium pyruvate (Gibco
®
), 1% L-glutamine (Gibco
®
) 
and 1% non-essential amino acids (Gibco
®
), at 37°C in a humidified atmosphere containing 5% 
CO2. For the transfection experiments, NPTr cells were plated 24 h prior to the experiment into 
24-well plates at 7.5 x 10
4
 cells/well. Subsequently, each well was provided with 10 µl of 
complex solution in 500 µl OPTIMEM, corresponding to 0.5 µg of pDNA or mRNA per well. 
After 4 h incubation, the transfection medium was replaced by fresh culture medium. To evaluate 
the effect of aerosolization on the physicochemical properties and transfection efficiency of the 
complexes, they were aerosolized using a Microsprayer
® 
Aerosolizer in combination with a high-
pressure syringe (Penn-Century, Wyndmoor, USA). Aerosolized complexes were collected in 
Eppendorfs. Typically more than 80% of the aerosolized solution could be recovered. Ten µl of 
each complex solution was used for size and zeta potential measurements and 10 µl for 
transfection experiments as described above.  
 
2.5. Flow Cytometry on transfected NPTr cells 
The eGFP expression was measured with a FACSCalibur flow cytometer (Beckton Dickinson, 
Erembodegem, Belgium) 24 h after transfection. To prepare cells for flow cytometry, cells were 
trypsinized and pelleted at 1300 rpm for 5 minutes. Then, cells were resuspended in 300 µl flow 
Aerosolized nucleic acid delivery in the vaginal tract of pigs 113 
 
buffer. As a control, non-transfected cells were used. For expression efficiencies, the fraction of 
cells expressing eGFP and the average fluorescence intensities were measured. 
 
2.6. Luciferase assay on transfected NPTr cells 
Four or 24 h after transfection, the culture medium was removed and the cells were washed twice 
with PBS (Gibco
®
). Then, 80 µl of Passive Lysis Buffer (Promega™, Leiden, The Netherlands) 
was added per well and the plates were incubated for 15 minutes while rocking. Lysed cells 
(20 µl/well) were transferred to 96-well plates and the luciferase activity of each sample was 
assayed using a GloMax
TM
 96 Luminometer (Promega™, Leiden, The Netherlands) after adding 
80 µl of the substrate solution to each well. The results were expressed as relative light units. 
 
2.7. Viability tests on transfected NPTr cells 
The viability of the cells 24 h post transfection was assayed with an MTT (3-(4,5-
dimethylthiazole-2yl)-2,5-diphenyl tetrazolium bromide) test (Cell Proliferation Kit I; Roche
®
, 
Vilvoorde, Belgium) according to the manufacturer‘s instructions. 100 µl of MTT stock solution 
(5 mg/ml MTT in PBS) was added to the cell culture medium in each well and plates were 
incubated for an additional 3 h. Subsequently, the medium was aspirated and 500 µl of DMSO 
was added to each well in order to dissolve the formazan crystals. The plates were placed on an 
orbital shaker for 10 min and the absorbance of the formed formazan crystals was determined at 
590 nm with reference at 690 nm using the Wallac Envision
TM
 multilabel reader (PerkinElmer, 
Zaventem, Belgium). 
 
2.8. In vivo transfections 
The two most effective gene carriers in NPTr cells, namely Lipofectamine
®
2000 and the cationic 
cyclodextrin ADM70 (N/P 6), were intravaginally administered to pigs to determine their in vivo 
transfection efficiency. Five 9-week-old conventionally bred female pigs were housed in isolation 
units and fed ad libitum with a commercial starting diet. Four pigs were anesthetized by 
intramuscular injection of Zoletil
®
 100 (Virbac Animal Health, Louvain La Neuve, Belgium) in 
2% Xylazine-M
®
 (VMD, Arendonk, Belgium). Subsequently, each of the four pigs received by 
intravaginal aerosolization 250 µg of Luc mRNA or pDNA complexed to Lipofectamine
®
2000 or 
ADM70. Luciferase was chosen over GFP to avoid false positive results due to in vivo 
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autofluorescence in the GFP channel. Therefore, bioluminescence imaging is the first option to 
study in vivo transfection efficiencies. The remaining pig served as control animal and received 
no nucleid acid complexes. Intravaginal aerosol delivery was performed using the Microsprayer
®
 
Aerosolizer in combination with a high-pressure syringe (Penn-Century, Wyndmoor, USA). 
Twenty-four hours after administration of the complexes, all pigs were euthanized by intravenous 
injection of an overdose of pentobarbital (70 mg/kg; Nembutal
®
, Ceva Santé Animale, Maassluis, 
the Netherlands). The experimental procedure was approved by the animal care and ethical 
committee of Ghent University (EC2012/078). 
At euthanasia, the vaginas of all pigs were collected and transported on ice to the laboratory for 
analysis. The expression of luciferase in the vaginal tissues was measured via ex vivo 
bioluminescent imaging within 30 minutes after euthanasia. 1 ml of a 1:10 dilution of D-luciferin 
(15 mg/ml, Gold Biotechnology, St. Louis, MO, USA) was applied to the vaginal tissue and ex 
vivo imaging was performed after 3 to 7 minutes with an IVIS Lumina II (Perkin-Elmer, 
Zaventem, Belgium). Bioluminescence images were obtained using a 7.5 cm field of view, 
binning of 16, f/stop 1 and 120 s exposure time. Regions of interest (ROI) were selected on the 
vaginal tissues with the automatic ROI tool using a threshold of 24%. Subsequently, the 
bioluminescence was measured quantitatively by the Living Image software. For each vaginal 
tissue, the average counts (the sum of all counts for all pixels inside the ROI/number of pixels) 
were determined. 
 
2.9. Statistical analysis 
Statistical analyses were performed using the non-parametric Mann-Whitney U or Wilcoxon 
signed-rank test. Results were considered significantly different if P ≤ 0.05.  
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3. Results 
3.1. Screening of non-viral gene delivery complexes 
In an initial set of experiments, we screened a broad range of non-viral gene delivery complexes, 
to determine which were most suitable to result in mRNA expression in NPTr cells. Figure IV-1 
shows the size and charge of each formulation containing mRNA as determined by dynamic light 
scattering (DLS) and zeta potential measurements. Most complexes had an average size between 
150 – 200 nm and a positive zeta potential between 20 – 40 mV. GL67 formed larger aggregates, 
presumably because of the neutral zeta potential of this formulation. Branched PEI 2 kDa N/P 
ratio 4 and especially 8 also formed larger complexes, although the zeta potential of these 
formulations was positive. Lipofectamine complexes had the most negative zeta potential (-16 ± 
3 mV) but were small in size (149 ± 25 nm).    
 
  
Figure IV-1: Size (bars) and zeta potential (squares) of different mRNA/carrier complexes as 
depicted in the x-axis.   
 
Then, complexes containing mRNA encoding for eGFP were used to transfect NPTr cells and 
eGFP expression was measured 24 h later. Both the number of eGFP positive cells (Figure IV-2, 
top graph) and the average eGFP expression per cell (Figure IV-2, bottom graph) were measured 
for each mRNA/carrier complex. Lipofectamine/mRNA complexes, which served as a positive 
control, indeed gave both the highest percentage of eGFP positive cells, as well as the highest 
average amount of protein expressed per cell. The mRNA complexes with the cationic liposomes 
DOTAP/DOPE at an N/P ratio of 4 and 8 and the GL67/mRNA complexes showed less eGFP 
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positive cells (20%, 25% and 11% respectively). Also the average amount of eGFP expression 
per cell was much less compared to the one for the lipofectamine/mRNA complexes. For the PEI 
based carriers JetPEI (lineair 22 kDa PEI) and 25 kDa brPEI, the number of cells expressing 
eGFP did not exceed 10%. The cells that did get transfected, however, expressed relatively high 
levels of eGFP. On the contrary, the transfection efficiency of the shorter 2 kDa brPEI was 
extreme low. The mRNA complexes with the cationic cyclodextrin ADM70 reached transfection 
efficiencies of 30-40% and resulted in high average fluorescence intensities per cell, which 
showed a decreasing trend with increasing N/P ratio of the complexes. Taken together, these data 
indicate that lipofectamine and the cationic cyclodextrin ADM70 were the most effective gene 
carriers in NPTr cells. 
 
 
Figure IV-2: Percentage of eGFP positive cells (top graph) and average fluorescence intensity per 
cell (bottom graph) following transfection of NPTr cells with different mRNA/carrier complexes as 
depicted in the x-axis. * Significantly different from the lipofectamine/mRNA complexes (P ≤ 0.05). 
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3.2. Cytotoxicity of mRNA/carrier complexes 
All mRNA complexes except for those with GL67 and JetPEI were cytotoxic (Figure IV-3). The 
most efficient complexes in terms of transfection efficiency, namely lipofectamine and 
cyclodextrins ADM70 N/P 4, 6, 8 and 10 resulted respectively in 30%, 45%, 33%, 52% and 47% 
of cell toxicity, indicating cell death, or that cells had become less metabolically active than the 
non-transfected cells. 
 
 
Figure IV-3: Cell viability of NPTr cells treated with different mRNA/carrier complexes as depicted 
in the x-axis. Blanc represents non-transfected cells and DMSO served as positive control. * Significantly 
different from non-treated cells (blanc) (P ≤ 0.05).    
 
3.3. Effect of aerosolization on in vitro GFP gene expression of selected complexes 
Cells were transfected with eGFP encoding mRNA or pDNA complexes collected after 
aerosolization and with non-aerosolized mRNA and pDNA complexes as control (Figure IV-4, A 
and B). Transfection efficiencies were normalized to the one of non-aerosolized lipofectamine 
complexes. For the mRNA complexes, only the transfection efficiencies of complexes with 
ADM70 at N/P 6 and 8 diminished after aerosolization, with a maximum decrease in efficiency 
of 40% (Figure IV-4A). Figure IV-4C shows that the size of the mRNA complexes did not 
change after aerosolization. The charge of the mRNA complexes, however, was slightly lower 
when using ADM70 at N/P 4, 6 or 8 (Figure IV-4C, circles). pDNA complexes were more 
affected by aerosolization than mRNA complexes. pDNA complexes with lipofectamine and 
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ADM70 at N/P 4, 6, 8 and 10 had a loss in transfection efficiency of 38%, 43%, 60%, 39% and 
30%, respectively, when compared to their non-aerosolized counterparts (Figure IV-4B). Figure 
IV-4D, however, shows that the charge did not change for any of the complexes upon 
aerosolization, while the size increased only for ADM70 at N/P 4 and 6. In conclusion, 
aerosolization can lead to some loss in transfection efficiency, but at least 60% to 40% of the 
initial transfection level can still be reached upon high pressure aerosolization of the mRNA and 
pDNA containing complexes, respectively. 
 
 
 
Figure IV-4: Normalized transfection efficiencies of mRNA complexes (A) and pDNA complexes (B) 
before (black bars) and after (grey bars) aerosolization. Transfection efficiencies were normalized to 
the one of lipofectamine complexes before aerosolization. (C) and (D) represent the size (white bars: 
before aerosolization, grey bars: after aerosolization) and zeta potential (square: before 
aerosolization, circle: after aerosolization) of mRNA and pDNA complexes, respectively.  
 
 
 
 
A      mRNA B                pDNA 
C      mRNA D                pDNA 
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3.4. In vivo transfection efficiencies 
For the in vivo experiment, lipofectamine and ADM70 N/P 6 complexes containing mRNA or 
pDNA encoding for luciferase were prepared. Twenty-four hours after the intravaginal 
aerosolization of the complexes, the pigs were euthanized and the luciferase expression in the 
vaginal tissues was determined via bioluminescent imaging (Figure IV-5 and Table IV-1). The 
bioluminescent signal of the vagina from the pig that received lipofectamine/pDNA complexes 
was much higher than the signals of the other vaginal tissues. The vagina of the pig administered 
with ADM70/mRNA complexes had a bioluminescent signal that was only slightly higher than 
the signal of the control tissue. The bioluminescence emitted by the vaginal tissues of the pigs 
that received ADM70/pDNA and lipofectamine/mRNA complexes was approximately three and 
six fold higher, respectively, than that of the control tissue. These data indicate that the in vivo 
transfection efficiency of aerosolized lipofectamine complexes was higher than that of 
aerosolized ADM70 complexes. Moreover, aerosolized pDNA complexes appeared to transfect 
the vaginal tissue of pigs more efficiently than aerosolized mRNA complexes. 
 
Table IV-1: Bioluminescent emission from vaginal tissues collected from pigs 24 hours post 
intravaginal aerosol administration of different complexes.  
Administered complex Average counts 
- (Control) 13.54 
ADM70/mRNA 23.23 
ADM70/pDNA 40.70 
Lipofectamine/mRNA 81.61 
Lipofectamine/pDNA 1008.00 
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Figure IV-5: Bioluminescent images of vaginal tissues collected from pigs 24 hours after 
intravaginal aerosol administration of ADM70/pDNA complexes (A), ADM70/mRNA complexes (B),  
lipofectamine/pDNA complexes (C) or lipofectamine/mRNA complexes (D).  
 
3.5. In vitro time dependent mRNA and pDNA luciferase gene expression 
The in vivo aerosolization results clearly show that lipofectamine/pDNA complexes perform 
much better on the 24 h time scale when compared to mRNA complexes. In the previous 
screening experiments with mRNA and pDNA encoding for eGFP, however, these differences 
were not observed that clearly. As it is known that the luciferase protein has a much shorter half-
life than the eGFP protein (3 h versus 24 h respectively), we wondered whether the luciferase 
expression peak for mRNA appeared sooner than the 24 h time scale chosen for the in vivo 
experiment. Therefore, NPTr cells were transfected in vitro with lipofectamine and ADM70 
complexes containing pDNA and mRNA coding for luciferase, and transfection efficiencies were 
determined after 4 h and 24 h to get insight in the time dependent expression kinetics. Figure IV-
6 shows that for pDNA containing complexes, the initial expression after 4 h was still very low 
(black bars). 20 h later, all expression efficiencies had increased respectively 700-fold, 350-fold, 
A B 
C D 
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6000-fold, 1750-fold and 1550-fold for lipofectamine and ADM70 at N/P 4, 6, 8 and 10, 
indicating that the 24 h time point is indeed a good time to read out pDNA induced protein 
expression (Figure IV-6, dark grey bars). For mRNA containing complexes, the expressed 
amount of luciferase was always higher at the 4 h time point (grey bars) than at the 24 h time 
point (white bars). Compared to the 4 h time point the luciferase expression at the 24 h time point 
was 8-fold, 5-fold, 5.5-fold, 2-fold and 4-fold lower for lipofectamine and ADM70 at N/P 4, 6, 8 
and 10, respectively. Although it is clear that there was already a decrease in the expected 
luciferase level 24 h after transfection, this does not explain the differences of luciferase 
expression observed in the in vivo transfection experiment. For lipofectamine/mRNA complexes, 
for example, the transfection efficiency after 24 h reached the same level as the one for 
lipofectamine/pDNA complexes in vitro (Figure IV-6, dark grey bars and white bars), while in 
vivo, only the lipofectamine/pDNA complexes resulted in a high level of luciferase expression 
(Table IV-1).       
 
 
Figure IV-6: Luciferase expression efficiencies of lipofectamine and ADM70 complexed to pDNA 
and mRNA, 4 h and 24 h following transfection. 
a 
Significantly lower luciferase expression than the one 
of the lipofectamine complexes with the same type of nucleic acid (pDNA or mRNA) at the same 
time point (4h or 24h) (P ≤ 0.05). b Significantly different from the ADM70 N/P 4 complexes with 
the same type of nucleic acid (pDNA or mRNA) at the same time point (4h or 24h) (P ≤ 0.05). c 
Significantly different from the ADM70 N/P 6 complexes with the same type of nucleic acid 
(pDNA or mRNA) at the same time point (4h or 24h) (P ≤ 0.05). d Significantly different from the 
ADM70 N/P 8 complexes with the same type of nucleic acid (pDNA or mRNA) at the same time 
point (4h or 24h) (P ≤ 0.05). 
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4. Discussion 
Nasal or vaginal vaccination is potentially the best strategy for inducing protective immunity 
against genital C. trachomatis infections, as both can give rise to strong mucosal immune 
responses in the female genital tract (Wassén et al., 1996; Johansson et al., 2001; Holmgren and 
Czerkinsky, 2005; Kanazawa et al., 2009). In recent years, attention has turned to nucleic acid 
vaccination as a way of inducing protective responses against intracellular bacteria. One of the 
main advantages of nucleic acid vaccination compared to the more conventional vaccination 
methods is that the vaccine antigens are produced de novo by the host cells. Consequently, DNA 
and mRNA vaccines mimic natural infection and are able to stimulate both branches of the 
adaptive immune system (Longbottom and Livingstone, 2006; Geall et al., 2013). During 
previous vaccination studies in pigs, intravaginal and combined intravaginal and intranasal 
immunization with an unformulated DNA vaccine induced significant protection against genital 
C. trachomatis challenge (Schautteet et al., 2011a, 2012). However, complete protection was 
never observed. The potency of the previously used DNA vaccine might be improved by 
increasing its transfection efficiency, as it is known that naked nucleic acids are often not 
efficiently taken up by cells. Therefore, nucleic acids can be complexed with carriers that 
facilitate their intracellular delivery. Non-viral vectors are preferred over viral ones, to avoid 
nonspecific immunological responses. Non-viral gene delivery systems, however, still suffer 
from limited transfection efficiency in living organisms.  
In the current study, we aimed to screen a variety of commonly used non-viral gene delivery 
systems for their ability to transfect NPTr cells. Based on the in vitro transfection data, a pilot 
experiment was performed in which selected complexes were aerosolized in the vaginal tract of 
pigs. Via this administration method the DNA or mRNA complexes can reach a large epithelial 
surface, as the generated droplets can be propelled much further in the genital tract and hence 
reach the endocervical mucosa, which contains an IgA transport mechanism and mucosa 
associated lymphoid tissues (Iwasaki, 2010). Lipofectamine was chosen as the reference lipid-
based carrier while 22 kDa JetPEI served as the commercially available polymer-based carrier. 
Other lipid-based carriers in the study were DOTAP/DOPE and GL67 based liposomes. As 
polymer-based carriers, brPEI of different molecular weights (2 kDa and 25 kDa) was tested as 
well as the promising cationic cyclodextrin ADM70. In vitro screening revealed that 
lipofectamine showed the best transfection results, both on the level of number of eGFP positive 
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cells and average protein production per cell, followed by the cationic cyclodextrins. Branched 
PEI 2 kDa, DOTAP/DOPE liposomes and GL67 based liposomes performed the least. The low 
transfection efficiency of 2 kDa brPEI is in agreement with Bettinger et al. (2001) who reported 
that mRNA transfection using small PEI polymers is low without the use of chloroquine. 
Furthermore, for the 2 kDa brPEI and the GL67 based liposomes the low transfection efficiency 
could be related to the larger size of the complexes and the lower zeta potential as observed in 
Figure IV-1. In general it is assumed that cationic complexes are better taken up in living cells 
due to their interaction with the negatively charged cell membrane. Complexes prepared with the 
commercially available lipofectamine, however, were very efficient despite the fact that they 
were the most negatively charged. JetPEI and 25 kDa brPEI resulted in a good level of protein 
expression per cell. Nevertheless, as only a small percentage of cells was transfected, both 
polymers were excluded from further aerosolization experiments. It has indeed been shown that 
these carriers are less effective for mRNA delivery than for pDNA delivery. The binding of these 
cationic polymers to single-stranded mRNA is stronger than to pDNA which prevents its 
cytosolic release (Karikó et al., 2008). 
When the most promising carriers lipofectamine and ADM70 were aerosolized before 
transfecting the cells, a decrease, of maximal 40%, in transfection efficiency was observed for 
ADM70 based mRNA complexes with a N/P ratio of 6 and 8. pDNA-based complexes were 
more sensitive for aerosolization, with on average 40% loss in transfection efficiency. This 
decrease in transfection efficiency cannot be attributed to an altered charge of pDNA complexes 
as no differences in zeta potential were observed before and after aerosolization.  Since the size 
of the pDNA complexes increased slightly for ADM70 at N/P 4 and 6 upon aerosolization, an 
altered size could contribute to the decrease in transfection efficiency for the cyclodextrins, but 
not for lipofectamine. Therefore, we hypothesize that pDNA containing complexes may have 
suffered from the friction caused by the high pressure aerosolization which potentially changed 
the tertiary structure of the pDNA. Overall, however, it seems that most complexes still retained a 
high potential to induce protein production in vitro, upon aerosolization.  
To our surprise, however, the in vivo data demonstrated that only lipofectamine/pDNA 
complexes resulted in a significant amount of expressed protein 24 hours following intravaginal 
aerosolization in pigs. Nevertheless, pDNA has to enter the nucleus where it is transcribed into 
mRNA molecules, which are subsequently translated in protein in the cytoplasm. It is well known 
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that the transport of pDNA in the nucleus is very ineffective in non-dividing cells (Capecchi, 
1980; Mirzayans et al., 1992; Thorburn and Alberts, 1993; Zabner et al., 1995). In contrast to 
pDNA, mRNA does not have to enter the nucleus to be successful. As most of the cells in the 
vaginal epithelium are non-dividing cells, one would expect that mRNA transfection would be 
much more effective than pDNA transfection. It should be noted that for the in vivo experiment, 
mRNA and pDNA coding for luciferase were used instead of nucleic acids encoding eGFP. 
Additional in vitro experiments demonstrated that mRNA complexes already resulted in high 
expression efficiencies 4 h after administration, which was the earliest measured time point. This 
agrees with the fact that mRNA complexes should only deliver their mRNA to the cytoplasm of 
the cells, where it directly can be translated to the corresponding protein. On the same time scale, 
pDNA, which had to reach the nucleus of the cells, resulted in significantly less protein 
expression. For lipofectamine, the mRNA induced protein expression level was 4500-fold higher 
than the pDNA induced expression on the 4 h time scale. On the 24 h time scale, mRNA induced 
protein levels had already decreased, while pDNA expression had increased, corresponding to the 
fact that more pDNA succeeded to reach the nucleus after 24 h. Also, the chance that cells have 
divided increases over 24 h, facilitating the nuclear entry of pDNA (Symens et al., 2012b). For 
mRNA, however, it can be expected that a large fraction of the delivered mRNA had already 
been degraded in the cytoplasm of the cells. Therefore, it seems that mRNA containing 
lipofectamine complexes were more active on the short time scale, while pDNA containing 
lipofectamine complexes resulted in a delay in protein expression, but longer expression in 
function of time. However, the transfection efficiency of the lipofectamine/mRNA complexes 
after 24 h reached the same level as the one for lipofectamine/pDNA complexes in vitro, while in 
vivo, only the lipofectamine/pDNA complexes resulted in a high level of luciferase expression. 
Therefore, it seems that the difference in expression kinetics between mRNA and pDNA 
complexes cannot explain why pDNA transfection was higher than mRNA transfection. 
Likewise, Andries et al. (2012) found that in the lungs of mice pDNA complexes result in a 
higher gene expression than mRNA complexes. They showed that this difference may be related 
to the lower stability of lipid based mRNA complexes in the presence of negatively charged 
biopolymers, which are abundantly present in lung as well as vaginal mucus. It is well known 
that mRNA is very vulnerable to degradation by ribonucleases, which are present in all 
organisms. Therefore, enzymatic degradation of mRNA and/or release of the bound mRNA from 
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the complexes after contacting biological fluids may be a possible explanation for the low 
transfection efficiency of mRNA complexes after intravaginal aerosolization in pigs. 
For ADM70 complexes, the same trend could be seen. The overall amount of expressed 
luciferase was however always lower when compared to lipofectamine. There are several 
possible reasons why ADM70 seemed to deliver less (intact) mRNA and pDNA in the cells. First 
of all, the complexes could carry less nucleic acids per complex and/or display a lower level of 
cellular internalization. Furthermore, lipofectamine might be much more efficient than the 
cyclodextrins on the level of endosomal escape, leading to less complexes escaping into the 
cytoplasm of the cells. Once in the cytoplasm, it is possible that the nucleic acids are too strongly 
attached to the cationic cyclodextrins, leading to a lower concentration of nucleic acids that 
dissociate from the complexes. Alternatively, nucleic acids could be too loosely attached, so 
premature release occurs in the extracellular environment or in the endosomal vesicles. Finally, it 
is possible that nucleic acids are less protected against nucleases in the extracellular and/or 
intracellular environment. As endosomal escape is one of the most important steps in intracellular 
nucleic acid delivery (Martens et al., 2014), we hypothesize that lipofectamine can deliver much 
higher concentrations of nucleic acids in the cytoplasm (and eventually also the nucleus) of the 
cells. It is indeed known that lipid-based carriers can efficiently escape the endosomal 
compartment, resulting in the release of free nucleic acids in the cytoplasm of the cells (Rehman 
et al., 2013b). Also, the endosomal vesicles can serve as a depot from which nucleic acids are 
constantly released over time. This is in contrast to PEI-based carriers, for example, which are 
known to escape the endosomes in a single burst event (Rehman et al., 2013a). It should be noted 
that for the cationic cyclodextrins used in this study, the mechanism of endosomal escape is not 
clear yet. Based on the in vitro data, however, we would expect at least some transfection 
efficiency in vivo for the ADM70/pDNA complexes at N/P 6, as they resulted in only a 9-fold 
lower level of luciferase expression after 24 h when compared to lipofectamine. It is well known 
that extracellular barriers like negatively charged biomolecules can alter the gene delivery 
complexes. Therefore, it is possible that the ADM70 complexes were less stable in the 
extracellular vaginal fluid when compared to lipofectamine complexes.         
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5. Conclusion 
In conclusion, both mRNA and pDNA containing lipofectamine and ADM70 complexes show 
promise for protein production in vitro, before and after aerosolization. In vivo, however, only 
lipofectamine/pDNA complexes resulted in high protein expression levels 24 h following 
intravaginal aerosolization in pigs. It is clear that mRNA-based complexes are better suited for 
protein expression on the short term (e.g. first 4 hours), while pDNA-based complexes have a lag 
phase before protein expression is observed, corresponding to the time the pDNA needs to reach 
the nucleus of the cells. A boost in antigen expression was shown to be preferred over a 
prolonged expression of antigens for optimal vaccination (Ponsaerts et al., 2003; Gilboa and 
Vieweg, 2004). The boost in antigen expression following mRNA vaccination better mimics 
antigen expression during an acute infection and therefore may be more favorable to induction of 
antigen-specific immune responses (Ulmer et al., 2012). However, aerosolized pDNA complexes 
appeared to transfect the vaginal tissue of pigs more efficiently than aerosolized mRNA 
complexes. Enzymatic degradation of mRNA and/or release of the bound mRNA from the 
complexes after contacting biological fluids may be a possible explanation for the low in vivo 
transfection efficiency of the mRNA complexes. The reasons why ADM70 did not result in high 
transfection levels in vivo remain unclear. It is also possible that these complexes are less stable 
in the vaginal fluid, an extracellular barrier that was not present in the in vitro setup. Furthermore, 
it should be noted that while in vitro both lipofectamine- and ADM70-based complexes showed 
toxicity toward the transfected cells, in vivo no signs of inflammation or irritation were observed 
at the site of aerosolization. As aerosolization was an easy and effective method to deliver 
complexes to the vaginal tract of pigs, we believe this application technique has future potential 
for both vaginal and nasal vaccination using non-viral gene delivery vectors.     
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Chlamydia suis is widespread in farmed pigs throughout the world and causes important 
economic losses (Schautteet et al., 2013). C. suis can cause conjunctivitis, rhinitis, pneumonia 
and enteritis as demonstrated by experimental infection of gnotobiotic and conventionally raised 
pigs (Rogers et al., 1996; Rogers and Andersen, 1996, 1999, 2000; Sachse et al., 2004; Reinhold 
et al., 2008; Guscetti et al., 2009). C. suis infections are also associated with numerous 
reproductive disorders (Sarma et al., 1983; Woollen et al., 1990; Schiller et al., 1997b; 
Eggemann et al., 2000; Kauffold et al., 2006a; Schautteet et al., 2013). However, the role of 
C. suis in reproductive problems is still controversial because studies involving experimental 
genital tract infection of pigs with C. suis are lacking. 
In chapter II, we proved the pathogenic potential of C. suis for the female porcine urogenital tract 
by infecting conventionally raised female pigs intravaginally with strain S45, the type strain of 
C. suis. Chlamydial replication occurred throughout the urogenital tract, causing inflammation 
and pathology. Thus, although C. suis is often still considered as an insignificant pathogen of 
pigs, it was demonstrated to be a primary pathogen of not only the respiratory system, 
gastrointestinal tract and eyes, but also the urogenital tract. Furthermore, we established an 
experimental challenge model that is suitable for further pathological and immunological 
investigations of urogenital C. suis infections and will probably also be useful for studying 
preventive measures, such as vaccines. 
Urogenital C. suis infections are believed to be mainly transmitted venereally during mating or 
artificial insemination, as these bacteria have been detected in the semen of boars (Kauffold et 
al., 2006b; Teankum et al., 2006; Schautteet et al., 2013). However, we showed that a C. suis 
strain obtained from feces of an asymptomatic pig was able to infect the urogenital tract of 
female pigs. This indicates that transmission might also occur through fecal contamination of the 
vagina. Therefore, the gastrointestinal tract could serve as a reservoir for chlamydial genital tract 
infection (Yeruva et al., 2013), especially since the majority of the natural intestinal C. suis 
infections seems to be subclinical (Zahn et al., 1995; Szeredi et al., 1996; Englund et al., 2012). 
Considering these two possible transmission routes, repeated genital C. suis infections probably 
occur frequently, especially in breeder sows. Therefore, we compared C. suis genital tract re-
infection with primo-infection. After the initial infection, the pigs developed partial immunity 
against re-infection, which implies that it would be possible to develop a vaccine against genital 
C. suis infections. We determined which immune cells may contribute to this partial protection 
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by analyzing the immune responses following primo- and re-infection and thus provided valuable 
information for vaccine development. Furthermore, the less severe macroscopic lesions following 
re-infection indicated that immunopathology was not induced after two consecutive infections. If 
immunopathology would not be an issue for urogenital C. suis infections, this would facilitate the 
development of a vaccine against these infections. On the other hand, repeated and chronic 
urogenital infections with C. trachomatis, which is phylogenetically highly related to C. suis, 
have been associated with the development of immunopathology (Debattista, 2003; Haggerty et 
al., 2010; Darville and Hiltke, 2010). Thus, further research is certainly needed to investigate the 
role of immunopathology in urogenital C. suis infections. 
Chlamydial infections in pigs are preferentially treated with tetracycline or its derivatives 
(Chopra and Roberts, 2001). However, tetracycline resistant C. suis strains have been isolated in 
the USA and more recently also in Europe and Israel (Andersen and Rogers, 1998; Di Francesco 
et al., 2008; Borel et al., 2012; Schautteet et al., 2013). Moreover, Suchland et al. (2009) 
demonstrated that the tetracycline resistance gene tet(C) can be transferred horizontally between 
C. suis and the human pathogen C. trachomatis in vitro. This might also occur in vivo, since 
C. suis was recently detected in human samples (Dean et al., 2013; De Puysseleyr et al., 2014a, 
2014b), indicating the zoonotic potential of this bacterium. In fact, Dean et al. (2013) found both 
C. suis and C. trachomatis in conjunctival samples from a few Nepalese people. The introduction 
and spread of tetracycline resistance into C. trachomatis strains would cause major public health 
concerns, because tetracycline and its derivatives are important therapeutic agents in the fight 
against these infections, particularly in the developing world. Therefore, the emergence of 
tetracycline resistance in C. suis strains is of great concern for both animal and human health and 
urges the need to develop preventive measures, such as vaccination. 
The ideal veterinary vaccine should be inexpensive, feasible for industrial mass application, safe, 
genetically and physically stable and induce long-term heterotypic protective immune responses 
with a single dose (van Drunen Littel-van den Hurk et al., 2000). Nucleic acid vaccines have the 
potential to address some or all of these qualities. One of the main advantages of nucleic acid 
vaccination compared to the more conventional vaccination methods is that the vaccine antigens 
are produced de novo by the host cells. Therefore, DNA and mRNA vaccines mimic natural 
infection and are able to elicit cell-mediated as well as humoral immune responses (Longbottom 
and Livingstone, 2006; Geall et al., 2013). However, the use of nucleic acid vaccines in food 
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producing animals should be carefully investigated to ensure that neither animals nor consumers 
develop unpredicted or undesirable side-effects (van Drunen Littel-van den Hurk et al., 2000). 
Nevertheless, mRNA vaccination encompasses less safety issues than DNA vaccination, as 
mRNA is expressed during a controlled period of a few days while the expression of pDNA is 
uncontrolled, since its expression in mice can be transient or last for months (Pascolo, 2008).  
Furthermore, since C. suis can infect the mucosal epithelium of the respiratory system, 
gastrointestinal tract, urogenital tract and the conjunctiva, an ideal C. suis vaccine should induce 
protective immunity at all of these mucosal surfaces. Parenteral vaccination may sometimes 
protect against mucosal pathogens, but usually a mucosal vaccination route is necessary to give 
rise to mucosal immunity. However, the immune responses induced at one mucosal site do not 
disseminate widely to other mucosal tissues because of the anatomic compartmentalization within 
the mucosal immune system. In general, the strongest immune response is obtained at the site of 
vaccine application and in anatomically adjacent mucosae. Nevertheless, a few exceptions have 
been found that may allow for more practical vaccine administration. Nasal immunization not 
only triggers an immune response in the respiratory tract but can also give rise to a strong 
immune response in the genital tract. Sublingual immunization can even induce immune 
responses in the gastrointestinal, respiratory and genital tract (Holmgren and Czerkinsky, 2005; 
Holmgren and Svennerholm, 2012). Unfortunately, sublingual vaccine administration will 
probably not be feasible to use in the pig industry. Therefore, a C. suis vaccine should be 
administered to multiple mucosal sites, for instance the conjunctival, nasal and rectal mucosa, to 
be able to protect against conjunctival, respiratory, gastrointestinal and urogenital infection. 
However, this would augment the cost price of vaccination. Therefore, it would probably be more 
cost-effective to focus on the urogenital C. suis infections as these are likely to cause the most 
important economic losses. Of course, this presumption needs further investigation.  
Differences in genetic susceptibility of various pig breeds to pathogens such as pseudorabies 
virus (Reiner et al., 2002b), porcine reproductive and respiratory syndrome virus (PRRSV) 
(Halbur et al., 1998), E. coli (Duchet-Suchaux et al., 1991; Michaels et al., 1994), and 
Sarcocystis miescheriana (Reiner et al., 2002a) have been reported. Therefore, it would be 
interesting to investigate whether pig breed-dependent differences in the susceptibility to C. suis-
associated disease also exist. Women carrying single-nucleotide polymorphisms in 
C. trachomatis PRR genes, such as TLR4 and TLR9, were shown to be at increased risk of tubal 
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pathology following a C. trachomatis infection (den Hartog et al., 2006). Since studies on the 
genetic diversity of TLRs identified pronounced differences between different pig breeds 
(Palermo et al., 2009; Yang et al., 2013), the analysis of polymorphisms in TLRs and their 
influence on susceptibility to C. suis may provide a useful tool in the selection of pigs that are 
more resistant to chlamydial infections (Mair et al., 2014). 
 
Chlamydia trachomatis is the most common cause of bacterial sexually transmitted disease 
globally with over 100 million new infections each year (WHO, 2012). These infections are an 
important public health concern as they cause substantial morbidity and economic cost 
worldwide, especially in women. Despite attempts to increase education regarding safe sex 
practices and the availability of antibiotic therapy, the incidence of C. trachomatis infections has 
continued to rise in many countries (ECDC, 2009, 2014; WHO, 2012). It is widely accepted that 
current control measures are insufficient and that definitive control of these infections will 
require the development of an effective vaccine (de la Maza and de la Maza, 1995). 
Animal models are indispensable for the study of C. trachomatis infections and the development 
and evaluation of candidate vaccines. Most studies have used mouse, guinea pig or non-human 
primate models (De Clercq et al., 2013). Our research group showed that pigs are a suitable large 
animal model for studying C. trachomatis genital infection and evaluating potential chlamydial 
vaccines (Vanrompay et al., 2005; Schautteet et al., 2011b). The pig model could be an 
intermediate animal model between rodents and non-human primates or even a substitute for the 
non-human primate models since pigs are immunologically, genetically and physiologically more 
closely related to humans than rodents and are ethically and practically more convenient for use 
as laboratory animals than primates (Bray et al., 2003; Tuggle et al., 2003; Dawson et al., 2013).  
In chapter III, we demonstrated that the pig model, which was established for investigating 
female genital tract infection with urogenital C. trachomatis serovars, can also be used to study 
genital infection with LGV serovars. LGV infections have been less intensively studied than 
infections with noninvasive urogenital serovars, because LGV is considered a rare tropical 
disease. However, since 2003 LGV outbreaks among MSM have been reported in many 
developed countries (Götz and Nieuwenhuis, 2004; Plettenberg et al., 2004; von Holstein et al., 
2004; Nieuwenhuis et al., 2004; Vall Mayans et al., 2005; Berglund et al., 2005; Kropp and 
Wong, 2005; Liassine et al., 2005; Ahdoot et al., 2006; Morton et al., 2006). In these countries, 
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LGV is very uncommon in women, but this may change in the near future by dissemination of 
the disease to bisexual men and subsequently to women (Verweij et al., 2012). Women are more 
likely to develop serious complications than men, since LGV infections remain more often 
subclinical, and thus untreated, in women (Stary and Stary, 2008).  
To obtain more knowledge about female genital tract infection with LGV serovars, we infected 
and re-infected female pigs intravaginally with the most recently discovered LGV strain, called 
L2c. Despite the induction of a systemic and mucosal antibody response following the initial 
infection, the pigs were not even partially protected against re-infection. At present, the 
importance of antibodies in immunity to C. trachomatis is still a matter of debate. However, in 
this study the humoral immune responses did not seem to contribute to protection. Since re-
infection resulted in more severe macroscopic lesions, this model might be useful to study the 
development of immunopathology following repeated C. trachomatis genital tract infections. 
The hypervirulent L2c strain, which was used in this study, appeared to be a recombinant of the 
invasive LGV strain L2 and the noninvasive urogenital strain D. Therefore, it was suggested that 
recombination might be a mechanism for emergence of new strains and can greatly impact 
disease severity (Somboonna et al., 2011). Historically, horizontal gene transfer among 
Chlamydiaceae was considered unlikely due to their obligate intracellular niche and because co-
infection, and therefore occasions for recombination, are rare (Harris et al., 2012). However, 
comparative genetics and genomics of various C. trachomatis strains have shown that 
recombination is frequent (Brunham et al., 1994; Dean et al., 1995; Millman et al., 2001; Gomes 
et al., 2006b, 2007; Somboonna et al., 2011; Joseph et al., 2011; Joseph and Read, 2012). The 
degree of recombination in C. trachomatis may complicate efficacious vaccine development as 
this requires the identification of genomic regions that are stable and cross protective (Joseph et 
al., 2012). 
 
Our research group developed a DNA vaccine expressing the major outer membrane protein 
(MOMP) of a C. trachomatis serovar E strain and tested its ability to induce protective immunity 
against genital C. trachomatis infection in the pig model following intradermal, intravaginal and 
combined intravaginal and intranasal administration (Schautteet et al., 2011a, 2012). Intradermal 
vaccination was significantly less efficient in protecting pigs against genital C. trachomatis 
challenge than mucosal vaccination, which indicates that a mucosal vaccine will be required to 
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control genital chlamydial infections. Moreover, combined intravaginal and intranasal 
vaccination resulted in a significantly higher level of protection than vaginal vaccination. This is 
in accordance with the findings of Johansson et al. (2001) who showed that not only vaginal but 
also nasal immunization can give rise to strong mucosal immune responses in the female genital 
tract. However, even the combined administration route could not completely eradicate the 
chlamydial bacteria. The protective ability of the DNA vaccine can probably be improved by 
increasing its transfection efficiency, as the spontaneous uptake of naked nucleic acids by host 
cells is very inefficient. To enhance nucleic acid delivery into the host cells, synthetic gene 
carriers, such as cationic liposomes and cationic polymers, can be used. These cationic carriers 
spontaneously interact with nucleic acids through electrostatic interactions to form positively 
charged nanoparticles that are more easily taken up by host cells. Moreover, they protect the 
nucleic acids against degradation by nucleases (De Smedt et al., 2000; Greenland and Letvin, 
2007). Furthermore, the immunogenicity of the C. trachomatis vaccine might be enhanced by 
using mRNA instead of DNA for immunization, as the boost in antigen expression following 
mRNA vaccination better mimics antigen expression during an acute infection and hence may be 
more favorable for induction of antigen-specific immune responses (Ulmer et al., 2012). 
Although mRNA does not contain CpG motifs, it can also act as a natural adjuvant by stimulating 
the innate defense system of the host through TLR3, which recognizes double-stranded RNA, or 
TLR7 and TLR8, which recognize single-stranded RNA (Heil et al., 2004; Karikó et al., 2004; 
Scheel et al., 2005; Smits et al., 2008; Tavernier et al., 2011).  
In chapter IV, we therefore screened several gene delivery carriers for their ability to transfect 
porcine tracheal cells. Furthermore, we examined the effect of aerosolization on the 
physicochemical properties and in vitro transfection efficiency of the nucleic acid/carrier 
complexes, as this is the preferred method for intranasal vaccine administration. Both mRNA and 
pDNA containing lipofectamine and ADM70 complexes showed promise for protein expression 
in vitro, before and after aerosolization. In addition, we performed a pilot experiment in which 
these complexes were aerosolized in the vaginal tract of pigs. Aerosolization appeared to be an 
easy and effective method for vaginal delivery of complexes and hence has future potential for 
vaginal vaccine administration. In contrast to the in vitro data, in vivo only lipofectamine/pDNA 
complexes resulted in high protein expression levels 24 hours following aerosolization. 
Unfortunately, lipofectamine is very expensive and therefore not feasible for use in future 
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vaccination studies in the pig model. The reasons why ADM70 complexes did not result in high 
transfection levels in vivo remain unclear. It is possible that these complexes were less stable in 
the extracellular vaginal fluid than the lipofectamine complexes. Therefore, we could try to 
improve the in vivo performance of the ADM70-based pDNA and mRNA complexes by 
increasing their stability. Alternatively, brPEI may be a suitable DNA delivery carrier for our 
purpose, as it was shown that the use of this cationic polymer improved the potency of a 
C. psittaci DNA vaccine following aerosol delivery (Verminnen et al., 2010). However, brPEI 
seems to be less suited for mRNA delivery, since the transfection efficiency of brPEI/mRNA 
complexes was much lower than that of lipofectamine and ADM70 complexes containing mRNA 
in our study.  
In future vaccination studies in the pig model, it would be interesting to test whether intranasal 
vaccination alone is sufficient to protect pigs against genital C. trachomatis infection, as nasal 
vaccination would be more practical than vaginal vaccination for future use in humans. 
Moreover, the outcome of vaginal vaccination might be dependent on the phase of the menstrual 
cycle of females, since sex hormones affect the immune responses in the female genital tract 
(Johansson et al., 2001; Hafner et al., 2013). For instance, they regulate both antigen presentation 
by dendritic cells and the number of macrophages and antigen-presenting cells found within 
vaginal and uterine tissues (Wira and Rossoll, 1995; Prabhala and Wira, 1995). However, 
Kanazawa et al. (2009) demonstrated that vaginal immunization promoted vaginal antibody 
production to a significantly greater extent than nasal immunization. Johansson et al. (2001), on 
the other hand, found that nasal vaccination elicited the strongest antibody responses in vaginal 
secretions, while vaginal vaccination was superior in inducing an antibody response in the cervix. 
Therefore, these authors suggested that a combination of nasal and vaginal vaccination might be 
the best strategy for inducing a protective antibody response in the female genital tract. 
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Summary 
Chlamydiaceae are obligate intracellular Gram-negative bacteria that cause a variety of diseases 
in humans and animals. This thesis focuses on the species Chlamydia suis and C. trachomatis. 
C. suis is widespread in commercial pig production and causes important economic losses 
(Schautteet et al., 2013). C. suis infections are associated with conjunctivitis, rhinitis, pneumonia, 
enteritis, periparturient dysgalactiae syndrome and numerous reproductive disorders (Sarma et 
al., 1983; Woollen et al., 1990; Rogers et al., 1996; Rogers and Andersen, 1996, 1999; Schiller et 
al., 1997b; Eggemann et al., 2000; Kauffold et al., 2006a; Reinhold et al., 2008; Guscetti et al., 
2009; Schautteet et al., 2013). The human pathogen C. trachomatis is worldwide the leading 
cause of bacterial sexually transmitted disease, with over 100 million new infections each year 
(WHO, 2012). Urogenital infection with noninvasive C. trachomatis strains can result in 
cervicitis, urethritis and post-infection complications such as pelvic inflammatory disease, 
ectopic pregnancy, infertility, chronic pelvic pain, epididymitis and infant pneumonia. The LGV 
strains cause a more invasive disease called lymphogranuloma venereum (LGV). Despite 
attempts to increase education regarding safe sex practices and the availability of antibiotic 
therapy, the incidence of C. trachomatis infections has continued to rise in many countries 
(ECDC, 2009, 2014; WHO, 2012). It is widely accepted that current control measures are 
insufficient and that definitive control of these infections will require the development of an 
effective vaccine (de la Maza and de la Maza, 1995). 
 
Chapter I gives a short overview of the taxonomy and biology of chlamydial infections, 
followed by a more detailed description of the epidemiology, pathogenesis, prevention and 
treatment of C. suis and C. trachomatis infections. Furthermore, the host immune response to 
genital C. trachomatis infection is reviewed as well as the different animal models used to study 
these infections. Finally, the general principle, advantages and disadvantages of nucleic acid 
vaccines and the current strategies to optimize them are described. 
 
In chapter II, we investigated the characteristic features of genital C. suis infection and re-
infection in female pigs. Conventionally raised Chlamydia-negative pigs were intravaginally 
infected and eight weeks later re-infected with C. suis strain S45, the type strain of this species, 
whereafter the immune response, pathological changes, replication of chlamydiae in the 
138  Summary 
urogenital tract and vaginal excretion of viable bacteria were examined. We demonstrated that 
S45 is pathogenic for the female urogenital tract. Chlamydia replication occurred throughout the 
urogenital tract, causing inflammation and pathology. Furthermore, genital infection elicited both 
cellular and humoral immune responses. Compared to the primo-infection of pigs with C. suis, 
re-infection was characterized by less severe macroscopic lesions and less chlamydial elementary 
bodies and inclusions in the urogenital tract. This indicates the development of a certain level of 
protection following the initial infection. Protective immunity against re-infection coincided with 
higher Chlamydia-specific IgG and IgA antibody titers in sera and vaginal secretions, higher 
proliferative responses of peripheral blood mononuclear cells (PBMC), higher percentages of 
blood B lymphocytes, monocytes and CD8
+
 T cells and upregulated production of IFN-γ and IL-
10 by PBMC.  
 
In chapter III, we examined the immune response, pathology and chlamydial replication and 
excretion following urogenital C. trachomatis serovar L2c infection and re-infection in the pig 
model developed by Vanrompay et al. (2005). Serovar L2c is the most recently discovered LGV 
strain and is a recombinant of the LGV strain L2 and the noninvasive strain D (Somboonna et al., 
2011). Intravaginal inoculation of pigs with this bacterium resulted in an infection that was 
confined to the urogenital tract, where inflammation and pathology were caused. Re-infection 
resulted in more severe gross pathology than primo-infection and chlamydial colonization of the 
urogenital tract was similar for primo-infected and re-infected pigs. This indicates that primo-
infection failed to induce protective immune responses against re-infection. Indeed, the 
proliferative responses of mononuclear cells from blood and lymphoid tissues to C. trachomatis 
strain L2c were never statistically different among groups, suggesting that C. trachomatis-
specific lymphocytes were not generated following infection or re-infection. Nevertheless, 
antichlamydial antibodies were elicited in sera and vaginal secretions after primo-infection and 
re-infection clearly resulted in a secondary systemic and mucosal antibody response. Apparently, 
the induced antibody response could not even partially protect the pigs against re-infection. 
 
In chapter IV, we searched for gene delivery carriers that can be used to improve the transfection 
efficiency of a C. trachomatis vaccine previously developed by our research group (Schautteet et 
al., 2011a). Furthermore, we looked for a suitable method for vaginal vaccine delivery, as vaginal 
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and/or nasal vaccination are promising strategies for inducing protective immunity against genital 
C. trachomatis infections. We screened a variety of commonly used non-viral gene delivery 
carriers for their ability to transfect porcine tracheal cells. Also, the effect of aerosolization on the 
physicochemical properties and transfection efficiency of the complexes was evaluated in vitro, 
as this is the preferred method for intranasal vaccine administration. Both mRNA and pDNA 
containing lipofectamine and ADM70 complexes showed promise for protein expression in vitro, 
before and after aerosolization. Subsequently, a pilot experiment was performed in which these 
complexes were aerosolized in the vaginal tract of pigs. In vivo, only lipofectamine/pDNA 
complexes resulted in high protein expression levels 24 hours following aerosolization. As 
aerosolization was an easy and effective method to deliver complexes to the vaginal tract of pigs, 
we believe this application technique has future potential for both vaginal and nasal vaccination 
using non-viral gene delivery vectors. 
 
Finally, chapter V describes our conclusions and perspectives for further research. 
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Samenvatting 
De familie van de Chlamydiaceae zijn obligaat intracellulaire Gram-negatieve bacteriën die 
verscheidene ziekten veroorzaken bij mens en dier. Deze thesis spitst zich toe op de species 
Chlamydia suis en C. trachomatis. C. suis is sterk verspreid in de varkenshouderij en veroorzaakt 
belangrijke economische verliezen (Schautteet et al., 2013). C. suis infecties worden geassocieerd 
met conjunctivitis, rhinitis, longontsteking, enteritis, periparturient dysgalactiae syndroom en 
verscheidene voortplantingsstoornissen (Sarma et al., 1983; Woollen et al., 1990; Rogers et al., 
1996; Rogers and Andersen, 1996, 1999; Schiller et al., 1997b; Eggemann et al., 2000; Kauffold 
et al., 2006a; Reinhold et al., 2008; Guscetti et al., 2009; Schautteet et al., 2013). De humane 
pathogeen C. trachomatis is wereldwijd de belangrijkste oorzaak van bacteriële seksueel 
overdraagbare aandoeningen (SOA‘s) en veroorzaakt jaarlijks meer dan 100 miljoen nieuwe 
infecties (WHO, 2012). Urogenitale infectie met niet-invasieve C. trachomatis stammen kan 
aanleiding geven tot cervicitis, urethritis, ‗pelvic inflammatory disease‘, buitenbaarmoederlijke 
zwangerschap, onvruchtbaarheid, chronische pijn in de onderbuik en epididymitis. De LGV 
stammen veroorzaken de invasieve ziekte lymphogranuloma venereum (LGV). Ondanks 
voorlichtingscampagnes en de beschikbaarheid van antibiotica, blijft het aantal C. trachomatis 
infecties stijgen in veel landen (ECDC, 2009, 2014; WHO, 2012). Algemeen wordt aangenomen 
dat de huidige maatregelen ontoereikend zijn en dat deze infecties slechts definitief zullen kunnen 
teruggedrongen worden door de ontwikkeling van een effectief vaccin (de la Maza and de la 
Maza, 1995). 
 
Hoofdstuk I start met een korte beschrijving van de taxonomie en biologie van chlamydiale 
infecties. Hierna wordt de epidemiologie, pathogenese, preventie en behandeling van  C. suis en 
C. trachomatis infecties in detail besproken. Vervolgens bespreken we de immuunresponsen van 
de gastheer tegenover genitale C. trachomatis infecties en de verschillende diermodellen die 
gebruikt kunnen worden om deze infecties te bestuderen. Tot slot wordt er een overzicht gegeven 
van het algemene principe en de voor- en nadelen van nucleïnezuur vaccins en de strategieën die 
aangewend kunnen worden om deze vaccins te optimaliseren.  
 
In hoofdstuk II werden de kenmerken van genitale C. suis infecties en herinfecties in zeugen 
onderzocht. Conventionele Chlamydia-seronegatieve varkens werden intravaginaal geïnfecteerd 
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en acht weken later geherinfecteerd met C. suis stam S45, de referentiestam van deze species, 
waarna de immuunrespons, pathologische veranderingen, chlamydiale vermeerdering in het 
urogenitaalstelsel en de vaginale excretie van levende kiemen werden onderzocht. We konden 
aantonen dat S45 pathogeen is voor het  urogenitaalstelsel van zeugen. Chlamydiale bacteriën en 
inclusies werden teruggevonden in alle onderdelen van het urogenitaalstelsel, waar ze ontsteking 
en pathologie veroorzaakten. De genitale C. suis infectie was in staat om zowel cellulaire als 
humorale immuunresponsen op te wekken. In vergelijking met de primo-infectie, resulteerde 
herinfectie in minder ernstige macroscopische letsels en minder chlamydiale replicatie in het 
urogenitaalstelsel. Dit wijst erop dat de initiële infectie leidde tot een zekere mate van immuniteit 
tegen herinfectie. Deze immuniteit was geassocieerd met hogere Chlamydia-specifieke IgG- en 
IgA-antistoftiters in sera en vaginale secreties, hogere proliferatieve responsen van perifere bloed 
mononucleaire cellen (PBMC), hogere percentages B-lymfocyten, monocyten en CD8
+
 T-cellen 
in het bloed en een hogere IFN-γ en IL-10 productie door PBMC. 
 
In hoofdstuk III onderzochten we de immuunrespons, pathologie en chlamydiale replicatie en 
excretie na een urogenitale C. trachomatis serovar L2c infectie en herinfectie in het 
varkensmodel dat ontwikkeld werd door Vanrompay et al. (2005). Serovar L2c is de meest recent 
ontdekte LGV stam en is een recombinant van de LGV stam L2 en de niet-invasieve stam D 
(Somboonna et al., 2011). Intravaginale infectie van varkens met deze bacterie resulteerde in een 
infectie die beperkt bleef tot het urogenitaalstelsel, waar ontsteking en pathologie veroorzaakt 
werden. Herinfectie gaf aanleiding tot ergere macroscopische letsels dan primo-infectie en de 
chlamydiale replicatie in het urogenitaalstelsel was na primo-infectie en herinfectie gelijkaardig. 
Dit geeft aan dat er geen beschermende immuniteit tegen herinfectie tot stand kwam na primo-
infectie. De proliferatieve responsen van mononucleaire cellen uit het bloed en lymfoïde weefsels 
tegenover C. trachomatis L2c waren inderdaad nooit statistisch verschillend tussen de drie 
groepen, wat doet vermoeden dat er geen C. trachomatis-specifieke lymfocyten werden 
aangemaakt na primo-infectie of herinfectie. Nochtans werden er wel anti-chlamydiale 
antistoffen opgewekt in sera en vaginale secreties na primo-infectie en resulteerde herinfectie 
duidelijk in een secundaire systemische en mucosale antistoffenrespons. De geïnduceerde 
antistoffenrespons kon de varkens blijkbaar zelfs niet gedeeltelijk beschermen tegen herinfectie. 
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In hoofstuk IV, gingen we op zoek naar carriersystemen die geschikt zijn om de transfectie-
efficiëntie van een C. trachomatis vaccin, dat eerder ontwikkeld werd in onze onderzoeksgroep, 
te verhogen (Schautteet et al., 2011a). Ook zochten we naar een geschikte methode voor de 
vaginale toediening van vaccins, aangezien vaginale en/of nasale vaccinatie hoogstwaarschijnlijk 
het best in staat zijn om beschermende immuniteit tegen genitale C. trachomatis infecties op te 
wekken. We screenden verscheidene veel gebruikte niet-virale carriersystemen op hun vermogen 
om tracheale varkenscellen te transfecteren. Verder werd het effect van aerosolisatie op de 
fysicochemische eigenschappen en transfectie-efficiëntie van de complexen getest in vitro, 
aangezien dit de geprefereerde methode is voor intranasale toediening van vaccins. Zowel 
lipofectamine als ADM70 complexen met mRNA of pDNA waren veelbelovend voor in vitro 
eiwitexpressie en bleken bestand tegen aerosolisatie. Vervolgens werd er een preliminair 
experiment uitgevoerd waarbij deze complexen geaerosoliseerd werden in de vagina van varkens. 
Enkel de lipofectamine/pDNA complexen resulteerden in een hoge eiwitexpressie 24 uur na de in 
vivo aerosolisatie. Aangezien aerosolisatie een gemakkelijke en effectieve manier was om 
complexen vaginaal toe te dienen aan varkens, zijn we van mening dat deze toedieningswijze 
potentieel heeft voor zowel vaginale als nasale vaccinatie. 
 
Tot slot worden in hoofdstuk V onze conclusies en mogelijkheden voor verder onderzoek 
besproken. 
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alhoewel ik die ‗steeds‘ gezien jouw slaapritme beter zou nuanceren tot ‗in de namiddag‘ ;-). Ook 
 bedankt om de boel op te vrolijken met je Borat- en andere imitaties. Stropke, bedankt om mij de 
laatste maanden bij tijd en stond van achter mijn computer te halen met jouw kattenkwaad.  
Last but not least wil ik mijn vriend Nicola bedanken. Nicola, bedankt voor jouw 
aanmoedigingen, jouw pogingen om mij op het rechte pad te houden als ik weer ‗uitstelgedrag‘ 
vertoonde (ook al waren deze meestal tevergeefs ;-)), mij op te beuren als ik het even moeilijk 
had, jouw onvoorwaardelijke steun en liefde,… Kortom, bedankt voor teveel om op te noemen!  
Ik denk dat je stiekem blij bent dat alles bijna achter de rug is, want je hebt het vooral de laatste 
maanden niet altijd gemakkelijk met mij gehad: eenzame avonden en weekends toen ik aan dit 
boekje bezig was, na een drukke werkdag nog je eigen potje moeten koken, stinkende 
varkensspullen in huis,... Nog even op de tanden bijten en dan maak ik het allemaal goed ;-). 
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